{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Catalyst Pharmaceutical Files 8K - Other Events >CPRX\b0\par\par\uc2 257 \uc2 words\par \uc2 11 August 2014\par 08:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Catalyst Pharmaceutical Partners Inc\uc2 . (CPRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 11, 2014.\par \par \uc2 On August 11, 2014, the Company issued a press release announcing that the final patient in its Phase 3 study of Firdapse (amifampridine phosphate) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) has completed the blinded portion of the study, and that top-line results from the study are on track to be reported later this quarter. In addition, the Company announced that all patients who were randomized into the study elected to continue in the two-year open label follow-up study.\par \par \uc2 A copy of the Company's press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1369568/000119312514303947/d774810d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1369568/000119312514303947/d774810d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1369568/000119312514303947/0001193125-14-303947-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1369568/000119312514303947/0001193125-14-303947-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Catalyst Pharmaceutical Partners, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US14888U1016"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US14888U1016}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 11, 2014 08:16 ET (12:16 GMT)\par \par \uc2 Document DJDN000020140811ea8b001k7\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Xeloda tablets\b0\par\par\uc2 90 \uc2 words\par \uc2 11 August 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of \uc2 Genentech\uc2 's Xeloda Tablets. Mylan received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. Capecitabine Tablets USP, 150 mg and 500 mg, had U.S. sales of approximately $773.8M for the 12 months ending June 30, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Document FLYWAL0020140811ea8b0020c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b  \highlight22\uc2 New Product Launch \highlight\uc2 , New Board Member, Major Contracts, Successful Testing, and Grants - Research Reports on Abbott, Illumina, \uc2 General Dynamics\uc2 , \uc2 Raytheon\uc2  and \uc2 Northrop Grumman\b0\par\par\uc2 1,402 \uc2 words\par \uc2 7 August 2014\par 08:50\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Editor Note: For more information about this release, please scroll to bottom \par  \f28 \par \par \uc2 \f2 NEW YORK, August 7, 2014 /PRNewswire/ --\f28 \par \par \uc2 Today, Analysts Review released its research reports regarding \uc2 Abbott Laboratories\uc2  (\uc2 NYSE\uc2 : ABT), \uc2 Illumina Inc\uc2 . (\uc2 NASDAQ\uc2 : ILMN), \uc2 General Dynamics Corp\uc2 . (\uc2 NYSE\uc2 : GD), \uc2 Raytheon Co\uc2 . (\uc2 NYSE\uc2 : RTN) and \uc2 Northrop Grumman Corporation (NYSE: NOC)\uc2 . Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/5543-100free"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/5543-100free}}}\uc2 .\par \par \uc2 --\par \par \uc2 Abbott Laboratories Research\uc2  Reports\par \par \uc2 On July 24, 2014, \uc2 Abbott Laboratories\uc2  (Abbott) launched new Similac(R) Breastfeeding Supplement, which is specially designed to enhance the levels of DHA, lutein and vitamin E in breast milk. Abbott studied the diets of more than 80 lactating women to assess their nutritional intake compared to dietary recommendations. The study revealed that few lactating women consistently consume enough key nutrients, like DHA, lutein and vitamin E, through their diet. "Moms are first encouraged to focus on food to obtain ideal nutrition," said Christina Sherry, Abbott Research Scientist who led the study. Christina added, "But as demonstrated by our study, the reality is that many women find it difficult to eat a well-balanced diet while adjusting to caring for a newborn. And even though many women may continue to take a prenatal vitamin during this time, many prenatal vitamins do not have, or have enough, DHA, lutein and vitamin E." The full research reports on Abbott are available to download free of charge at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/Aug-07-2014/ABT/report.pdf"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/Aug-07-2014/ABT/report.pdf}}}\par \par \uc2 --\par \par \uc2 Illumina Inc\uc2 . Research Reports\par \par \uc2 On July 31, 2014, \uc2 Illumina Inc\uc2 . (Illumina) announced that \uc2 Jeff Huber\uc2 , who currently works as Senior Vice President at \uc2 Google Inc\uc2 . (\uc2 Google\uc2 ), has joined the Company's Board of Directors. Huber joined \uc2 Google\uc2  in 2003 and led development for \uc2 Google\uc2  Maps, \uc2 Google\uc2  Apps and \uc2 Google\uc2  Ads. Commenting on the appointment, Illumina's CEO, \uc2 Jay Flatley\uc2  said, "We are pleased to welcome Jeff to the \uc2 Illumina Board\uc2  and to leverage his expertise as we work to make genomic data accessible to the widest possible community of researchers and clinicians." The full research reports on Illumina are available to download free of charge at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/Aug-07-2014/ILMN/report.pdf"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/Aug-07-2014/ILMN/report.pdf}}}\par \par \uc2 --\par \par \uc2 General Dynamics Corp\uc2 . Research Reports\par \par \uc2 On July 29, 2014, \uc2 General Dynamics Corp\uc2 . (\uc2 General Dynamics\uc2 ) announced that its business unit, \uc2 General Dynamics Advanced Information Systems\uc2  (GD Advanced) was awarded a $25.4 million full-production contract from \uc2 Lockheed Martin\uc2  to support the \uc2 U.S. Air Force\uc2  Global Positioning System (GPS) III Network Communications Element (NCE) for space vehicles seven and eight (SV 07-08). According to the Company, \uc2 General Dynamics\uc2  is now under contract with \uc2 Lockheed Martin\uc2  for GPS III SV 01-08. \uc2 General Dynamics\uc2 ' NCE components provide the communications functions for the GPS III satellites, including the ground-to-space command and control channel, the space-to-space inter-satellite channel and the command and telemetry communications channels within each satellite. "For more than 50 years, we have been a premier provider of spacecraft communications and navigation equipment for the nation's military and government agencies," said Carlo Zaffanella, Vice President and General Manager of Intelligence, Surveillance and Reconnaissance at GD Advanced. The full research reports on \uc2 General Dynamics\uc2  are available to download free of charge at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/Aug-07-2014/GD/report.pdf"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/Aug-07-2014/GD/report.pdf}}}\par \par \uc2 --\par \par \uc2 Raytheon Co\uc2 . Research Reports\par \par \uc2 On July 31, 2014, \uc2 Raytheon Co\uc2 . (\uc2 Raytheon\uc2 ) and \uc2 MD Helicopters, Inc\uc2 ., jointly announced the successful firing of four TALON laser guided rockets from the MD 530G armed aerial scout (AAS) helicopter during a series of tests at Yuma Proving Ground, Arizona. "This test further demonstrates the maturity of the TALON Laser Guided Rocket weapon system as a complement to MD's AAS platform," said Darryl Kreitman, \uc2 Raytheon\uc2  TALON Program Director. Kreitman added, "In just a few months, \uc2 Raytheon\uc2  worked closely with MD to integrate TALON onto the MD 530G, subjecting the helicopter and rocket to number of realistic mission profiles." The full research reports on \uc2 Raytheon\uc2  are available to download free of charge at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/Aug-07-2014/RTN/report.pdf"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/Aug-07-2014/RTN/report.pdf}}}\par \par \uc2 --\par \par \uc2 Northrop Grumman Corporation\uc2  Research Reports\par \par \uc2 On August 4, 2014, \uc2 Northrop Grumman Corporation\uc2  (\uc2 Northrop Grumman\uc2 ) announced that it awarded $50,000 in grants to 167 K-12 schools nationwide to promote education in the science, technology, engineering and mathematics (STEM) disciplines. The Company informed that the 167 schools are located in 11 different states and in the communities near 17 separate \uc2 Northrop Grumman\uc2  campuses. According to the Company, the Engineers Week STEM Grants seek to provide teachers with funding for projects that increase student awareness of the excitement and opportunity to be found in STEM fields. "\uc2 Northrop Grumman\uc2  strongly believes in promoting STEM education as a means to better ensure the nation's long-term economic success," said Melissa Sandlin, Manager of Corporate Citizenship for \uc2 Northrop Grumman\uc2 's eastern region. The full research reports on \uc2 Northrop Grumman\uc2  are available to download free of charge at:\par \par {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com/Aug-07-2014/NOC/report.pdf"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com/Aug-07-2014/NOC/report.pdf}}}\par \par \uc2 --\par \par \uc2 About Analysts Review\par \par \uc2 We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.\par \par \uc2 ===============\par \par \uc2 EDITOR'S NOTES:\par \par \uc2 ===============\par \par \uc2 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.\par \par \uc2 2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.\par \par \uc2 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.\par \par \uc2 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com}}}\uc2 .\par \par \uc2 5. For any urgent concerns or inquiries, please contact us at compliance [at] {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com}}}\uc2 .\par \par \uc2 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] {\field{\*\fldinst{HYPERLINK "http://www.analystsreview.com"}}{\fldrslt{\cf2 \uc2 http://www.analystsreview.com}}}\uc2  for consideration.\par \par \uc2 COMPLIANCE PROCEDURE\par \par \uc2 Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.\par \par \uc2 NOT FINANCIAL ADVICE\par \par \uc2 Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.\par \par \uc2 NO WARRANTY OR LIABILITY ASSUMED\par \par \uc2 Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.\par \par \uc2 CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by \uc2 CFA Institute\uc2 .\par \par \uc2 SOURCE Analysts Review\par \par \uc2 /\par \par \uc2 Document PRN0000020140807ea870007k\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 NewLink Genetics\uc2  Files 8K - Other Events >NLNK\b0\par\par\uc2 185 \uc2 words\par \uc2 5 August 2014\par 07:23\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 NewLink Genetics Corp\uc2 . (NLNK) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on August 05, 2014.\par \par \uc2 On August 5, 2014, \uc2 NewLink Genetics\uc2  (NASDAQ:NLNK) announced a letter contract with the United States Defense Threat Reduction Agency (DTRA) for studies that will bring an Ebola vaccine licensed from the \uc2 Public Health Agency of Canada\uc2  closer to human clinical trials.\par \par \uc2 The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623414000142/nlnk-20140805x8k2.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623414000142/nlnk-20140805x8k2.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623414000142/0001126234-14-000142-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623414000142/0001126234-14-000142-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 05, 2014 07:23 ET (11:23 GMT)\par \par \uc2 Document DJDN000020140805ea85001ep\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 BIOTIME\uc2  FILES CURRENT REPORT\b0\par\par\uc2 824 \uc2 words\par \uc2 2 August 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, Aug. 2 -- \uc2 BioTime Inc\uc2 ., Alameda, Calif., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on July 31.\par \par \uc2 State or other jurisdiction of incorporation: California\par \par \uc2 Forward-Looking Statements\par \par \uc2 Any statements that are not historical fact (including, but not limited to statements that contain words such as "may, "will," "believes," "plans," "intends," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in \uc2 BioTime\uc2 's periodic reports filed with the \uc2 SEC\uc2  under the heading "Risk Factors" and other filings that \uc2 BioTime\uc2  may make with the \uc2 Securities and Exchange Commission\uc2 . Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, \uc2 BioTime\uc2  disclaims any intent or obligation to update these forward-looking statements.\par \par \uc2 Section 8 - Other Events\par \par \uc2 Item 8.01 Other Events\par \par \uc2 Our subsidiary OncoCyte Corporation has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.\par \par \uc2 The goal of the current clinical trial is to compare the performance of OncoCyte's proprietary PanC-Dx bladder cancer markers to the performance of cystoscopy. Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer. Cystoscopy and biopsy results will be compared with the results of OncoCyte's proprietary diagnostic test panel in determining the overall performance of the PanC-Dx markers. PanC-Dx is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers discovered by OncoCyte scientists through an analysis of broad gene expression patterns in numerous cancer types. The performance of the test in detecting the absence, presence, or progression of urothelial carcinoma in patients will determine the specific nature of the bladder cancer diagnostic to be developed and the regulatory approval pathway that OncoCyte will pursue.\par \par \uc2 Urothelial carcinoma (UC) constitutes more than 90% of bladder cancers in the Americas, Europe and Asia. Although most patients with bladder cancer can be treated with organ-sparing chemotherapy, UC has a relapse rate of nearly 70% and can progress to invasive, metastatic, and lethal disease. The regular surveillance and treatment of recurrent disease from the time of diagnosis for the remainder of a patient's life makes UC the most costly malignancy on a per patient basis. The problem is amplified because the two standard methods for surveillance - microscopic assessment of urinary cytology specimens and bladder cystoscopy- possess significant limitations with respect to both performance and cost. Although urine cytology does have a very high positive predictive value (low false positive rate), it has a low negative predictive value and a high indeterminate rate. Patients who have indeterminate urine cytology results commonly undergo cystoscopy, which is painful, time consuming, costly, and unnecessary in many cases since a neoplasm is often not present. In UC, as in virtually all other cancers, earlier and more accurate diagnosis, including diagnosis of disease recurrence, is generally associated with better outcomes and lower cost.\par \par \uc2 Overall markets for bladder cancer diagnostics are large and growing. Based on \uc2 National Cancer Institute\uc2  statistics released in 2012, it was estimated that in 2013 over 72,000 new cases of bladder cancer would occur in the United States and a total of over 550,000 men and women alive would have a history of bladder cancer and be subject to recurrence surveillance testing using cystoscopy or urine cytology.\par \par \uc2 Section 9 - Financial Statements and Exhibits\par \par \uc2 Item 9.01 Financial Statements and Exhibits.\par \par \uc2 Exhibit Number - Description\par \par \uc2 99.1 - Press Release Dated July 31, 2014\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/a50916009.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/a50916009.htm}}}\par \par \uc2 Document INDFED0020140802ea82005ki\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Alexza Pharmaceuticals\uc2  Files 8K - Other Events >ALXA\b0\par\par\uc2 273 \uc2 words\par \uc2 31 July 2014\par 16:49\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Alexza Pharmaceuticals Inc\uc2 . (ALXA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 31, 2014.\par \par \uc2 On July 31, 2014, \uc2 Alexza Pharmaceuticals, Inc\uc2 ., a Delaware corporation, issued a press release announcing that (i) in the second half of 2014, it expects to initiate a Phase 2a study of AZ-002 (Staccato alprazolam) which is being developed for the management of patients with acute repetitive seizures and (ii) it has identified two new Staccato-based product candidates for development AZ-008 and AZ-009 which will incorporate the active pharmaceutical ingredient ropinirole, a dopamine agonist, into Alexza's Staccato system. Alexza plans to develop AZ-008 for the acute treatment of restless legs syndrome and AZ-009 for hypomobility, or freezing, during "off periods" in Parkinson's disease patients. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1344413/000119312514289837/d769250d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1344413/000119312514289837/d769250d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1344413/000119312514289837/0001193125-14-289837-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1344413/000119312514289837/0001193125-14-289837-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Alexza Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US0153842093"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US0153842093}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 31, 2014 16:49 ET (20:49 GMT)\par \par \uc2 Document DJDN000020140731ea7v004y6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 BioTime\uc2  Files 8K - Other Events >BTX\b0\par\par\uc2 731 \uc2 words\par \uc2 31 July 2014\par 09:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 BioTime Inc\uc2 . (BTX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 31, 2014.\par \par \uc2 Our subsidiary OncoCyte Corporation has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte's initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx(tm) bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.\par \par \uc2 The goal of the current clinical trial is to compare the performance of OncoCyte's proprietary PanC-Dx(tm) bladder cancer markers to the performance of cystoscopy. Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer. Cystoscopy and biopsy results will be compared with the results of OncoCyte's proprietary diagnostic test panel in determining the overall performance of the PanC-Dx(tm) markers. PanC-Dx(tm) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers discovered by OncoCyte scientists through an analysis of broad gene expression patterns in numerous cancer types. The performance of the test in detecting the absence, presence, or progression of urothelial carcinoma in patients will determine the specific nature of the bladder cancer diagnostic to be developed and the regulatory approval pathway that OncoCyte will pursue.\par \par \uc2 Urothelial carcinoma (UC) constitutes more than 90% of bladder cancers in the Americas, Europe and Asia. Although most patients with bladder cancer can be treated with organ-sparing chemotherapy, UC has a relapse rate of nearly 70% and can progress to invasive, metastatic, and lethal disease. The regular surveillance and treatment of recurrent disease from the time of diagnosis for the remainder of a patient's life makes UC the most costly malignancy on a per patient basis. The problem is amplified because the two standard methods for surveillance - microscopic assessment of urinary cytology specimens and bladder cystoscopy possess significant limitations with respect to both performance and cost. Although urine cytology does have a very high positive predictive value (low false positive rate), it has a low negative predictive value and a high indeterminate rate. Patients who have indeterminate urine cytology results commonly undergo cystoscopy, which is painful, time consuming, costly, and unnecessary in many cases since a neoplasm is often not present. In UC, as in virtually all other cancers, earlier and more accurate diagnosis, including diagnosis of disease recurrence, is generally associated with better outcomes and lower cost.\par \par \uc2 Overall markets for bladder cancer diagnostics are large and growing. Based on \uc2 National Cancer Institute\uc2  statistics released in 2012, it was estimated that in 2013 over 72,000 new cases of bladder cancer would occur in the United States and a total of over 550,000 men and women alive would have a history of bladder cancer and be subject to recurrence surveillance testing using cystoscopy or urine cytology.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/a50916009.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/a50916009.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/0001157523-14-003167-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/876343/000115752314003167/0001157523-14-003167-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 BioTime, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US09066L1052"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US09066L1052}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 31, 2014 09:00 ET (13:00 GMT)\par \par \uc2 Document DJDN000020140731ea7v002m0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: THERAPEUTICSMD FILES CURRENT REPORT\b0\par\par\uc2 1,961 \uc2 words\par \uc2 31 July 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, July 31 -- \uc2 TherapeuticsMD Inc\uc2 ., Boca Raton, Fla., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on July 30.\par \par \uc2 State or other jurisdiction of incorporation: Nevada\par \par \uc2 Item 8.01. Other Events.\par \par \uc2 On July 30, 2014, \uc2 TherapeuticsMD, Inc\uc2 ., a Nevada corporation, filed a prospectus supplement with the \uc2 Securities and Exchange Commission\uc2  under its effective shelf registration statements on Form S-3 (the "Prospectus") pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The discussion below contains certain updated disclosures regarding the Company's business included the Prospectus. Unless the context otherwise requires, all references in this Current Report on Form 8-K to "\uc2 TherapeuticsMD\uc2 ," "TXMD," "Company," "our company," "we," "us," or "our" refer to \uc2 TherapeuticsMD, Inc\uc2 ., a Nevada corporation, and its subsidiaries, VitaMedMD, LLC, a Delaware limited liability company, or VitaMed, and BocagreenMD, Inc., a Nevada corporation, or BocaGreenMD. vitaMedMD(R), \uc2 TherapeuticsMD\uc2 (R), and BocaGreenMD(R) are registered trademarks of our company.\par \par \uc2 Our Company\par \par \uc2 We are a women's health care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins and cosmetics.\par \par \uc2 We have obtained \uc2 U.S. Food and Drug Administration\uc2 , or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for four of our hormone therapy drug candidates: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our vaginal suppository estradiol alone. We are currently conducting phase 3 clinical trials for TX-001HR and TX-002HR; and we currently intend to begin a phase 3 clinical trial for TX-004HR in the third quarter of 2014. We have no current plans to conduct clinical trials for TX-003HR.\par \par \uc2 Hormone Therapy Market\par \par \uc2 The menopause hormone therapy market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies. On November 27, 2013, the Drug Quality and Security Act became law and the FDA was given additional oversight over compounding pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically referred to as bioidenticals, when produced and sold by compounding pharmacies, are not easily measured or monitored. We estimate the non-FDA approved compounded bioidentical hormone therapy combination sales of estradiol and progesterone products sold by compounding pharmacies approximate $1.5 billion per year and the FDA-approved market approximates $625 million per year. Our phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our bioidentical drug candidates at specific dosage levels. We intend our hormone therapy drug candidates, if approved, to provide hormone therapies with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bioidentical market. This aim is based on our belief that our drug candidates will offer advantages in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost as a result of insurance coverage and improved access as a result of availability from major retail pharmacy chains than custom order or formulation by individual compounders.\par \par \uc2 Pipeline of our Hormone Therapy Drug Candidates\par \par \uc2 TX-001HR\par \par \uc2 TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats and sleep disturbances for post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman's body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone (biologically identical or bioidentical to the estradiol and progesterone produced by the ovaries), would be approved for use in a single combined product. According to Source Healthcare Analytics, the total FDA-approved market for menopause-related combination estrogen/progestin was approximately $625 million in U.S. sales for the 12 months ended December 31, 2013.\par \par \uc2 On September 5, 2013, we began enrollment of the REPLENISH trial, a multicenter, double-blind, placebo-controlled, phase 3 study of TX-001HR in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to one of five treatment arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, 6 months and 12 months. We intend to enroll approximately 1,750 patients at approximately 80 sites. We currently anticipate that enrollment in the REPLENISH Trial will be complete during the fourth quarter of 2014 and that results of the trial will be reported during the fourth quarter of 2015.\par \par \uc2 TX-002HR\par \par \uc2 TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The product would be chemically identical to the hormones that naturally occur in a woman's body. We believe it will be similarly effective to traditional treatments, but may be effective at lower dosages. According to Source Healthcare Analytics, the total FDA-approved market for oral progestin was approximately $364 million in U.S. sales for the 12 months ended December 31, 2013. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we temporarily suspended enrollment in the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. We intend to update the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if approved by the FDA, will allow us to ease the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol that we intend to propose.\par \par \uc2 TX-004HR\par \par \uc2 TX-004HR is a vaginal suppository estradiol drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. According to Source Healthcare Analytics, the total FDA-approved market for VVA treatment was approximately $1 billion in U.S. sales for the 12 months ended December 31, 2013, which represents a 20% annual growth rate over the past five years.\par \par \uc2 We currently intend to begin a multicenter, double-blind, placebo-controlled phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause. Based on discussions with the FDA, we expect to conduct a single 12 week study, evaluating three different doses of estradiol: 4 mcg, 10 mcg and 25 mcg. The FDA has to date noted that in order to approve a drug based on a single trial, the trial would need to show statistical significance at a 0.01 level. The study has been designed to include four primary endpoints: the reduction of vaginal pH levels to less than 5.0, an increase in superficial cells, a decrease in parabasal cells and the improvement of dyspareunia. If approved, the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA. The trial is designed to enroll approximately 800 patients across approximately 60 to 80 sites. We currently anticipate that enrollment in the trial will be complete during the second quarter of 2015 and that results of the trial will be reported during the third quarter of 2015. Based on such timeline and successful reports of the trial, we would anticipate filing an NDA for TX-004HR during the fourth quarter of 2015 and that such NDA would be approved by the FDA during the fourth quarter of 2016.\par \par \uc2 Early Clinical Development\par \par \uc2 Based upon leveraging our hormone platform technology, we have four early clinical projects in development, including our proposed combination estradiol and progesterone and progesterone-alone products in a topical cream form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer to as TX-007HR and TX-008HR, respectively. We recently completed a pilot pharmacokinetic, or PK, study of TX-005HR in eight patients that tested the topical administration on the upper arm of 50 mcg of estradiol and 25 mg of progesterone. The results of the PK study suggest that topical formulations of estradiol and progesterone may be possible using our proprietary solubilized forms of the compounds. We intend to file an IND with respect to TX-005HR and TX-006HR during the fourth quarter of 2014 and then commence phase 1 clinical trials. We may in the future engage with a financing partner to advance our topical cream and transdermal patch projects.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/25743/000119312514287056/d766830d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/25743/000119312514287056/d766830d8k.htm}}}\par \par \uc2 Document INDFED0020140731ea7v004n4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Targacept\uc2  Files 8K - Other Events >TRGT\b0\par\par\uc2 190 \uc2 words\par \uc2 28 July 2014\par 17:02\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Targacept Inc\uc2 . (TRGT) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 28, 2014.\par \par \uc2 On July 28, 2014, \uc2 Targacept, Inc\uc2 . issued a press release announcing top-line results from its Phase 2b clinical trial of TC-5214 in overactive bladder. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1124105/000119312514282501/d765171d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1124105/000119312514282501/d765171d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1124105/000119312514282501/0001193125-14-282501-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1124105/000119312514282501/0001193125-14-282501-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Targacept, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US87611R3066"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US87611R3066}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 28, 2014 17:02 ET (21:02 GMT)\par \par \uc2 Document DJDN000020140728ea7s003f0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Stemline Therapeutics\uc2  Files 8K - Other Events >STML\b0\par\par\uc2 184 \uc2 words\par \uc2 28 July 2014\par 12:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Stemline Therapeutics Inc\uc2 . (STML) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 28, 2014.\par \par \uc2 Stemline Therapeutics, Inc\uc2 . (the "Company") announced today the opening of its SL-401 Investigational New Drug (IND) and initiation of a broad clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). A copy of the press release is being furnished as Exhibit 99.1 to this report.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1264587/000110465914053918/a14-17889_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1264587/000110465914053918/a14-17889_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1264587/000110465914053918/0001104659-14-053918-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1264587/000110465914053918/0001104659-14-053918-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 28, 2014 12:01 ET (16:01 GMT)\par \par \uc2 Document DJDN000020140728ea7s0027y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Lpath Files 8K - Other Events >LPTN\b0\par\par\uc2 653 \uc2 words\par \uc2 24 July 2014\par 17:08\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Lpath Inc\uc2 . (LPTN) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 24, 2014.\par \par \uc2 On July 24, 2014, \uc2 Lpath, Inc\uc2 . (the "Company") issued a press release announcing interim data from the Phase 2a single-arm, open-label trial for its drug candidate ASONEP . ASONEP is being investigated in the Phase 2a trial as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent(R)/sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor(R)/everolimus), with a maximum of three failed treatments in all. The full text of the Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report"), and is incorporated herein by reference.\par \par \uc2 Forward-Looking Statements\par \par \uc2 The Company cautions you that the statements included in this Current Report that are not a description of historical facts are forward-looking statements. These include statements regarding: the potential benefits and therapeutic uses of ASONEP and its other drug candidates; the Company's ability to successfully complete additional preclinical studies, development activities and clinical trials for its drug candidates, including ASONEP; and the Company's ability to complete additional discovery and development activities for drug candidates utilizing its proprietary ImmuneY2 drug-discovery process. Actual results may differ materially from those set forth in this Current Report due to the risks and uncertainties inherent in the Company's business, including, without limitation: the final results of the Company's preclinical studies and clinical trials may be different from interim data results and may not support further clinical development and/or the commercialization of ASONEP or its other drug candidates; the Company may not successfully complete its existing and any additional clinical trials for its drug candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any of its drug candidates; the Company may not be successful in maintaining its commercial relationship with \uc2 Pfizer Inc\uc2 . or any third party that acquires \uc2 Pfizer\uc2 's exclusive option to iSONEP; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in the Company's filings with the \uc2 Securities and Exchange Commission\uc2  (the "SEC"), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Such documents may be read free of charge on the SEC's website at {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 . You are cautioned not to place undue reliance on these forward-looking statements, which are effective only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Current Report to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1251769/000110465914053317/a14-17743_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1251769/000110465914053317/a14-17743_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1251769/000110465914053317/0001104659-14-053317-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1251769/000110465914053317/0001104659-14-053317-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Lpath, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US5489103060"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US5489103060}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 24, 2014 17:08 ET (21:08 GMT)\par \par \uc2 Document DJDN000020140724ea7o0048w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Puma Biotechnology Files 8K - Other Events >PBYI\b0\par\par\uc2 228 \uc2 words\par \uc2 22 July 2014\par 16:29\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Puma Biotechnology Inc\uc2 . (PBYI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 18, 2014.\par \par \uc2 On July 22, 2014, the Company issued a press release announcing the Amendment. In addition, the Company issued a press release announcing top line results from the Phase III clinical trial of the Company's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial). A conference call has been scheduled to be held July 22, 2014 at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Amendment and the trial results. Copies of the press releases are filed herewith as Exhibits 99.1 and 99.2 and are incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514275593/d761599d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514275593/d761599d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514275593/0001193125-14-275593-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514275593/0001193125-14-275593-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 22, 2014 16:29 ET (20:29 GMT)\par \par \uc2 Document DJDN000020140722ea7m003h3\par }\page {\par\fs20\b \uc2 Startup Conducts Unusual Funding 'Experiment'\b0\par\par\uc2 Brittany Meiling   \par \uc2 971 \uc2 words\par \uc2 21 July 2014\par \uc2 San Diego Business Journal\par \uc2 SDBJ\par 3\par \uc2 Volume 35; Issue 29; ISSN: 87506890\par \uc2 English\par \uc2 \u169\'00\'A9 2014 San Diego Business Journal. Provided by ProQuest Information and Learning. All Rights Reserved.   \par \par \uc2 A local biotech startup and its 22-year-old CEO - with support of local industry veterans - are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.\par \par \uc2 Last month, Batu Biologics \b \highlight22\uc2 launched\b0 \highlight\uc2  a crowd funding campaign on \uc2 IndieGoGo\uc2  to raise $100,000 to help further research for its lung cancer vaccine, Vallovax. President and CEO Samuel Wagner plans to use the money for filing an investigational \b \highlight22\uc2 new drug\b0 \highlight\uc2  application with the \uc2 U.S. Food and Drug Administration\uc2  to start phase one clinical trials. As of July 14, Batu has raised nearly $54,000 from 86 funders.\par \par \uc2 The crowdfunding approach is a departure from typical biotech startups that raise a few million to several million dollars from angel investor groups, venture capital or even initial public offerings to fund expensive research. Batu, by contrast, has self-funded its preclinical research so far, seeking to avoid diluting its value as it raises money.\par \par \uc2 "If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion of our shares," Wagner said. "If we want to have the biggest payout for the founders, it's really in our benefit to raise the least amount of capital in the early stages of the company."\par \par \uc2 Batu's laboratory is housed at Janssen Labs, a life-science business incubator in La Jolla. The research facility charges Batu a modest rental fee for access to all shared equipment, tissue culture labs and other resources without taking equity in the startup.\par \par \uc2 "It's really ideal for us," Wagner said. "It gives the opportunity for startup companies to develop their ideas and later hopefully graduate out and move to bigger facilities."\par \par \uc2 Batu's new cancer vaccine is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than about 1 millimeter, Wagner said, adding that tumors need those blood vessels to become malignant.\par \par \uc2 "Everybody has been attacking the tumor directly," Wagner said. "We're choosing a different approach. ... We're trying to choke it of this blood supply."\par \par \uc2 Growing 'Zuckerberg of Biotechnology'\par \par \uc2 Wagner left the \uc2 University of California, San Diego\uc2  - where he studied mechanical engineering during his senior year to join a peer's biotech startup called Vaxenta Biotechnologies. Contributing money earned by trading stocks in college, Wagner joined as director of investor relations and eventually became vice president. At Vaxenta, Wagner met his current mentor and founder of Batu Biologics, Thomas Ichim, who was helping the startup as an adviser.\par \par \uc2 Ichim is board chairman at Batu and chief scientific officer of Regen Biopharma, a stem cell company and subsidiary of \uc2 Bio-Matrix Scientific Group Inc\uc2 . (OTC: BMSN). Ichim moved to the U.S. from Canada in 2004 when he co-founded Biorasi, a contract research organization now located in Miami. In 2007, he joined the San Diego-based stem cell company \uc2 Medistem Inc\uc2 . acquired this year by \uc2 Intrexon Corp\uc2 . (NYSE: XON) for a reported $26 million - as chief scientific officer and eventually CEO. In 2012, Ichim asked Alan Lewis to join as CEO while Ichim remained as president.\par \par \uc2 Last year, Ichim founded Batu Biologics and appointed Wagner as president and CEO despite his youth and limited experience.\par \par \uc2 "When I was Sam's age, nobody believed in me," Ichim said. "So I figured if I had somebody who had a lot of the characteristics that I had at that age, and I provide the right resources and the right environment, then maybe I can develop the Mark Zuckerberg of biotechnology."\par \par \uc2 Wagner has surrounded himself with industry veterans such as Lewis, who has 37 years of experience as an executive in life sciences. Lewis spent 15 years at pharmaceutical company Wyeth-Ayerst - bought in 2009 by \uc2 Pfizer Inc\uc2 . (NYSE: PFE) - as vice president of research. He later became the CEO of Signal Pharmaceuticals, which was acquired by \uc2 Celgene Corp\uc2 . (Nasdaq: CELG) in 2010. Since leaving Celgene, Lewis has raised $27 million as CEO of Novocell, now called \uc2 ViaCyte Inc\uc2 ., and over $45 million as CEO of Ambit Biosciences Corp. (Nasdaq: AMBI).\par \par \uc2 Through Ichim, Lewis developed a relationship with Wagner late last year, and was appointed to Batu's scientific advisory board earlier this month.\par \par \uc2 "Frankly, [Wagner is] young to be a CEO, and he has a lot to learn," Lewis said. "But you've got to start somewhere. He's got ambitions, and he's at that part of his career where he's like a sponge, picking up information on a daily basis. He's very enthusiastic, and that's a great thing I see in him. It's kind of like I'm doing a bit of mentoring at the same time."\par \par \uc2 Delaying VCs to 'Focus on the Science'\par \par \uc2 Batu has five full-time employees, only two of whom earn salaries: Chief Scientific Officer Hong Ma and Dimitri Theofilopoulos, who is chief operating officer and in-house counsel.\par \par \uc2 "This goes back to efficiency and really working with the capital that we have to make things work on a really low budget," Wagner said.\par \par \uc2 After the startup moves past clinical testing, Batu may consider venture capital and investor funding to grow.\par \par \uc2 "Venture capital is the very important lifeblood of our industry," Ichim said. "But it's very difficult to raise money from venture capital people on terms that are a win-win for everybody right now. Once we have FDA approval for our vaccine, then obviously all sorts of different financing opportunities exist. But right now, I think it's very important to focus on the science."\par \par \uc2 Copyright San Diego Business Journal Jul 21, 2014\par \par \uc2 Document SDBJ000020140807ea7l0000e\par }\page {\par\fs20\b \uc2 Mylan Inc\uc2 . Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Micardis(R) Tablets\b0\par\par\uc2 352 \uc2 words\par \uc2 21 July 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 69\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com    \par \par \uc2 2014 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of \uc2 Boehringer Ingelheim\uc2 's Micardis(R) Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.\par \par \uc2 Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales of approximately $259.2 million for the 12 months ending March 31, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 305 ANDAs pending FDA approval representing $107.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 Keywords for this news article include: \uc2 Mylan Inc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020140718ea7l00016\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Theravance Files 8K - Other Events >THRX\b0\par\par\uc2 260 \uc2 words\par \uc2 16 July 2014\par 07:30\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Theravance Inc\uc2 . (THRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 16, 2014.\par \par \uc2 On July 16, 2014, \uc2 GlaxoSmithKline plc\uc2  (GSK) and \uc2 Theravance, Inc\uc2 . announced the launch of ANORO(R) (umeclidinium/vilanterol) in Germany following the approval by \uc2 European Commission\uc2  in May 2014. ANORO(R) ELLIPTA(R) is indicated as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). ANORO(R) ELLIPTA(R) is a combination of two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single dry powder inhaler, the ELLIPTA(R). The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 .\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414001128/theravance8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414001128/theravance8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414001128/0001102624-14-001128-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414001128/0001102624-14-001128-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Theravance, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 16, 2014 07:30 ET (11:30 GMT)\par \par \uc2 Document DJDN000020140716ea7g001dl\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 ZS Pharma\uc2  Files 8K - Regulation FD >ZSPH\b0\par\par\uc2 252 \uc2 words\par \uc2 14 July 2014\par 16:12\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 ZS Pharma Inc\uc2 . (ZSPH) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on July 14, 2014.\par \par \uc2 On July 14, 2014, \uc2 ZS Pharma, Inc\uc2 . issued a press release announcing that it has completed enrollment in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. A copy of the press release is furnished as Exhibit 99.1 hereto.\par \par \uc2 In accordance with General Instruction B.2 of Form 8-K, the press release is deemed to be "furnished" and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference into any filing under the Securities Act or the Securities Exchange Act of 1934, each as amended.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1459266/000119312514267722/d759098d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1459266/000119312514267722/d759098d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1459266/000119312514267722/0001193125-14-267722-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1459266/000119312514267722/0001193125-14-267722-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 14, 2014 16:12 ET (20:12 GMT)\par \par \uc2 Document DJDN000020140714ea7e0035p\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Kythera Biopharma Files 8K - Other Events >KYTH\b0\par\par\uc2 197 \uc2 words\par \uc2 11 July 2014\par 06:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Kythera Biopharmaceuticals Inc\uc2 . (KYTH) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 10, 2014.\par \par \uc2 On July 10, 2014, \uc2 KYTHERA Biopharmaceuticals, Inc\uc2 . issued a press release announcing that its New Drug Application for ATX-101 (deoxycholic acid) has been accepted for filing by the \uc2 U.S. Food and Drug Administration\uc2  with a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465914051069/a14-17032_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465914051069/a14-17032_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1436304/000110465914051069/0001104659-14-051069-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1436304/000110465914051069/0001104659-14-051069-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 11, 2014 06:01 ET (10:01 GMT)\par \par \uc2 Document DJDN000020140711ea7b0012z\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Regado Biosciences\uc2  Files 8K - Other Events >RGDO\b0\par\par\uc2 255 \uc2 words\par \uc2 10 July 2014\par 06:02\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Regado Biosciences Inc\uc2 . (RGDO) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 09, 2014.\par \par \uc2 On July 9, 2014, \uc2 Regado Biosciences, Inc\uc2 ., or the Company, issued a press release announcing, among other things, that further to the Company's previously announced decision to voluntarily pause enrollment in its Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI, the \uc2 United States Food and Drug Administration\uc2  informed the Company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the REGULATE-PCI trial. The foregoing summary of the press release does not purport to be complete and is qualified in its entirety by reference to the complete press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1311596/000119312514264453/d755202d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1311596/000119312514264453/d755202d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1311596/000119312514264453/0001193125-14-264453-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1311596/000119312514264453/0001193125-14-264453-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 10, 2014 06:02 ET (10:02 GMT)\par \par \uc2 Document DJDN000020140710ea7a001cf\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Par  \highlight22\uc2 Launches \highlight\uc2  Fluphenazine Decanoate Injection\b0\par\par\uc2 123 \uc2 words\par \uc2 9 July 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.   \par \par \uc2 Par Pharmaceuticals\uc2  announced that it has received final approval from the FDA for Fluphenazine Decanoate Injection.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/par-pharmaceutical-inc/manufacturer/11482/"}}{\fldrslt{\cf2 \uc2 Par Pharmaceuticals}}}\uc2  announced that it has received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for {\field{\*\fldinst{HYPERLINK "http://www.empr.com/fluphenazine-decanoate-inj/drug/3183/"}}{\fldrslt{\cf2 \uc2 Fluphenazine Decanoate Injection}}}\uc2 .\par \par \uc2 Fluphenazine Decanoate is an {\field{\*\fldinst{HYPERLINK "http://www.empr.com/psychiatric-disorders/section/3005/"}}{\fldrslt{\cf2 \uc2 antipsychotic}}}\uc2  indicated for the management of patients requiring prolonged parenteral neuroleptic therapy (eg, chronic {\field{\*\fldinst{HYPERLINK "http://www.empr.com/psychosis/category/16/0/"}}{\fldrslt{\cf2 \uc2 schizophrenia}}}\uc2 ). Fluphenazine is a piperazine phenothiazine that works by blocking postsynaptic mesolimbic dopaminergic receptors in the brain.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/skull-chip-implant-research-for-psych-disorders/article/348767/?DCMP=OTC-MPR_Related-Links"}}{\fldrslt{\cf2 \uc2 RELATED: Skull Chip Implant Research for Psych Disorders }}}\par \par \uc2 Fluphenazine Decanoate Injection is available as a 25mg/mL strength in 5mL multi-dose flip-top vials. Par has begun shipping the product.\par \par \uc2 For more information call (800) 828-9393 or visit {\field{\*\fldinst{HYPERLINK "http://www.parpharm.com/"}}{\fldrslt{\cf2 \uc2 ParPharm.com}}}\par \par \uc2 Document MPRMPR0020140710ea7900006\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 MONISTAT(R)  \highlight22\uc2 Announces New \highlight\uc2  Suite of Complete Care(TM) Products\b0\par\par\uc2 1,098 \uc2 words\par \uc2 9 July 2014\par 11:00\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par #1 Doctor-Recommended Yeast Infection Treatment Brand \f28 \b \highlight22\uc2 \f2 Introduces\f28 \b0 \highlight\uc2 \f2  Three New Innovative Products for Feminine Health \par  \f28 \par \par \uc2 \f2 TREVOSE, Pa., July 9, 2014 /PRNewswire/ -- MONISTAT(R), the #1 OTC doctor-recommended yeast infection treatment brand, today \f28 \b \highlight22\uc2 \f2 announced the launch\f28 \b0 \highlight\uc2 \f2  of a new suite of products offering women solutions to maintain their vaginal health. The new MONISTAT Complete Care(TM) products include the Vaginal Health Test, a one-step test that can determine if an infection is present; Probiotics plus Antioxidants, which contains the only probiotic strains that are clinically proven to help maintain both urinary tract and vaginal health; and Stay Fresh Feminine Freshness Gel, an easy-to-use, odor-neutralizing gel that lasts for up to three days. These \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  join the popular Chafing Relief Powder Gel(R) and Instant Itch Relief Cream, now under the Complete Care(TM) banner.\f28 \par \par \uc2 "While MONISTAT has been synonymous with yeast infection treatment for years, there is so much more to vaginal health that women both want and need to know about," said \uc2 Jennifer Moyer\uc2 , vice president of marketing for INSIGHT Pharmaceuticals, LLC, distributors of MONISTAT(R). "Our new Complete Care products give women the tools they need to be in greater control of their health in the comfort and privacy of their own home."\par \par \uc2 Though yeast infections are common in women and can be treated with an over-the-counter product like MONISTAT, many women suffer from other vaginal infections that may require attention from a physician. With the new MONISTAT Complete Care(TM) Vaginal Health Test, women can now determine if their infection is consistent with that of a yeast infection or if they should seek care from a healthcare professional. The simple swab, which is the same accurate test used by doctors, changes color in just seconds to indicate signs of abnormal vaginal pH, which can indicate an infection.\par \par \uc2 "Even in today's culture of oversharing, many women find it difficult to ask their doctors questions about their vaginal health," said Dr. Yvonne Bohn, OB/GYN and author. "Being informed about your own health is the most powerful tool you can have in making sure you receive the care you need. Putting a screening test in women's hands, that uses the same technology doctors use, is an empowering advancement for women and their vaginal health."\par \par \uc2 Moyer noted that many women have concerns over non-infection related vaginal issues. "Vaginal infections of any kind can make women feel uncomfortable, but research has shown that feminine odor is a huge source of insecurity," she said. "That's why we've introduced a new product that is unlike any other -- a feminine freshness gel that doesn't just mask, but actually neutralizes odor."\par \par \uc2 The MONISTAT Complete Care(TM) Stay Fresh Feminine Freshness Gel helps to eliminate feminine odor with a paraben-free, easy-to-use formula. As the only OTC product specifically designed to match healthy vaginal pH levels and relieve feminine odor, one application delivers results that last for up to three days. Additionally, the gel stays in place so it's not messy for women to use.\par \par \uc2 "I always tell my patients to stay away from douches and any scented vaginal products," said Dr. Bohn. "If it has a fragrance and it's supposed to make contact with the vagina, there's potential for a subsequent infection of some kind. Your vagina has a natural odor that is unique to you, and that's perfectly normal. Your normal scent -- whatever that may be -- comes with balanced pH levels in the vagina. And the new Stay Fresh Gel is specially formulated to maintain vaginal balance."\par \par \uc2 Also included in the new suite of products is MONISTAT Complete Care(TM) Probiotics plus Antioxidants, a proactive approach to vaginal health. The oral capsule, taken daily, contains the only probiotic strains clinically proven to help maintain both urinary and vaginal health. Paired with antioxidants (Vitamin A and Vitamin C) to support the immune system, the capsule contains lactobacillus reuteri and lactobacillus rhamnosus, which have shown to be effective in managing recurring urinary tract infections and recurring yeast infections.\par \par \uc2 "With most other probiotics, it is not clear how much benefit actually reaches the vaginal canal," Dr. Bohn continued. "With the probiotics in Complete Care Probiotics Plus Antioxidants, studies were done which showed that the probiotics reached the vaginal canal and helped maintain the normal vaginal balance."\par \par \uc2 The popular Chafing Relief Powder-Gel(R), which provides daily prevention from chafing and irritation by forming a silky, breathable barrier on skin; and the benzocaine-free Instant Itch Relief Cream, which provides long-lasting relief from intense itch by helping heal the skin instead of just numbing it, continue to offer the same great benefits, now under the Complete Care banner.\par \par \uc2 "We've been proud to offer women relief from everyday issues like vaginal itching, razor burn and chafing for years, and we're thrilled that we've been able to truly take the MONISTAT brand from cure to care with the introduction of our Complete Care line," said Moyer.\par \par \uc2 To learn more about the new MONISTAT Complete Care(TM) products, visit {\field{\*\fldinst{HYPERLINK "http://www.monistat.com"}}{\fldrslt{\cf2 \uc2 www.monistat.com}}}\uc2 .\par \par \uc2 About MONISTAT(R)\par \par \uc2 MONISTAT(R) Vaginal Antifungal products are the #1 doctor-recommended over-the-counter, antifungal yeast infection treatment that relieves symptoms and cures the infection. The Brand offers a portfolio of products, including 1-, 3- and 7-Day treatments, which are available in three forms -- ovule, cream and suppository -- and are designed to help women confidently address their vaginal health needs on their terms. And now MONISTAT(R) goes beyond curing yeast infections to complete feminine care with the Complete Care(TM) line of products. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.monistat.com"}}{\fldrslt{\cf2 \uc2 www.monistat.com}}}\uc2 .\par \par \uc2 The active ingredient in MONISTAT(R) is Miconazole Nitrate.\par \par \uc2 About \uc2 Insight Pharmaceuticals\uc2 :\par \par \uc2 INSIGHT Pharmaceuticals, LLC is a consumer products company whose strategy is to generate growth by acquiring brands with solid consumer equity that can be further developed through their merchandising and marketing expertise. The company strengthens its portfolio of brands by employing a variety of strategies, all with an in-depth understanding of the heritage of the brand and the needs of the consumer. Additional information about \uc2 Insight Pharmaceuticals\uc2  can be found at {\field{\*\fldinst{HYPERLINK "http://www.InsightPharma.com"}}{\fldrslt{\cf2 \uc2 www.InsightPharma.com}}}\uc2 .\par \par \uc2 \f2 \par  \par Media Contact:                      Company Contact: \par Kaitlin Bitting                     Cassie Hallberg \par allen & gerritsen                   INSIGHT Pharmaceuticals, LLC \par Vice President -- Public Relations  Brand Director, MONISTAT(R) \par KBitting@a-g.com                    challberg@insightpharma.com \par 856-986-4206                        267-852-0542 \par  \f28 \par \par \uc2 \f2 Photo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20140709/125451"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20140709/125451}}}\par \par \uc2 \f2 SOURCE MONISTAT\f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.monistat.com"}}{\fldrslt{\cf2 \uc2 http://www.monistat.com}}}\par \par \uc2 Document PRN0000020140709ea79000c9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Vital Therapies Files 8K - Other Events >VTL\b0\par\par\uc2 224 \uc2 words\par \uc2 9 July 2014\par 08:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Vital Therapies Inc\uc2 . (VTL) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 09, 2014.\par \par \uc2 On July 9, 2014, \uc2 Vital Therapies, Inc\uc2 . issued a press release providing an update on the status of its clinical trials of ELAD (R), a cell-based therapy targeting treatment of acute liver failure, and on advice received from the European Medical Agency through the Scientific Advice Working Party process. As a part of this update, \uc2 Vital Therapies, Inc\uc2 . reported enrollment of 123 subjects in its VTI-208 Phase 3 randomized, controlled clinical trial targeting 200 subjects with alcohol-induced liver decompensation, or AILD. A copy of this press release is attached hereto as Exhibit 99.1.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1280776/000119312514263703/d755985d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1280776/000119312514263703/d755985d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1280776/000119312514263703/0001193125-14-263703-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1280776/000119312514263703/0001193125-14-263703-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 09, 2014 08:31 ET (12:31 GMT)\par \par \uc2 Document DJDN000020140709ea79001n6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Acorda Therapeutics\uc2  Files 8K - Other Events >ACOR\b0\par\par\uc2 258 \uc2 words\par \uc2 9 July 2014\par 06:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Acorda Therapeutics Inc\uc2 . (ACOR) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on July 09, 2014.\par \par \uc2 Acorda Therapeutics, Inc\uc2 . ("Acorda") expects to initiate a Phase 3 clinical trial by the end of this year studying the use of dalfampridine administered twice daily (BID) to improve walking in people who have experienced a stroke. Acorda has been exploring a once-daily (QD) formulation of dalfampridine for use in the post-stroke clinical program. Based on the results of an in-vitro alcohol dose dumping study and a subsequent fed-fasted study, Acorda has determined that the current QD formulation is not practical for further testing. Acorda is working with external partners to develop a new QD formulation that could be included in future post-stroke clinical trials.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1008848/000100884814000039/report_stroke-070914.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1008848/000100884814000039/report_stroke-070914.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1008848/000100884814000039/0001008848-14-000039-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1008848/000100884814000039/0001008848-14-000039-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Acorda Therapeutics, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US00484M1062"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US00484M1062}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 09, 2014 06:04 ET (10:04 GMT)\par \par \uc2 Document DJDN000020140709ea7900101\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Micardis\b0\par\par\uc2 144 \uc2 words\par \uc2 8 July 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Telmisartan Tablets, the generic version of \uc2 Boehringer Ingelheim\uc2 's Micardis.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-inc/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced it has received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Telmisartan Tablets, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/boehringer-ingelheim-pharmaceuticals/manufacturer/11318/"}}{\fldrslt{\cf2 \uc2 Boehringer Ingelheim's}}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/micardis-hct/drug/4076/"}}{\fldrslt{\cf2 \uc2 Micardis}}}\uc2 .\par \par \uc2 Telmisartan is an angiotensin II receptor blocker indicated for the treatment of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/hypertension/category/6/0/"}}{\fldrslt{\cf2 \uc2 hypertension}}}\uc2 , to decrease blood pressure, and {\field{\*\fldinst{HYPERLINK "http://www.empr.com/cardiovascular-disease/section/1944/"}}{\fldrslt{\cf2 \uc2 cardiovascular risk}}}\uc2  reduction in patients \u8805\'22\'6555 years of age who are unable to take ACE inhibitors. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/hypertension-treatments-arbs/article/221238/?DCMP=OTC-MPR_Related-Links"}}{\fldrslt{\cf2 \uc2 RELATED: Hypertension Treatments: ARBs}}}\par \par \uc2 Telmisartan Tablets are available in 20mg, 40mg, and 80mg strengths.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020140709ea7800009\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  Telmisartan Tablets\b0\par\par\uc2 88 \uc2 words\par \uc2 8 July 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of \uc2 Boehringer Ingelheim\uc2 's Micardis Tablets. Mylan received final approval from the FDA for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application, or ANDA, for this product, which is indicated for the treatment of hypertension, to lower blood pressure. Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales of approximately $259.2M for the 12 months ending March 31 according to \uc2 IMS Health\uc2 . \par \par \uc2 Document FLYWAL0020140708ea78001mo\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Micardis(R) Tablets\b0\par\par\uc2 337 \uc2 words\par \uc2 8 July 2014\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, July 8, 2014 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) today announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of \uc2 Boehringer Ingelheim\uc2 's Micardis(R) Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.\par \par \uc2 Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, had U.S. sales of approximately $259.2 million for the 12 months ending March 31, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 305 ANDAs pending FDA approval representing $107.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020140708ea780003m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 BRAZIL INTERACTIVE MEDIA\uc2  FILES CURRENT REPORT\b0\par\par\uc2 485 \uc2 words\par \uc2 2 July 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, July 2 -- \uc2 Brazil Interactive Media Inc\uc2 ., Denver, files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on July 1.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Item 1.01 Entry Into a Material Definitive Agreement On June 27, 2014, \uc2 Brazil Interactive Media, Inc\uc2 ., through its Hollister & Blacksmith (d/b/a American Cannabis Company) division (the "Company"), entered into an Exclusive Marketing and Sales Agreement (the "Marketing Agreement") with Kush Bottles, Inc./DANK Bottles, LLC ("Kush"). The Marketing Agreement provides for the sale and distribution of the Company's The Satchel, a child-resistant bag for use by dispensaries as an industry-approved exit package of cannabis-based products, through the Company's diversified, multi-product distribution division, The Trade Winds. Pursuant to the Marketing Agreement, the Company will ship and bill for 500,000 units of The Satchel, in two increments of 170,000 units and a third and final order of 160,000 units, through December 2014. The Marketing Agreement further provides that Kush will be the Company's exclusive seller of The Satchel, subject to the shipment, billing and delivery of a combined total of 500,000 units of The Satchel to the Company's customers in a 12 month period. Kush's continuing right to exclusivity is subject to its ordering 500,000 units of The Satchel during each subsequent 12 month period. In addition, Kush may option to renew the Marketing Agreement each year for up to ten years, with such option consisting of an order of 170,000 units of The Satchel. The foregoing summary of the Marketing Agreement and the transactions contemplated thereby do not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Marketing Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference. Item 8.01 Other Events On June 30, 2014, the Company issued a press release tilted, "American Cannabis Company Secures 500,000 Unit Order for Its Recently Launched Product, The Satchel". A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 10.1 - Exclusive Marketing and Sales Agreement, dated June 27, 2014, by and between Hollister & Blacksmith Inc. and Kush Bottles, Inc. /DANK Bottles, LLC. ({\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148kex101.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148kex101.htm}}}\uc2 ) 99.1 - Press Release tilted "American Cannabis Company Secures 500,000 Unit Order for Its Recently Launched Product, The Satchel", dated June 30, 2014. ({\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148kex991.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148kex991.htm}}}\uc2 )\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/945617/000072174814000644/bimi0701148k.htm}}}\par \par \uc2 Document INDFED0020140702ea72000dn\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Flamel Technologies\uc2  announces FDA approval of Vazculep\b0\par\par\uc2 114 \uc2 words\par \uc2 30 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Flamel Technologies\uc2  announced that the FDA has approved the company's \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application, or NDA, for Vazculep. Vazculep Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Flamel expects to \b \highlight22\uc2 launch\b0 \highlight\uc2  Vazculep in the next few months in 1 mL single use vials, and 5 mL and 10 mL pharmacy bulk package vials. The drug strength is the same in all vials at 10 mg/mL. Phenylephrine hydrochloride is used in operating rooms and is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. \par \par \uc2 Document FLYWAL0020140630ea6u001p8\par }\page {\par\fs20\b \uc2 GI Laboratories to  \highlight22\uc2 launch \highlight\uc2  diclofenac sodium topical solution 1.5% product on 28 March 2015 upon settlement with Mallickrodt\b0\par\par\uc2 143 \uc2 words\par \uc2 27 June 2014\par \uc2 FinancialWire\par \uc2 FNWIR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 FinancialWire. All rights reserved.   \par \par \uc2 Pharmaceutical company \uc2 IGI Laboratories\uc2  (\uc2 NYSE\uc2  MKT: IG) on Thursday reported an agreement to settle a declaratory judgment action concerning its filing of an abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  application (ANDA) with the \uc2 US Food and Drug Administration\uc2  (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w.\par \par \uc2 The company has signed the agreement with \uc2 Mallinckrodt LLC\uc2 , \uc2 Mallinckrodt Inc\uc2  and \uc2 Nuvo Research Inc\uc2  (NRI.TO) (together Mallickrodt).\par \par \uc2 As part of this agreement, \uc2 Mallinckrodt\uc2  granted \uc2 IGI\uc2  a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on 28 March 2015.\par \par \uc2 IGI\uc2  received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on 7 May 2014.\par \par \uc2 ((Distributed by M2 Communications {\field{\*\fldinst{HYPERLINK "http://www.m2.com"}}{\fldrslt{\cf2 \uc2 www.m2.com}}}\uc2 ))\par \par \uc2 Document FNWIR00020140627ea6r000rt\par }\page {\par\fs20\uc2 A\par \b \uc2 Targacept \highlight22\uc2 launches \highlight\uc2  study for  \highlight22\uc2 new drug \highlight\b0\par\par\uc2 RICHARD CRAVER; JOURNAL REPORTER \par \uc2 657 \uc2 words\par \uc2 26 June 2014\par \uc2 Winston-Salem Journal\par \uc2 XWSJ\par \uc2 DAILY\par 11\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Piedmont Publishing Company, Inc. All Rights Reserved. \par \par \uc2 Targacept Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  an exploratory study for a drug compound as a potential treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. The Winston-Salem biopharmaceutical company said May 7 it was entering the health care sector with the TC-6499 drug compound. \uc2 Targacept\uc2  develops drug compounds based on the use of nicotinic receptors to treat diseases, with a primary focus on the central nervous system. It has served as an anchor of the Triad\u8217\'20\'19s biotechnology sector for several years. According to the \uc2 American Diabetes Association\uc2 , gastroparesis is a disorder affecting people with Type 1 and Type 2 diabetes in which the stomach takes too long to empty its contents. It affects an estimated 5 percent to 12 percent of patients with diabetes.\par \par \uc2  The goal with the drug compound is to modulate the activity of the alpha3beta4 and other neuronal nicotinic receptors, which are in the gastrointestinal tract.\par \par \uc2 The company said the study will involve at least 18 U.S. patients. \u8220\'20\'1CCurrent treatments for gastroparesis are inadequate and range from dietary changes to drugs with side effects that limit long-term use,\u8221\'20\'1D Dr. Kenneth Koch, chief of gastroenterology at \uc2 Wake Forest University\uc2  Baptist Medical Center, said in a statement. \u8220\'20\'1CThese approaches provide either incomplete relief, have a negative impact on quality of life, or both. Patients and treating physicians would welcome a safe and effective oral drug with effects targeted at nicotinic receptors located in the gut.\u8221\'20\'1D \uc2 Targacept\uc2  said it has evidence from previous clinical trials that TC-6499 may increase gastric motility. Motility is a term used to describe the contraction of the muscles that mix and propel contents in the gastrointestinal tract. In a Phase 2a clinical trial involving 24 subjects, TC-6499 outperformed placebo on an objective secondary efficacy outcome measure \u8212\'20\'14 the number of spontaneous bowel movements per week \u8212\'20\'14 but not on the primary efficacy outcome measure of global symptom relief. \u8220\'20\'1CThis clinical study will, at relatively modest cost, allow us to determine whether the early clinical data on TC-6499 is predictive of a meaningful improvement in gastric motility for subjects with diabetic gastroparesis, and thus warrant further development of TC-6499 in this therapeutic area,\u8221\'20\'1D \uc2 Dr. Stephen Hill\uc2 , \uc2 Targacept\uc2 \u8217\'20\'19s president and chief executive, said in a statement, \u8220\'20\'1CWe view this as an important step in building a sustainable company focused on improving patients\u8217\'20\'19 lives.\u8221\'20\'1D The study patients will receive one of four treatments \u8212\'20\'14 2, 5 or 10 milligrams of TC-6499 or a placebo \u8212\'20\'14 in a randomized, crossover manner on each of four treatment visits, with each dosing period separated by seven days. \uc2 Targacept\uc2  has struggled financially since its most promising compound TC-5214, touted by analysts as a potential billiondollar drug discovery, failed in Phase 3 clinical trials in 2011 and 2012 to do better than a placebo for major depressive disorder. \uc2 Targacept\uc2 \u8217\'20\'19s downsizing steps over the past 2\u189\'00\'BD years include: the resignation of Don deBethizy, its chief executive; the reduction of its workforce by 91 employees, or 64 percent, to 43 employees; moving its headquarters from \uc2 Wake Forest\uc2  Innovation Quarter to another downtown facility; closing its laboratory; and a sharp drop in its share price. Alan Carr, an analyst with \uc2 Needham & Co\uc2 ., has said he expects \uc2 Targacept\uc2 \u8217\'20\'19s share price to remain stable until it begins to receive results from its remaining clinical trials. The share price has ranged between $3.52 and $6.11 over the past 52 weeks. It closed Wednesday down 6 cents to $4.21. Analysts and investors pay more attention to \uc2 Targacept\uc2 \u8217\'20\'19s clinical-trial updates for guidance on how the company is performing. Hill said in May the company expects results by mid-year of two pivotal Phase 2b clinical trials: TC-5214 compound for treatment of overactive bladders; and TC-1734 for Alzheimer\u8217\'20\'19s disease. \par \par \uc2 Document XWSJ000020140629ea6q00013\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mallinckrodt\uc2  grants IGI Labs non-exclusive license to  \highlight22\uc2 launch \highlight\uc2  generic PENNSAID\b0\par\par\uc2 174 \uc2 words\par \uc2 26 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 IGI Laboratories\uc2  (IG) announced that it has entered into an agreement with \uc2 Mallinckrodt\uc2  (MNK) and \uc2 Nuvo Research\uc2  to settle a declaratory judgment action brought by \uc2 IGI\uc2 , concerning \uc2 IGI\uc2 's filing of an abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  application with the FDA seeking approval to market a generic version of PENNSAID 1.5% w/w. Under the terms of this agreement, \uc2 Mallinckrodt\uc2  granted \uc2 IGI\uc2  a non-exclusive license to \b \highlight22\uc2 launch\b0 \highlight\uc2  its diclofenac sodium topical solution 1.5% product on March 28, 2015. \uc2 IGI\uc2  received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7. IGI CEO \uc2 Jason Grenfell-Gardner\uc2  said, "The agreement provides \uc2 IGI\uc2  with a date certain \b \highlight22\uc2 launch\b0 \highlight\uc2  of diclofenac sodium topical solution 1.5%. We remain confident in our ability to obtain final FDA approval of our ANDA for diclofenac sodium topical solution 1.5% prior to our agreed upon \b \highlight22\uc2 launch\b0 \highlight\uc2  date. The agreement allows \uc2 IGI\uc2  to continue to expand its portfolio of generic topical prescription drug products."\par \par \uc2 Document FLYWAL0020140626ea6q0025x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Senesco Presents Company Update at 2014 BIO International Convention\b0\par\par\uc2 1,105 \uc2 words\par \uc2 25 June 2014\par 14:05\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par BRIDGEWATER, N.J.--(BUSINESS WIRE)--June 25, 2014-- \f28 \par \par \uc2 \f2 Senesco Technologies, Inc\f28 \uc2 \f2 . ("Senesco" or the "Company") (OTCQB:SNTI) provided an overview of the company's current research and development status at the 2014 BIO International Convention in San Diego. Acting CEO, \f28 \uc2 \f2 Vaughn V. Smider, M.D\f28 \uc2 \f2 ., Ph.D., presented the update, including the announcement of the completion of the administrative and financial integration of Fabrus with Senesco. The presentation will also be released in an 8-K filing and can be accessed via the company's website.\f28 \par \par \uc2 "The rapid integration of the Company's activities is an example of how efficiently the two teams operate," said Dr. Smider. "The management team members are highly complementary to one another and worked diligently to ensure a seamless continuation of our activities during the transition."\par \par \uc2 Integrated Company Research Overview\par \par \uc2 Fabrus and Senesco have recently combined to create a biologics company with multiple novel drug candidates as well as the underlying enabling technologies able to generate a sustainable pipeline of first and best-in-class experimental therapeutics. The company is using its proprietary technology and breadth of expertise in antibody therapeutics to generate drug candidates targeting difficult target classes like multispanning transmembrane receptors. In this vein, its cow antibody platform with ultralong CDR3's has been engineered to recognize and modulate ion channels involved in several therapeutic areas. The company's lead candidate (FB001) targets the Kv1.3 potassium ion channel, which has been strongly implicated in T-cell activation in patients suffering from multiple autoimmune diseases. The Company has shown robust activity of FB001 in multiple human T-cell activity assays. A second antibody (FB002) modulates a unique pathway of angiogenesis thought to be utilized in the progression of several solid tumors including renal cell carcinoma. Phase 1 trials for both candidates are expected to begin in 18-24 months.\par \par \uc2 The company's antibody discovery technology is similar to a product engine and identifies lead molecules directly on the cell surface, obviating the need for target antigen purification. Spatially addressed antibody libraries can be screened in high-throughput directly on cells to identify lead molecules against multipass transmembrane proteins like GPCRs and ion channels. This technology, coupled with the unique cow antibody scaffold recently published in Cell, provides an integrated suite of antibody capabilities that address important unmet needs in targeting important disease antigens.\par \par \uc2 The Company's chimerasome nanocage (acquired through the Fabrus combination) has been validated in preclinical models as a particle to deliver nucleic acids and other payloads. This technology is synergistic with both the antibody platform and eIF5A modulation technology, and plans to integrate these technologies are underway. The Company plans to update on new therapeutic candidate and technology development timelines as the integration proceeds.\par \par \uc2 Clinical Development Update\par \par \uc2 The clinical evaluation of SNS01-T has proceeded well. Top-line results are delayed due to slow patient enrollment despite the recent addition of two sites in the Republic of South Africa. In cohort 4 (0.375 mg/kg dose level) three of the required six patients are evaluable and three additional evaluable patients are needed to complete the Phase 1b/2a study. The study is expected to be completed in the second half of 2014.\par \par \uc2 Future Plans\par \par \uc2 The overall goal of the newly combined company is to become a preeminent player in advanced biologics drugs and technologies, including antibody and nanoparticle therapeutics. A detailed development strategy will be announced in early Q3 2014. The Company plans to seek a listing on a major exchange as soon as it meets and can maintain listing requirements.\par \par \uc2 About \uc2 Senesco Technologies, Inc\uc2 .\par \par \uc2 Senesco Technologies\uc2  is a clinical-stage biotech company specializing in cancer therapeutics and immunological diseases driven by a unique combination of gene regulation and antibody therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and protect healthy cells from premature death. The antibody approach is a novel discovery paradigm with the proven capability to identify functional therapeutic monoclonal antibodies against challenging cell surface targets that previously have been highly resistant to therapeutic antibody discovery. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's B-cell lymphomas. The Company has several antibodies in its preclinical pipeline. The first to move forward is a potentially first/best in class candidate antibody that targets an ion channel important in autoimmunity and inflammation. For more information, please visit Senesco.com or connect with us on \uc2 Facebook\uc2 , \uc2 Twitter\uc2 , LinkedIn and Google+.\par \par \uc2 Forward-Looking Statements\par \par \uc2 Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to integrate the Fabrus science and operations; the Company's ability to continue as a going concern; the Company's ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company's gene and antibody technology; the approval of the Company's patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company's common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company's periodic filings with the \uc2 Securities and Exchange Commission\uc2  (the "\uc2 SEC\uc2 "). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\par \par \uc2 Document BWR0000020140625ea6p000co\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Opko Health Files 8K - Regulation FD >OPK\b0\par\par\uc2 472 \uc2 words\par \uc2 24 June 2014\par 11:39\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Opko Health Inc\uc2 . (OPK) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 23, 2014.\par \par \uc2 On June 23, 2014, \uc2 OPKO Health, Inc\uc2 . (the "Company") presented the information in the presentation posters attached hereto as Exhibits 99.1 and 99.2 at the 16th International Congress of Endocrinology and \uc2 The Endocrine Society\uc2 's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago and discussed 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product (Lagova ) to treat pediatric growth hormone deficiency disorder (GHD). The Company also announced positive interim six-month Lagova data from its Phase 2 dose-finding study in a press release issued on June 23, 2014. A copy of the press release regarding this announcement is attached as Exhibit 99.3 hereto and is incorporated herein by reference.\par \par \uc2 In addition, on June 24, 2014, the Company held a conference call and slide presentation webcast to review the data. A copy of the webcast slide presentation is furnished as Exhibit 99.4.\par \par \uc2 Statements made in the posters and presentations which are not historical are forward-looking statements that reflect management's current views with respect to future events and performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Such statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The fact that these materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.\par \par \uc2 The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibits 99.1, 99.2, 99.3 and 99.4 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act, unless expressly stated otherwise.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/944809/000119312514246675/d748462d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/944809/000119312514246675/d748462d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/944809/000119312514246675/0001193125-14-246675-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/944809/000119312514246675/0001193125-14-246675-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 OPKO Health, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US68375N1037"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US68375N1037}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 24, 2014 11:39 ET (15:39 GMT)\par \par \uc2 Document DJDN000020140624ea6o002fc\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Rockwell Medical\uc2  receives FDA approval for Calcitriol\b0\par\par\uc2 74 \uc2 words\par \uc2 23 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Rockwell Medical\uc2  announced that the FDA has approved the company's Supplemental Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application to manufacture Calcitriol. Calcitriol is Rockwell's low-cost generic active vitamin D drug. The company said, "We believe Rockwell is uniquely positioned to generate dynamic sales growth by offering the dialysis market the original, low-cost generic vitamin D injection in vials. We are targeting commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  for year end."\par \par \uc2 Document FLYWAL0020140623ea6n00241\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Cellular Biomedicine Files 8K - Regulation FD >CBMG\b0\par\par\uc2 214 \uc2 words\par \uc2 23 June 2014\par 14:14\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Cellular Biomedicine Group Inc\uc2 . (CBMG) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 18, 2014.\par \par \uc2 On June 19, 2014, the Company issued a press release announcing the six-month data for its Phase I/IIa clinical trial of its Rejoin(tm) human adipose-derived mesenchymal precursor cell therapy for Knee Osteoarthritis. A copy of the press release is attached hereto as Exhibit 99.1.\par \par \uc2 On June 20, 2014, the Company issued a press release announcing the completion of the Financing discussed in Item 3.02 above. A copy of the press release is attached hereto as Exhibit 99.2.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1378624/000135448814003397/cbmg_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1378624/000135448814003397/cbmg_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1378624/000135448814003397/0001354488-14-003397-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1378624/000135448814003397/0001354488-14-003397-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 23, 2014 14:14 ET (18:14 GMT)\par \par \uc2 Document DJDN000020140623ea6n002kv\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 NewLink Genetics\uc2  Files 8K - Entry Into Definitive Agreement >NLNK\b0\par\par\uc2 645 \uc2 words\par \uc2 23 June 2014\par 12:26\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 NewLink Genetics Corp\uc2 . (NLNK) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on June 23, 2014.\par \par \uc2 On June 19, 2014, \uc2 NewLink Genetics Corporation\uc2  (the "Company") entered into a Development and Manufacturing Terms and Conditions (the "Agreement") with \uc2 WuXi AppTec, Inc\uc2 . ("\uc2 WuXi AppTec\uc2 "), pursuant to which the Company may submit to \uc2 WuXi AppTec\uc2  work orders for manufacturing or related services ("Services") to be performed by \uc2 WuXi AppTec\uc2  under the Agreement upon mutual agreement and execution of each such work order. Also on June 19, 2014, the Company and \uc2 WuXi AppTec\uc2  entered into a Development and Process Transfer Program Leading to Commercial Manufacturing for algenpantucel-L HyperAcute Pancreas (the "First Work Order").\par \par \uc2 Under the terms of the Agreement, \uc2 WuXi AppTec\uc2  must process the cell bank supplied by the Company and other starting materials into product ("Product") in accordance with the product specifications set forth in the applicable work order or otherwise agreed by the parties ("Product Specifications") and must package, label and deliver the Product. Under the Agreement, the Company grants \uc2 WuXi AppTec\uc2  a non-exclusive right to use the cell bank, any other starting materials and the Company's confidential information, solely for the purpose of performing the Services for the Company. The Company may reject any delivered Product that fails to meet Product Specifications. The Agreement will expire on the later of (a) June 19, 2016 or (b) the completion of all Services under the last work order executed by the parties prior to June 19, 2016. The Company may terminate the Agreement or any work order for any reason upon two months' notice, and each party may terminate the Agreement upon the occurrence of certain events. In the event of any dispute under the Agreement that the parties fail to resolve, either party may submit the dispute to binding arbitration. The Agreement also provides for certain indemnification obligations and insurance requirements of both parties.\par \par \uc2 Under the terms of the First Work Order, the Company will provide the cell bank, documents and information necessary to manufacture Product, and \uc2 WuXi AppTec\uc2  will adapt facilities and equipment for production, generate batch records and other documents, perform studies and test manufacturing runs and conduct process validation and characterization. Costs to the Company for Services provided by \uc2 WuXi AppTec\uc2  under the First Work Order will be based on a combination of labor and raw materials costs, and portions of such costs will be payable at signing and upon \uc2 WuXi AppTec\uc2 's initiation or completion of various components of the Services set forth in the First Work Order. The First Work Order expires on December 31, 2015.\par \par \uc2 The foregoing description of the Agreement and the First Work Order is not complete and is qualified in its entirety by reference to the full text of such agreements, copies of which will be filed with the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2014, portions of which will be subject to a FOIA Confidential Treatment Request to the \uc2 Securities and Exchange Commission\uc2  pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted material will be included in the request for confidential treatment.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623414000130/nlnk-20140623x8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623414000130/nlnk-20140623x8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1126234/000112623414000130/0001126234-14-000130-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1126234/000112623414000130/0001126234-14-000130-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 23, 2014 12:26 ET (16:26 GMT)\par \par \uc2 Document DJDN000020140623ea6n002hi\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Versartis\uc2  Files 8K - Other Events >VSAR\b0\par\par\uc2 199 \uc2 words\par \uc2 23 June 2014\par 12:24\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Versartis Inc\uc2 . (VSAR) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 23, 2014.\par \par \uc2 On June 23, 2014, the Company announced positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of na ve, pre-pubertal children with growth hormone deficiency (GHD). A copy of the press release regarding this announcement, titled "\uc2 Versartis\uc2  Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results" is attached as Exhibit 99.2 hereto and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1513818/000119312514244874/d743904d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1513818/000119312514244874/d743904d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1513818/000119312514244874/0001193125-14-244874-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1513818/000119312514244874/0001193125-14-244874-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 23, 2014 12:24 ET (16:24 GMT)\par \par \uc2 Document DJDN000020140623ea6n002c9\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Paraplatin(R) Injection\b0\par\par\uc2 418 \uc2 words\par \uc2 23 June 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 123\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com    \par \par \uc2 2014 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of \uc2 Bristol-Myers Squibb\uc2 's Paraplatin((R)) Injection. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. Mylan also received final approval for Carboplatin Injection, 150 mg/15 ml, 450 mg/45 ml, 600 mg/60 ml, in multi-dose vials, and intends to \b \highlight22\uc2 launch\b0 \highlight\uc2  these presentations subsequently.\par \par \uc2 Carboplatin Injection, 50 mg/5 ml, 150 mg/15 ml, 450 mg/45 ml, and 600 mg/60 ml had U.S. sales of approximately $30.4 million for the 12 months ending March 31, 2014, according to \uc2 IMS Health\uc2 . This launch bolsters Mylan's growing portfolio of cancer treatment and supportive care products.\par \par \uc2 Currently, Mylan has 299 ANDAs pending FDA approval representing $105.2 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Mylan Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020140620ea6n0002r\par }\page {\par\fs20\b \uc2 Breckenridge; Breckenridge Announces Approval for Duloxetine Delayed-release Capsules\b0\par\par\uc2 155 \uc2 words\par \uc2 23 June 2014\par \uc2 Pharma Business Week\par \uc2 PHBW\par 28\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Pharma Business Week via NewsRx.com    \par \par \uc2 2014 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma \uc2 Business Week\uc2  -- \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announced the immediate \b \highlight22\uc2 launch\b0 \highlight\uc2  of Duloxetine Delayed-release Capsules. The \uc2 U.S. Food and Drug Administration\uc2  granted final approval for the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA), which is being manufactured and supplied by its parent company, \uc2 Laboratorios Dr. Esteve, S.A\uc2 . Barcelona, Spain, and will be available in 20mg, 30mg and 60mg strengths. Duloxetine Delayed-release Capsules are AB rated to Cymbalta(R), a drug marketed by \uc2 Eli Lilly\uc2 , for the treatment of (MDD) Major Depressive Disorder. This milestone signifies the first vertically-integrated product developed and commercialized between Breckenridge and Esteve.\par \par \uc2 (The API is sourced from \uc2 Esteve Quimica\uc2 , Esteve's API division.)\par \par \uc2 Keywords for this news article include: Breckenridge.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document PHBW000020140620ea6n00004\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw237\pich40\picscaley100\picscalex100\picwgoal3555\pichgoal600
47
4946383961ED002800F7000095A4CED1D8EA677EB88598C64964AAF0F2F8B3BEDCC2CBE33957A32A4A9CE1E5F1A4B1D5768BBF5871B1F2F4F9F9FAFCFAFBFDEA
EDF5E9ECF5F3F5FAFDFDFEDDE2EFFBFBFDF1F3F8F5F7FAFCFDFEA5B2D5E6E9F3F4F6FAE7EAF4E2E6F2FEFEFFF8F9FCF6F7FBD2D9EAECEFF6F7F8FBE6EAF38597
C6C1CAE2D9DFEECCD3E7DADFEEDEE3F0F3F5F9D3D9EAC9D1E6CFD6E9C3CCE3EFF1F86077B5CED5E8EEF0F7EEF1F7E8EBF4FBFCFDFDFEFEDAE0EEC0C9E2D4DAEB
FCFCFDA9B6D85F76B5B7C2DEB0BCDBCDD4E7D4D9EA9CAAD1F6F7FA697FB9697FB85E75B5D0D6E9C6CEE4C5CDE4E3E7F2D4DAEAD9DFEDBCC6E0BEC8E1BFC8E162
79B7FAFAFDC6CEE5677EB9EFF1F7E4E8F2D1D7E9A0AED3ACB8D9EDEFF6B7C1DDCBD3E78597C7B1BCDBB5C0DDE5E8F29BAAD0788CC08C9DC9DFE4F0FEFEFED3DA
EBD8DEEDAAB7D86F84BDE2E7F2E3E7F1E0E5F19BA9D0FAFAFCA6B3D5D9DEECF3F4F9B6C1DDBAC4DF657BB79AA9D0EBEEF68394C5BEC7E1E0E4F092A1CCC8D0E5
D7DDED8496C6DEE3EF97A7CF4F69AEA6B3D6CAD2E6B2BDDB7387BEC4CCE3C5CEE4DBE1EF1B3D95FFFFFF00000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000ED0028000008FF0013091C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2434418336ADC88
9180018B20438A1C49B2A4C98B1C536EFC78B2A5CB97306356544913A300993873EADC4932E381850508606CC0B3A8D1A34805FA6408002302824D392E10B840
E5D4444237264834206500810D38DE14D875E3538109080CCCBA516DA20088880E2C8068ECC0A6080A10EC0AA0A101AF6401C3E5C820D10144670722C89B4800
22BD5839BAFDCBB12F578E891B2E5D18357353968914D415E8F8EB40B885239BDE8BC87241D103A0BA46E056A0810190D30A846B973422056F3B024F44B77701
048E630FE4DB90C1E3D3034C33370857B940045B2FBB6E7AD5B15EDE0485EAFFFDDB9B206D82B7216BC6F893B353A888408B1E5B9A2078D506A7BF4E993A1102
C903E9165C79F5C115560253154710030914D0D56AFA29E49C56C345781A22D6F9979D867A15206063CFDD67DB40E421F45F5B106DA65067F049E5DB6A030AC4
1622106A541B581C6D58D646A60928E28BC10110C07F0C28B85B6BC49D17986B0A51B691653B2272E3601BF557A273AB7917E35D2C3989917A977104E3422A22
14D450F07DE4587F20C2789F50636A77500002C0A8A5834C7E86965B3FB6192471610965D78C18418924531956B7E49C1826D254036082D854865AFE285E2225
1A84679A0FD544536F7A82281788FCC948637E871654558E02890658223ED2FF041C5CAE953556533012C0988526A6642893172AD71401C309E421626056AAD2
78A319E4AA989D7A9A12688EC63790630D7CB52A47EDC1892A471F9D59E5B500EEB9564A72D18A5E02372990C0A8B68D1625461B161495460954386D70D6E175
95404D01AB6564E3629A92728EA118ADB41979945444197C9088044008B447060F67ACB152EC6D5C9206122412410F89E0B0000F1EA76C54992A5784C6082304
92C8066D2472430D5B60DCF2CE2FB1CC734312D49188204D2472081B6468108708737C81C1CF509BE473D409451046222FB4F080098984B0C1CC1780E042000A
A040F5D9144D8D76412CA49008160E20F4801A0E4C40C2DA78A384487B7917FF5404173688914810712B9482191D4CD0F7E206A98DF7090E5050881B0E718001
058C67AE794249B04088160505302122091499881D397420C5E6AC6F1EC11128DB5B97690B1090C04F17385078EBBCAFDD0715893CA082EC7C0FC440612358D0
FBF2689F8144224CF840908719326FFDE255C84044417F157BD061FF56BBD15487695458F919C15BED704D01179646E15F2F7F225618B13BC0F57E8F48F8CE11
846455C359405FC057908C28A07D00FB4D221A901804006B7ECC03041C1271872140257F0621A0F110E1BF016E8428E8CBCC5D14B8BE058E0F82F34B43051261
0830A0E73909D1A040FA3790FFB986014F91A14110584206A2F0870389C209ED0AE2A10712047D85BA5746A6A2C4B818E683DC330B58440844F979A10230F000
7C8A37C3D4604079550CA34E0661B637CC40760208A0ED0E70831C948003628CA34CBAE0841AF8E17B09239DE91211031AC0518E807C8910E85086315C80210F
A8800226F080403AF22410800005B20001857CC0011798C0D31EC94992FC410E8930010D9E3005835040793B78410942D6C9568224040FC0811220B0060F64C0
051D48041F1261831F8820046074A5304182871D2442061158420B40A003155452042B88C030A75911287C250F2B488406B4A883195C819AE004C907F4008244
C0608524884138D7C9CEA80504003B}}
\par\par \b \uc2 Breckenridge to  \highlight22\uc2 Introduce \highlight\uc2  Duloxetine Delayed-release Capsules\b0\par\par\uc2 137 \uc2 words\par \uc2 21 June 2014\par \uc2 Professional Services Close-Up\par \uc2 PSVCLU\par \uc2 English\par \uc2 (c) 2014. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announced the immediate \b \highlight22\uc2 launch\b0 \highlight\uc2  of Duloxetine Delayed-release Capsules.\par \par \uc2 In a release, the Company noted the \uc2 U.S. Food and Drug Administration\uc2  granted final approval for the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application, which is being manufactured and supplied by its parent company, \uc2 Laboratorios Dr. Esteve, S.A\uc2 . Barcelona, Spain, and will be available in 20mg, 30mg and 60mg strengths. Duloxetine Delayed-release Capsules are AB rated to Cymbalta, a drug marketed by \uc2 Eli Lilly\uc2 , for the treatment of Major Depressive Disorder.\par \par \uc2 This milestone signifies the first vertically-integrated product developed and commercialized between Breckenridge and Esteve. (The API is sourced from \uc2 Esteve Quimica\uc2 , Esteve's API division.)\par \par \uc2 Breckenridge is a pharmaceutical marketing, research and development company.\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document PSVCLU0020140621ea6l0001f\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 NephroGenex\uc2  Files 8K - Other Events >NRX\b0\par\par\uc2 919 \uc2 words\par \uc2 20 June 2014\par 16:33\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 NephroGenex Inc\uc2 . (NRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 18, 2014.\par \par \uc2 On June 18, 2014, \uc2 NephroGenex, Inc\uc2 . (the "Company") issued a press release announcing the initiation of patient enrollment in the first of two Phase 3 clinical trials in the Company's PIONEER program for oral PyridorinTM. In addition, on June 18, 2014, the Company announced a conference call to be held on June 19, 2014 to provide an overview of the Company's PIONEER clinical program. The press release announcing the initiation of patient enrollment and the conference call is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. A copy of the transcript of the conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.\par \par \uc2 In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 8.01, the press release attached to this report as Exhibit 99.1 and the transcript attached to this report as Exhibit 99.2 are "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.\par \par \uc2 The press release attached hereto as Exhibit 99.1 and the transcript attached hereto as Exhibit 99.2 contain certain statements that may be deemed to be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout the presentation and include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned discovery and development of drugs targeting kidney diseases, the strength and breadth of the Company's intellectual property, the Company's ongoing and planned preclinical studies and clinical trials, the timing of and the Company's ability to make regulatory filings and obtain and maintain regulatory approvals for the Company's product candidates, the degree of clinical utility of the Company's products, particularly in specific patient populations, expectations regarding clinical trial data, the Company's results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that the Company will be able to continue to fund operating expenses and capital expenditures, the Company's expected financing needs and sources of financing, the industry in which the Company operates and the trends that may affect the industry or the Company.\par \par \uc2 By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in the presentation, the Company cautions you that forward-looking statements are not guarantees of future performance and that the Company's actual results of operations, financial condition and liquidity, and the development of the industry in which the Company operates may differ materially from the forward-looking statements contained in the presentation as a result of, among other factors, the factors referenced in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the \uc2 Securities and Exchange Commission\uc2  during March 2014. In addition, even if the Company's results of operations, financial condition and liquidity, and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in the presentation, they may not be predictive of results or developments in future periods. Any forward-looking statements that the Company makes in the presentation speak only as of the date of such statement, and the Company undertakes no obligation to update such statements to reflect events or circumstances after the date of the presentation, except as required by law.\par \par \uc2 You should read carefully the Company's "Forward-Looking Statements" and the factors described in the "Risk Factors" sections of the Company's Annual Report on Form 10-K to better understand the risks and uncertainties inherent in the Company's business.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1338095/000110465914047459/a14-15752_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1338095/000110465914047459/a14-15752_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1338095/000110465914047459/0001104659-14-047459-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1338095/000110465914047459/0001104659-14-047459-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 20, 2014 16:33 ET (20:33 GMT)\par \par \uc2 Document DJDN000020140620ea6k0036q\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw134\pich21\picscaley100\picscalex100\picwgoal2010\pichgoal315
47
494638396186001500B30000FFFFFF8989892A2A2AEDEDEDCCCCCC666666A8A8A8DBDBDBBBBBBB000000777777444444111111999999F5F5F555555521F90400
000000002C00000000860015000004FFB0C849ABBD38EBCDBBFF1F208E64699E68AAAE6CEBBEAC04CF23320E07ADEF7C5CF4AEC0E860031A8F33190211281202
06072217051800CFAAA14170180204D193396C34A287F0C09643BA91CA86B51B901A0E57F0D2EBC003140E0053000D0E0E756422078808878236426F923D4A39
4444224201690885070A01500091A1A10798A343454206039193B03B4A364B03727E4C5272B6000E619177580EBCAE65007E59B1CA344AA17256A600C50661D0
9BA9C7A15782010DAF8BA103220A6D3FCBE72A95E8278EEBEE28EA6B4B45336B6D2DD762F482D53A4B240410885B86A0DF08193512284CC0E0D90B04095EB508
248241444509CCE950F86A41827D25FF060249B0C0044211100530613803A2C41505E8296420CE258F85CF3C821C41E0C1119226350A024A402121300FE42078
B020C0C09E0B145CEC96CD86AB050BE404C8B809A2C71F5BAF7C5A50E0D43503579E1030B0E041988509E4E8C45220AAB8010C04740B47280793300DB03EFB5B
400100A2A1449C1C0AD7B047010214A4945AF2000306013C0A016AF36B80B202120858B036A2CEAD022F0760503222DE920B041425BB392E43023A2DEB653D8A
61D4AD4E3302104073EB83075345433EBC6000F16A8B5386AAA6591A7271529FC41DBAB9A4CBA2425167FA788024F2DEA32D0E2FB09501C43B97AB196D1F7A65
13E46F4B4ACBBBD5B690BC2210D79BE24FE29897C03600440714091E8DD0606F2B5D611367114164D808E22598400EFD31D05B13FF14101A72A3897159810928
B6D04AEC45B3606F092870194DCC89D060868741C6C03D0AEAE7608A22349091010016A59254FFA954DD650D20904785073CE81C850B74228790020CA010600D
14F0D161400280DC47463AA95F5EFFE0B5A19791B0B915585F8A4092910709E555090F66621169415A149A104232C02616631A3625030400288201C28DE2675A
5F46A6678C728639A50D0D84A657900A9913804F890E34809719898323506F2A26D43BACB60A0F08B0C62AEBACB4D65A4004003B}}
\par\par \b \uc2 Symmetry Medical  \highlight22\uc2 Launches \highlight\uc2  Dual Connection Offset Acetabular Reamer Driver\b0\par\par\uc2 453 \uc2 words\par \uc2 20 June 2014\par \uc2 ThomasNet News\par \uc2 PNN\par \uc2 English\par \uc2 Copyright (c) 2014. Thomas Publishing Company. All Rights Reserved.   \par \par \uc2 Innovative \b \highlight22\uc2 New Product\b0 \highlight\uc2  Designed to Accommodate Various Surgical Approaches for Total Hip Arthroplasty\par \par \uc2 WARSAW, Ind., - \uc2 Symmetry Medical Inc\uc2 . (\uc2 NYSE\uc2 :SMA), a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays, announced today that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  the Dual Connection Offset Acetabular Reamer Driver through its OEM Solutions team. The product will be featured in Symmetry Medical's booth #431 at the 10th Annual Orthopedic Manufacturing & Technology Exposition and Conference (OMTEC exhibition) in Chicago on June 11-12, 2014.\par \par \uc2 Symmetry's new Dual Connection Offset Acetabular Reamer Driver is used during Total Hip Arthroplasty ("THA") surgery to easily introduce acetabular reamers to the hip joint and to enhance visibility in minimally invasive procedures such as Direct Anterior Approach THA surgery. The driver features a patented drive shaft assembly designed and tested to meet the demands of THA surgery. The product highlights include:\par \par \uc2 - Improved access to the acetabulum due to the low-profile reamer/driver connection\par \par \uc2 - Innovative design allowing easy disassembly to facilitate the cleaning and sterilization of the internal components\par \par \uc2 - An ergonomic silicone over-molded stabilization handle\par \par \uc2 - Compatibility with Symmetry's flagship 420SS Acetabular Reamers as well as the Low-Profile Parabolic Reamers\par \par \uc2 Thomas W. Barrett\uc2 , Senior Vice President and Chief Commercial Officer, Symmetry Medical OEM Solutions, said, "The launch of the Dual Connection Offset Acetabular Reamer Driver is a significant advancement in our proven line of acetabular preparation products and further enhances our comprehensive offering of instruments for the anterior surgical approach for hip arthroplasty. Our New Product Development team tested this device extensively to validate the mechanical longevity with a focus in optimizing the long term functional performance and the overall ease of use. By providing valuable proprietary product innovation that can be added to our customers' surgical instrument sets, we continue to support our OEM customers, orthopedic surgeons and the patients that they serve."\par \par \uc2 Mr. Barrett added, "The product launch is also consistent with our strategy to grow our OEM Solution sales opportunities through use of our own proprietary medical device solutions."\par \par \uc2 About \uc2 Symmetry Medical Inc\uc2 .\par \par \uc2 Symmetry Medical Inc\uc2 . is a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company's thousands of Teammates provide design, development and worldwide production capabilities for these products to customers in the orthopedic industry, other medical device markets, and specialized non-healthcare markets. Symmetry's trusted reputation and brands, broad Intellectual Property portfolio and commitment to innovation enable it to collaborate with hundreds of global medical device manufacturers as well as thousands of hospitals to provide solutions for today's needs and tomorrow's growth.\par \par \uc2 Document PNN0000020140620ea6k0000b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Lumenis to Ring the \uc2 NASDAQ Stock Market\uc2  Closing Bell on June 19, 2014\b0\par\par\uc2 637 \uc2 words\par \uc2 19 June 2014\par 08:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Lumenis to Ring the \uc2 NASDAQ Stock Market\uc2  Closing Bell on June 19, 2014\par \par \uc2 2014 Proves to Be Transformative for Lumenis With Multiple \b \highlight22\uc2 New Product Launches\b0 \highlight\uc2  and Increased Revenue\par \par \uc2 YOKNEAM, ISRAEL--(Marketwired - Jun 19, 2014) - \uc2 Lumenis Ltd\uc2 . (NASDAQ: LMNS), the world largest medical energy-based solutions company for surgical, ophthalmology and aesthetic applications, will be ringing the closing bell at the NASDAQ MarketSite in Times Square, New York, NY on Thursday, June 19, 2014, at 4:00 p.m. ET.\par \par \uc2 Chief Executive Officer Tzipi Ozer-Armon and the Lumenis management team will participate in the bell ringing ceremony from 3:45 to 4:00 p.m. ET, to commemorate the listing of Lumenis on the NASDAQ Global Select Market on February 27, 2014 under the symbol "LMNS". A live webcast will be available at {\field{\*\fldinst{HYPERLINK "https://new.livestream.com/nasdaq/live"}}{\fldrslt{\cf2 \uc2 https://new.livestream.com/nasdaq/live}}}\uc2 .\par \par \uc2 "2014 thus far has been a pivotal year for Lumenis," said Ms. Ozer-Armon. "Following our successful IPO in February, the Company has launched an unprecedented number of new products in 2014, including the Pulse 120H, the most powerful holmium laser for urological procedures, two additions to our gold standard LightSheer laser hair removal platform and also rolled out globally the Array. The IPO was an important milestone for us, and as we are commemorating it today by ringing the NASDAQ closing bell, we are excited about our future growth opportunities."\par \par \uc2 About Lumenis\par \par \uc2 Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.\par \par \uc2 For more information visit: {\field{\*\fldinst{HYPERLINK "http://www.lumenis.com"}}{\fldrslt{\cf2 \uc2 www.lumenis.com}}}\par \par \uc2 Forward-Looking Statements\par \par \uc2 Information provided in this release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the \uc2 Securities and Exchange Commission\uc2 . These forward-looking statements are made only as of the date hereof, and Lumenis undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.\par \par \uc2 For further information:\par \par \uc2 Jeff Jacomowitz\par \par \uc2 Lazar Partners Ltd\uc2 .\par \par \uc2 (212) 867-1762\par \par \uc2 jrjacomowitz@lazarpartners.com\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 19, 2014 08:00 ET (12:00 GMT)\par \par \uc2 Document DJDN000020140619ea6j001gu\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Provectus Biopharma Files 8K - Regulation FD >PVCT\b0\par\par\uc2 230 \uc2 words\par \uc2 19 June 2014\par 06:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Provectus Biopharmaceuticals Inc\uc2 . (PVCT) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 19, 2014.\par \par \uc2 On June 19, 2014, \uc2 Provectus Biopharmaceuticals, Inc\uc2 . (the "Company") issued a press release relating to the Company's previously announced conference call to be held on Thursday, June 19, 2014 to discuss the outline of the Company's proposed phase 3 study of the Company's oncology drug candidate PV-10 in the treatment of melanoma as well as developments in the use of PV-10 in other cancer indications and to discuss the Company's dermatological drug candidate PH-10. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312514241533/d744399d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312514241533/d744399d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312514241533/0001193125-14-241533-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312514241533/0001193125-14-241533-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 19, 2014 06:04 ET (10:04 GMT)\par \par \uc2 Document DJDN000020140619ea6j0014r\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Discovery Laboratories\uc2  Files 8K - Other Events >DSCO\b0\par\par\uc2 376 \uc2 words\par \uc2 18 June 2014\par 05:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Discovery Laboratories Inc\uc2 . (DSCO) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 13, 2014.\par \par \uc2 On June 17, 2014, the Company issued a press release announcing that it has been awarded the final $1.9 million of a $2.4 million Fast Track Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the \uc2 National Institutes of Health\uc2  (NIH). On June 13, 2014, the Company received from NHLBI a notice of award in the amount of $1,880,292. Under the terms of the grant, the funds are currently available for draw and will remain available through May 30, 2015. The Company expects to draw substantially all of the funds under the grant in 2014 to support the ongoing phase 2a clinical trial for AEROSURF(R).\par \par \uc2 On December 16, 2010, Discovery Labs announced that it had been awarded Phase I of the SBIR from the NIH to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS). The Company had submitted a proposal, with a total budget of $2.4 million, for the development of the Company's proprietary capillary aerosol generating (CAG) device technology to be followed by a Phase 2a clinical trial of aerosolized KL4 surfactant in preterm infants with or at risk for RDS, and had at that time received the initial amount of $580,000 to support certain development activities related to its capillary aerosol generator technology.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114025987/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114025987/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/946486/000114036114025987/0001140361-14-025987-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/946486/000114036114025987/0001140361-14-025987-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Discovery Laboratories, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US2546684034"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US2546684034}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 18, 2014 05:00 ET (09:00 GMT)\par \par \uc2 Document DJDN000020140618ea6i0011l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Flexion Therapeutics\uc2  Files 8K - Other Events >FLXN\b0\par\par\uc2 367 \uc2 words\par \uc2 18 June 2014\par 05:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Flexion Therapeutics Inc\uc2 . (FLXN) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 17, 2014.\par \par \uc2 On June 17, 2014, we announced positive topline clinical trial results from a Phase 2a synovial fluid pharmacokinetic study of FX006. The trial results demonstrated that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks. Treatment with FX006 also resulted in a six-fold increase in the duration of drug residency in the joint compared with immediate-release triamcinolone acetonide (TCA).\par \par \uc2 In the multi-center, open-label study of 50 patients with osteoarthritis (OA) of the knee, researchers assigned patients sequentially to one of five groups that received a single IA injection of either 10 or 40 mg of FX006 or 40 mg of immediate-release TCA. Synovial fluid concentrations of drug were measured at 12 weeks in all dose groups and also at 16 and 20 weeks in the FX006 40 mg dose group. At 12 weeks both the FX006 10 mg and 40 mg dose groups had therapeutic concentrations of drug in synovial fluid. In contrast, the 40 mg immediate-release TCA dose group had concentrations of drug that were below the lower limit of quantitation. The FX006 40 mg dose group also demonstrated readily measurable concentrations of drug at 16 weeks, which fell to below the lower limit of quantitation at 20 weeks.\par \par \uc2 A press release announcing the results of the Phase 2a synovial fluid pharmacokinetic study is attached hereto as Exhibit 99.1.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1419600/000119312514239219/d745103d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1419600/000119312514239219/d745103d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1419600/000119312514239219/0001193125-14-239219-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1419600/000119312514239219/0001193125-14-239219-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 18, 2014 05:00 ET (09:00 GMT)\par \par \uc2 Document DJDN000020140618ea6i0013i\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw133\pich40\picscaley100\picscalex100\picwgoal1995\pichgoal600
47
494638396185002800F7FF00FBEAEAE6797CEB9EA1919191F0F0F0828282EEA4A6F2F2F2ADADAD9E9E9EB5B5B5D0D0D06E6E6E3333332C2C2CD8282CFBD5D6E3
696B898989F6D2D2F0AAABD30103F2B8B9A9A9A9CDCDCD9B9B9B7E7E7EFEFAFAF6D6D6B1B1B1E36165141414F4F4F4A2A1A1DEDEDEF1B5B6FAEDED666666E573
76BFBFBF8E8E8EFCF2F2C4C4C43B3B3B4A4A4AE8E8E8DD4E50BABABAFEF8F8F0B0B1DD5154DADADA616161EEEEEEDCDCDCECECECF1C2C3EAEAEAFDF4F4696969
E15B5EFDF6F6CACACAF5C9CAF8D9DA5E5E5EC8C8C8404040CE0000FBE6E6FCF0F0E88184BCBCBCB8B8B84444440C0C0CE3E3E3E88385D2D2D2D9252AF4C5C6E5
777AF9E0E0959595E9888AF8DCDDE6E6E6E36468F9DEDED8D8D8DE484C767676EBBBBCDB4448E1555AC2C2C27A7A7AE7AFB1DC3D415A5A5AEEA2A41D1D1D7070
70E77E80D72C31DF6264F4C1C2C6C6C6575757E88486A6A6A6181818E0E0E0505050E49597212121868686787878DB4045E4E4E4F5CDCE262626EEA8AAF4C7C8
C90000EEADAFD5D5D5EB9495EA9192E46E71C40000DA3136CD1619FAE4E4FFDFE0FCEDEEE25F62D6D6D6EC9597EB9798EEA6A7D41418EEA1A2737373C0C0C0FD
FBFAEA8C8EEC999AD1090D000000F6D0D1F7DEDEE77B7EE98A8DE88082F1CCCDDD3A3FFAE7E7F0AFB1EA8E90EB9C9ED51D22F2C5C7F0A7AAF2BABBEA9395FDFE
FE060606DA353AF9E6E7FAE2E2F2BDBEF2B7B8F8E4E4F8D8D9F5C2C4E04A4FF0B2B4EC9A9CFFFFFFFBFBFBFEFEFEFDFDFDFCFCFCFFFEFEFAFAFAF9F9F9FFFDFD
F8F8F8F6F6F6F7F7F7FEFDFDFDF8F8F9E1E2FEFCFCFEFFFFFDF7F7FAE5E6FBEBEBFFFEFFF9E3E3FCEEEEFFFCFCE4A8AAEFABADEC5C5FCF2025FEDADBABC0BF9B
B1B0080909F3C3C4FFE3E30F1010F1D3D2D20F12DF5A5DE8B7B9FFFEFDE04C50DF6D6FEA8487FDF5F5F5BEBFFCF1F1F3BBBDF9E5E6707D7CD8464AE78C8EF4A2
A4768786F6D3D4FAE3E4EC9294F4BFC0F8DADCEDC1C3F9DDDEF9DFDFE9AAAADA7C7EFEFBFBFBE1E1FCEFF0535453F3D8D9E68789E1575BFFFDFCF9ECEC8E9393
E8282D232323E8999BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A45324541463245354338373545323131413343304437443032394336463539432220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A32463439334235323531303231314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A45314543363134303531303131314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F70204353352E312057696E646F7773223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D22786D702E6969643A4533454146324535433837354532313141334330443744303239433646353943222073745265663A646F63756D656E7449443D22
786D702E6469643A4532454146324535433837354532313141334330443744303239433646353943222F3E203C2F7264663A4465736372697074696F6E3E203C
2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEB
EAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACAB
AAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B
6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B
2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000850028004008FF
006DE9A245B020AD5CBA66D5F255EB9F4387B374D9FA372B572E83B4784D7CC89162BE591C73E570020744C78B1DFFD962A872A0C15B1C6FE94AB9B021C759BD
4072B4C5CB66CA9F401F12A8B4A3E3964A493A3AA904E6DF824A1A66499DAAD3612D79527578E133E15F824A2B6A3CACE5A6D292890D2A4DB1396B46A54A13EB
54F2F15042A5062069F5AB34D32192B7952EFC1351E90D0A3088252CA974E09F864A2A66DD2268D167D094B36000AB4A952A4712449EC4F2E4C800050AF366ED
AD14A4EA974A05FE0DADC4C087930574DECE8C5349C1BF1780C53A6C51A9DABF036F1324C8C07C409659652A0D58CE7C0A827F3B2A6D4182408182016F277EFF
A8B4E01F83B765723D6452C9CCBF5A792AD53BB1C0CFD74A4E1C1671D1A8118F4E0E5D2041552901D344139824884900819833CC3E0558F68F1075A8F0101C1A
34504D0328F8124206FF28508708836DD14247076830C03FB948A0811930C2C84002B52000C6230CC498632F428071C74D12B0D1D8612776A081491CB5B0C509
0F1D80C210D538B0058F412043C53FF820D24D009AE0A1493783A0124514BF3C44C6208E50F1008097B54989096DC6091417686812800B98E022E79EFA69C227
47BDD06654256E1C70430E3780B054534F3D22902EBAF8B211506154F0CC3F959C424B4A76CD80E9079B725440254C8E8AC14D8F90FA4F190E30514D25A7FEFF
734225D739948574FFF046C043A322F1E7AFC0062BECB0C412AB0711040E430404D000F6D60B1D81C6C93B58B8E3CE1E8550F4D6A6BD9C02EB5017D4F2964DD9
01F6C83F2520F5DB5C0ED1C01A08D27C70DC294B0821840A2A9C40A22D0E5482840FF87EE14343EE3AC0020B6F55D30248BAF45B9EBB24CE125F0220E0BAD80D
0E29E0EC29C576ECF1C72003E5CA19FF44D0032EB8C8B38B43F890D111007670808B307A7C224F171CCCD249397D440003317B6CE0CFCAF1B8FC8F0ED8EC6100
337A30934A1AF2E0420A108800300B1EADDCA38832EF14430C10DEFCC14D32F3781308370FC96189430180F2CF19B1EC5285144600D1430469F491C92E8560FF
118116B3786347307DE839822CC7C0F0C33B0138E4C21E6D66D08F030EBCF116E50EE401C214B476E44325254C78791EA4E7F1C614416D22881AEFC507150219
A4554916FFDCF2967A1C9DE79B19959451021B41B89B294CD1E1FA50129524C0D16B6FD1FED0791D7C3C54511C8151090B60C8A881BBB13D95C7233494504210
4905950D11D49852C9103F61C06E6104FE63976FB939FB5606BDFC43CB1C95C0F4542520604FADDC570F5D10A0172BA804C6FE312A68790C0473880D47063007
0B7144047958D10CF250865378D08377C1DD3FF4710D2210211480D093555E20BB4C49605742390F605640178764A00C357408081A200D38FC43090E10A143FF
425006261060091AC04C3DAA610B48F4E30D4BA88614ABB10448842C28B84847313AC1452E4AC11BFF60C20CFAF2105DF841382C9AC10B3280041B88B00659F0
C53F7CE107183EC4163660C27BE0600311F8D18F33D8550B66F04740FE880084F4631E5BD0188A0C523D378863476E910534DA42046B4C422278F1905208A20D
96B0442004318A7FD4A31290F8C2094ED00132FE033483D8C30FA0B0073500415B79E08512A0E210E08460168B09D54FD8A02EE0B4E02973E0247BDE30AF53BC
205F274082A76C9116044013092A20186466618B5AD82207D1D95474CA138453E882736380091C2A21817FF4EB443FE9011F02F19059440059E3905750F441FF
0458C0E09F3090C706E4510B69544298C4794B3B3FD71BDCDD213ACA4B575280931F88C8CE01C7C9140826438B5BF8A227D1B9014727D38B5A6447080FF91C13
F5E7B07FB80B9EFA034C1203953C4E1E272D2CB8A24E77CAD39EFAF4A7404D091064F18F409C011054E88AE35ED1113BB88223A5A9533114D10D7174E10731E0
0431D2100555E0031D0FD98018FE410C7CFC2305A84047150261842B50A010F8408628B631017C30E31268E0400C52208A41B08311247808174CF0030BA80110
B388850726000B5630E21AEC300038A6318809444106BF10C008CE108A48F0C003AAB084175461010AC8030DA490021A8C112790CC6217B0DD854EA402147AFF
8091ACE498850E5448566240E4B70EE12D4440020C703C0417C9E08811789B027940C408DAB80967F4348B64F0D6086572483256F60F5C1897221D49C106804B
DBCBA4EA2DA79883E500438017BCC1820F994119DA9985328CC77E5B080A0708B136FDB9E155806100896A37870608D3210378035D125086C500A61A60D8952D
E2F0860410C8071F702044D8200D061028C1F015962D6C310BE47878C413B11E4A93C414A754020598090A1788B0B6C7D04084B340DE413F756006AACA5437D1
DD3F34E4AD5AFDE335469E8534DEB04E8CF2CA5FD2234A47AC673FC0D0C1C5550EC265965181F455220E3FB9155D2AF10121FE23374CCA8D036810871D30C0FF
72FDA805742AF18F8A41E61F6BE81C45DE700A98F0E22E4FF695C7A637A81C0EA7127570F18AF87409414000539530F33FE4E2A94A48237EE942E9633AC0CDA5
CC4127FBAB841C656516B908E61F09AC72537C1C6262D5E07A1D09829E1FE23E1AE0F92D799883AEE750863808D31E4410831D88208807088322B2AEC4180EB3
9853E4C02139F0D60724300084F5C621E9F20D441258006E7ACBA60EE15C6FC45509983AC40F95C8C32C46758A0F7CD08382FE1537E3578B5BC44F320DE1268A
F72DA159C80306F173C82D0E500302B8922386AA01082645117B77443230A98584042E1598FC443252E9A6C4374EE2A07AFCE320FF93314CC88792975C10CDFF
F8C7AB5640A0BF306038C5034C19E03984C0FC03016FF10347ACF016D978ABCA6C585595DF320B19DA6F09D09A85E550CA9B25D871309508FA716AEE2C69C097
149430E13558F78F1038C083D2F0D6021DA20F3E5CE127B5F8C01CE2B3039D40E2C5E822544714F001BA8CA19895E85725F2F70F9E33133965F8092DC60394BB
0FF821BC11CB38B1238DB4BC4127EC4934CE73CA9105CC210800E003233862002228E31C4BB80C0928510193F341108D7048CF67319EEB2CA595990A95081210
020424E1D9B29E6825ACE0E33270B330C7B9AFB398F9C3A137265D80F9C06A125D8BC5BB0B26A7CC69C550F716181280F61778C102624184EC3A2412443044FF
344E810209D00105E67E251F3C80F66D1D1A746A41357E1C420B02D42204F197E8BACA53BB7439A01A739051C4D711B4603985471E147103D2500DB8C30B2DE5
2EBCF70FBC8053B0611EF1F71E04700B79B602FFB0077C100A07D2087CF0687B11700FD1097C60422A48047CC00FEA13691CE116A043111A831E6F6150EE9116
21D07577F610B7906AFFF06A4397078337740A942ED10311A9520D52F11616921687771CAF2275186050BDE3609912724161825A08325CD8856018866238861E
370BE3D503D48205C1A003C1500546600CEC2005C27508316001CE452C3A708757F40B9D500555500C5F382CB8305E7BC20180F00F54700C299106E1D01196FF
2003DC050069A003EC30029FD00DBE150C02A00829F00FC1100399B00E1D410AB1000AC9F50FEF700454C001FF200FEA00089E0012D320000600125060008AB0
01B3600106300984F80F02100C0FA10500F00F7A4006AC4011E1C00864706C6AE008A320156A400131508C2460014405055490093DB0015730029200566DC201
6E6302459002D8F51032F00D1D21034CF5104D600072F010FB15016AB00A927009380012F020000F210994100E9E4004C2B009D6F010AE10050F310CCEA008AC
300264B0015030098C9002C2E0098B100BC020586D100C92100A0E410E2330027DB0082960017F100306B20823600147900C161003EF1005A9D007208109DEAC
D70947E01026200A6D020E31F00F4D20035780082E80050EC1085090128520063CE0021EA027E47005262006EEF00F9E100126300AB880032B13063FE01002B0
0A1C91093AF00A32900626800BC6D0057FA303FFB020F8600CC0800F47700624900C2E400567508C0ED10EACD85DB0200FF2C003478008E04002DBF00967600C
BF600267E00152900251A0094D7004298007D4150857A0053F00037AE010A5500540850B7E4986A8F9130101003B}}
\par\par \b \uc2 CareFusion; CareFusion to  \highlight22\uc2 Launch \highlight\uc2  Three New Infection Prevention Products at APIC 2014\b0\par\par\uc2 526 \uc2 words\par \uc2 18 June 2014\par \uc2 Journal of Engineering\par \uc2 JOENG\par 411\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Journal of Engineering via VerticalNews.com   \par \par \uc2 2014 JUN 18 (VerticalNews) -- By a News Reporter-Staff News Editor at Journal of Engineering -- At the 41(st) Annual Conference of the \uc2 Association for Professionals in Infection Control and Epidemiology\uc2  (APIC), CareFusion (NYSE:CFN), a leading global medical technology company, will \b \highlight22\uc2 launch\b0 \highlight\uc2  three \b \highlight22\uc2 new products\b0 \highlight\uc2  that are designed to help reduce surface contamination or the presence of microorganisms that can potentially cause infections during hospital stays and procedures.\par \par \uc2 The ChloraPrep((R)) 1mL applicator is a new addition to the ChloraPrep line of preoperative skin preparation products. It provides clinicians with a unique applicator design and the same formulation they know and trust in a new 1 mL size. With its unique delivery system and winged activation design, the 1 mL applicator is easy to use and can help promote aseptic techniques and best practices. ChloraPrep skin prep products have been proven to be more effective than povidone-iodine at eliminating microorganisms on the skin that may cause infection.[1][2][3]\par \par \uc2 The ChloraShield((R)) IV dressing with chlorhexidine gluconate (CHG) antimicrobial is a flexible and breathable dressing, that enhances patient care during vascular access procedures. The dressing features BeneHold((TM)) CHG, an innovative adhesive technology from Vancive Medical Technologies(TM), an \uc2 Avery Dennison\uc2  business, which comfortably secures the dressing to the skin, absorbs fluid and protects the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth. ChloraShield dressings are designed to be easy for clinicians to apply and remove, and comfortable for patients to wear. CareFusion is the exclusive distributor of the dressing in North America.\par \par \uc2 The MaxZero((TM)) needleless connector from CareFusion is a new extension to a proprietary portfolio of needleless connectors and is designed to help improve patient safety and promote nursing best practices. With a solid, sealed surface, the connector provides a barrier to bacteria and contamination and enables effective three second disinfection with an alcohol pad. The design of the MaxZero needleless connector prevents reflux of blood into the catheter at disconnect and also has a smaller profile. A clear fluid path enhances flushing and anti-reflux technology prevents the need for a clamping sequence, helping save nurses time and reducing process steps.\par \par \uc2 In addition to new products, new data is being presented on tools that can improve patient compliance with physician cleansing instructions and how increased compliance can affect the amount of antiseptic present on the skin. A unique reminder system to improve bathing compliance is one of the key features to the StartClean Cleansing Program from CareFusion, where patients receive a 4 percent CHG cleanser with disposable sponges and an individualized service that contacts patients via text, email, or voice message reminding them to use the cleanser in accordance with physician instructions. The data will be presented by Dr. Charles Edmiston from the Medical College of Wisconsin during a poster presentation on Saturday, June 7 from 12:30 to 1:30 p.m.\par \par \uc2 Keywords for this news article include: CareFusion, Technology.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document JOENG00020140613ea6i0004e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Inergetics\uc2  to Debut Bikini Ready(R) Fiber Flavors Gummies, Martha Stewart(TM) Essentials Vegetarian Multivitamin Gummies and New & Improved SlimTrim at ECRM Tradeshow in Miami\b0\par\par\uc2 791 \uc2 words\par \uc2 17 June 2014\par 08:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.  \par \par \uc2 \f2 \f28 \b \highlight22\uc2 \f2 New Products\f28 \b0 \highlight\uc2 \f2  and Recently Acquired OmEssentials(R) Product Line to be Presented in Brickell South Room \par  \f28 \par \par \uc2 \f2 NEWARK, N.J., June 17, 2014 /PRNewswire/ -- \f28 \uc2 \f2 Inergetics, Inc\f28 \uc2 \f2 . (OTCBB: NRTI), a leading developer of nutritional supplements, today announced that it will \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  Bikini Ready(R) Fiber Flavors Gummies and Martha Stewart(TM) Essentials Vegetarian Multivitamin Gummies at the ECRM Tradeshow in Miami. The company also will \f28 \b \highlight22\uc2 \f2 introduce\f28 \b0 \highlight\uc2 \f2  to ECRM attendees a new and improved formulation for its SlimTrim Weight Loss Solution featuring scientifically advanced weight control ingredients including Garcinia Cambogia, Saffron, Sinetrol(R) as well as Cayenne Pepper and extracts of Green Tea.\f28 \par \par \uc2 Martha Stewart Essentials Vegetarian Multivitamin Gummies deliver a blend of essential vitamins and minerals to support and nurture total body health. The entire line of Martha Stewart Essentials products recently received \uc2 NSF\uc2  certification, the industry's highest accreditation. All products labels in this growing line will soon bear the "\uc2 NSF\uc2  Contents Tested & Certified" mark to show consumers they have been tested and certified to meet \uc2 NSF\uc2 's stringent criteria.\par \par \uc2 "\uc2 NSF\uc2  certification is a wonderful achievement for Martha Stewart Essentials and represents the superior quality of the entire \uc2 Inergetics\uc2 ' family of nutritional supplements," said \uc2 Jim Kras\uc2 , CMO of \uc2 Inergetics\uc2 . "We are proud to continue the growth of our offering with innovative, high-quality nutritional supplements targeted to meet the needs of consumers as they seek to improve their health and quality of life."\par \par \uc2 Bikini Ready Fiber Flavors Gummies are packed with prebiotic soluble fiber and designed to promote digestive health and curb appetite. Fiber Flavors Gummies are the most recent addition to the Bikini Ready line of women's weight loss solutions, which include Energy Gummies, Weight Loss Catalyst(R) , Fashion Multi and Cleanse Cleanse nutritional supplements, as well as Yummy Nutrition Shakes. The new supplement and the entire Bikini Ready product line is currently being supported through the national Back2Body(TM) summer advertising campaign featuring Bikini Ready spokeswoman and professional surfer, Christa Alves.\par \par \uc2 "After launching five new products, including Bikini Ready Energy Gummies, at the ECRM tradeshow in Chicago earlier this year, I am thrilled to continue our momentum with these two great new products," said \uc2 Mike James\uc2 , CEO of Inergetics. "Our customers love the taste and convenience of our nutritional supplement gummies and we are excited to address additional health and wellness needs with the launch of a fiber-based product and a vegetarian multivitamin."\par \par \uc2 Inergetics\uc2  will also use the occasion of this ECRM show to present its recently acquired OmEssentials(R) product line for the first time to leading national buyers and retailers.\par \par \uc2 ECRM will be held from June 17-19 at the Hyatt Regency Miami in Miami, FL and the \uc2 Inergetics\uc2  room will be located in Brickell South.\par \par \uc2 Martha Stewart Essentials Vegetarian Multivitamin Gummies are available at \uc2 Walgreens\uc2  and other retailers nationwide. Bikini Ready Fiber Flavor Gummies are expected to be available in national and regional food and drug retail stores starting this fall.\par \par \uc2 Media Contact\par \par \uc2 RLM Finsbury\par \par \uc2 (646) 805-2025\par \par \uc2 Inergetics@rlmfinsbury.com\par \par \uc2 About \uc2 Inergetics, Inc\uc2 .\par \par \uc2 Inergetics\uc2 ' portfolio of brands includes: Martha Stewart(TM) Essentials, a complete line of whole-food-based supplements created specifically for women; Surgex(R) Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready(R) , a leader in weight loss lifestyle solutions; SlimTrim, the affordable, premium value diet brand; and OmEssentials(R) , a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals.\par \par \uc2 To learn more about \uc2 Inergetics\uc2 , visit {\field{\*\fldinst{HYPERLINK "http://www.inergetics.com"}}{\fldrslt{\cf2 \uc2 www.inergetics.com}}}\uc2 , and the \uc2 Inergetics\uc2  brand websites: {\field{\*\fldinst{HYPERLINK "http://www.marthastewartessentials.com"}}{\fldrslt{\cf2 \uc2 www.marthastewartessentials.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.surgexsports.com"}}{\fldrslt{\cf2 \uc2 www.surgexsports.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.surgexsportsblitz.com"}}{\fldrslt{\cf2 \uc2 www.surgexsportsblitz.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.slimtrim1.com"}}{\fldrslt{\cf2 \uc2 www.slimtrim1.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.slimtrim.net"}}{\fldrslt{\cf2 \uc2 www.slimtrim.net}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.bikinireadylifestyle.com"}}{\fldrslt{\cf2 \uc2 www.bikinireadylifestyle.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.kahunasands.com"}}{\fldrslt{\cf2 \uc2 www.kahunasands.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.omessentials.com"}}{\fldrslt{\cf2 \uc2 www.omessentials.com}}}\uc2 .\par \par \uc2 Safe Harbor Statement\par \par \uc2 This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of \uc2 Inergetics\uc2  set forth herein and those preceded by or that include the words "believes," "expects," "given," "targets," "intends," "anticipates," "plans," "projects," "forecasts," or similar expressions, are "forward-looking statements." Although \uc2 Inergetics\uc2 ' management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause \uc2 Inergetics\uc2 ' future results to differ materially from those anticipated. \uc2 Inergetics\uc2  assumes no obligation to update any of the information contained or referenced in this press release.\par \par \uc2 SOURCE \uc2 Inergetics, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.inergetics.com"}}{\fldrslt{\cf2 \uc2 http://www.inergetics.com  }}}\par \par \uc2 Document PRN0000020140617ea6h0007j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Selecta\uc2  Accelerates Immune Tolerance Therapeutics and  \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Product \highlight\uc2  Candidate, SEL-212, for Refractory and Tophaceous Gout\b0\par\par\uc2 1,394 \uc2 words\par \uc2 17 June 2014\par 07:00\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par    -- \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's immune tolerance pipeline includes programs in gout, hemophilia \par       A and food allergies \par  \par    -- \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  continues to advance key immune activation programs, with \par       newly-announced funding totaling $9.35 million from the \f28 \uc2 \f2 Bill & Melinda \par       Gates Foundation\f28 \uc2 \f2  and NIH/NIDA \par WATERTOWN, Mass.--(BUSINESS WIRE)--June 17, 2014-- \f28 \par \par \uc2 Selecta Biosciences, Inc\uc2 ., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today provided an update on the company's product development pipeline, revealing its focus on immune tolerance applications of its proprietary Synthetic Vaccine Particle (SVP) platform. The company announced a new product candidate for its pipeline of tolerogenic immunotherapies: SEL-212 will be the first non-immunogenic treatment for refractory and tophaceous gout. \uc2 Selecta\uc2  is now developing products for three applications of antigen-specific tolerance, the inhibition of immunogenicity for biologic therapies, treatment of allergies, and treatment of autoimmune diseases. While the company is focused to accelerate product opportunities in immune tolerance in the near-term, \uc2 Selecta\uc2  continues to advance its key SVP immune activation programs, with a grant of $1.25 million from The \uc2 Bill and Melinda Gates Foundation\uc2  for malaria vaccines and an award of $8.1 million from the \uc2 National Institutes of Health\uc2  (\uc2 NIH\uc2 ) for \uc2 Selecta\uc2 's nicotine vaccine for smoking cessation and relapse prevention.\par \par \uc2 "Our SVP platform is highly versatile, providing us with the opportunity to develop breakthrough products for immune tolerance and differentiated vaccines to prevent and treat disease," said \uc2 Werner Cautreels, PhD\uc2 , President and Chief Executive Officer of Selecta. "We are rapidly advancing our first-in-class tolerogenic products to the clinic. Grants and partnerships enable us to develop more effective vaccines in parallel."\par \par \uc2 Selecta\uc2 's latest immune tolerance SVP compound is SEL-212, a novel drug candidate for refractory and tophaceous gout. SEL-212 is designed to be the first non-immunogenic version of uricase, addressing the undesired immunogenicity that has been observed in more than 90% of patients(1) treated with a marketed version of uricase. Treatment-related immunogenicity can lead to a loss of efficacy and severe allergic responses. Through an exclusive license to pegsiticase, \uc2 Selecta\uc2  is applying its immunomodulatory SVP platform to dramatically reduce the risk of immunogenicity of other uricase products.\par \par \uc2 "Severe gout is a highly debilitating disease without good treatment options that affects around 100,000 patients in the US," said \uc2 Tony Fiorino\uc2 , MD, PhD, former CEO of EnzymeRx, a company that pioneered the early clinical development of uricase compounds for the treatment of severe gout. "Initial clinical studies with pegsiticase demonstrated its efficacy in clearing plasma uric acid, however immunogenicity could hamper its long term use. SEL-212 has the potential to significantly reduce immunogenicity and unlock the full potential of uricase for the treatment of severe gout."\par \par \uc2 In addition to the lead immune tolerance drug candidate, SEL-212, \uc2 Selecta\uc2  has built a pipeline of immune tolerance drug programs through collaborations as follows:\par \par \uc2 \f2 \par    -- Anti-Drug Antibody (ADA) program for Hemophilia A: \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  has \par       collaborated with researchers at the \f28 \uc2 \f2 Uniformed Services University\f28 \uc2 \f2  (USU) \par       on SEL-201, a candidate for use as an adjunct to Factor VIII therapy in \par       the treatment of hemophilia A. Approximately 25-30%2 of severe Hemophilia \par       A patients develop anti-drug antibodies against Factor VIII, which can \par       compromise its efficacy and lead to bleeding complications. Pre-clinical \par       proof of concept for SEL-201 in Factor VIII-deficient mice was presented \par       at the 2013 \f28 \uc2 \f2 American Society for Hematology\f28 \uc2 \f2  (ASH) International \par       Conference. \par  \par    -- Food allergen program: \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  and \f28 \uc2 \f2 Sanofi\f28 \uc2 \f2  are engaged in a strategic \par       global collaboration to discover highly targeted, antigen-specific \par       immunotherapies for life-threatening allergies. Under the agreement, \par       \f28 \uc2 \f2 Sanofi\f28 \uc2 \f2  has obtained an exclusive license to develop an SVP immunotherapy \par       designed to abate acute immune responses against one life threatening \par       food allergen and an option to develop two additional candidate \par       immunotherapies for allergies each to a specific food or aeroallergen. \par  \par    -- Type 1 diabetes program: \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  has partnered with the Juvenile Diabetes \par       \f28 \uc2 \f2 Research Foundation\f28 \uc2 \f2  (JDRF) to demonstrate pre-clinical proof of concept \par       for SVP induction of antigen-specific T regulatory cells, which have the \par       potential to inhibit undesired immune reactions in autoimmune diseases. \par       \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  is planning to translate these results into immunomodulating SVP \par       therapeutics that contain up to four antigens that are responsible for \par       the immune attack on insulin producing beta cells in Type 1 diabetes. \f28 \par \par \uc2 \f2 The application of \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's SVP platform for immune activating vaccine programs includes several therapeutic programs involving research with government agencies and foundations, as follows:\f28 \par \par \uc2 \f2 \par    -- Nicotine vaccine program: SEL-068, the company's nicotine vaccine \par       candidate for smoking cessation and relapse prevention, successfully \par       completed a Phase 1 clinical trial. This trial included 80 subjects and \par       demonstrated that SEL-068 was safe and well-tolerated. Today's \par       announcement that \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  has secured an $8.1 million research grant from \par       the \f28 \uc2 \f2 National Institute on Drug Abuse\f28 \uc2 \f2  (NIDA), an institute at \f28 \uc2 \f2 NIH\f28 \uc2 \f2 , is \par       based on the data from the Company's Phase 1 clinical trial. The NIDA \par       award will support the advancement of \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's nicotine vaccine program \par       for smoking cessation and relapse prevention with the goal of optimizing \par       therapeutic efficacy. Under a previous research contract initiated in \par       2010, NIDA funded $3 million of research by \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  on pre-clinical \par       development and Phase 1 clinical testing of its nicotine vaccine. \par  \par    -- Malaria vaccine program: \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  has been awarded a $1.25 million grant \par       from the \f28 \uc2 \f2 Bill & Melinda Gates Foundation\f28 \uc2 \f2  to support the advancement by \par       \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  of a novel dual action, immune-activating SVP vaccine for \par       malaria. With this grant, \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's malaria program will build on efforts \par       that began in 2011 under a Leidos' (formerly SAIC) Malaria Vaccine \par       Production and Support Services contract with the \f28 \uc2 \f2 National Institute of \par       Allergy and Infectious Diseases\f28 \uc2 \f2  (NIAID). \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's malaria vaccine \par       candidate was selected based upon its demonstrated ability in preclinical \par       studies to outperform benchmarks in terms of antibody levels and \par       protection in a malaria parasite challenge model in mice. \par  \par    -- Human Papilloma Virus (HPV) Cancer Program: \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  is collaborating with \par       the \f28 \uc2 \f2 Skolkovo Foundation\f28 \uc2 \f2  to establish a development program of a \par       therapeutic vaccine for head and neck cancers caused by HPV. The vaccine \par       candidate is designed to elicit strong and durable cytolytic T cell \par       responses targeted to kill tumor cells expressing the E6 and E7 protein \par       of HPV. \f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Selecta\f28 \par \par \uc2 \f2 Selecta Biosciences, Inc\f28 \uc2 \f2 . is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's proprietary Synthetic Vaccine Particle (SVP(TM)) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles.\f28 \par \par \uc2 \f2 Selecta\f28 \uc2 \f2 's immunomodulatory SVPs can induce antigen-specific immune tolerance, enabling them to be applied in a variety of therapeutic areas with large unmet medical need. The company is focused on three key near-term applications: inhibition of immunogenicity for biologic therapies, treatment of allergies, and treatment of autoimmune diseases. Immunogenicity adversely affects the safety and efficacy profile for many biological therapies, and has caused the termination of a number of promising biological therapies in clinical development. \f28 \uc2 \f2 Selecta\f28 \uc2 \f2 's SVP is a product engine that has the potential to unlock the full therapeutic value of biological therapies.\f28 \par \par \uc2 \f2 Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, \f28 \uc2 \f2 Selecta\f28 \uc2 \f2  is building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases. \f28 \uc2 \f2 Selecta Biosciences, Inc\f28 \uc2 \f2 . is based in Watertown, Massachusetts, USA. For more information, please visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.selectabio.com"}}{\fldrslt{\cf2 \uc2 www.selectabio.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 (1) The KRYSTEXXA(R) product label states that, in a clinical trial, anti-pegloticase antibodies developed in 92% of patients treated with KRYSTEXXA every 2 weeks, see (\f28 {\field{\*\fldinst{HYPERLINK "http://krystexxa.com/pdfs/KRYSTEXXA_Prescribing_Information.pdf"}}{\fldrslt{\cf2 \uc2 http://krystexxa.com/pdfs/KRYSTEXXA_Prescribing_Information.pdf}}}\uc2 \f2  section 6.2 on p.8)\f28 \par \par \uc2 \f2 (2) van den Berg HM. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors. Haemophilia. 2014 May; 20 Suppl 4:76-9. and\f28 \par \par \uc2 \f2 Gouw SC et al.; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.\f28 \par \par \uc2 Document BWR0000020140617ea6h0002n\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 SunTech Medical\uc2  & AtCor  \highlight22\uc2 Launch \highlight\uc2  Innovative ABPM for Central BP\b0\par\par\uc2 438 \uc2 words\par \uc2 17 June 2014\par 03:00\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2014  Business Wire. All Rights Reserved.   \par \par \uc2 \f2 \par MORRISVILLE, N.C.--(BUSINESS WIRE)--June 17, 2014-- \f28 \par \par \uc2 \f2 SunTech Medical\f28 \uc2 \f2  and AtCor Medical, the two most trusted names in blood pressure (BP) measurement technology, announce the development of the new SunTech Oscar 2 Ambulatory Blood Pressure Monitor (ABPM) with SphygmoCor Inside. Specifically designed to measure central aortic BP in an ambulatory study, this \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  incorporates AtCor's globally-recognized Gold Standard SphygmoCor technology into \f28 \uc2 \f2 SunTech Medical\f28 \uc2 \f2 's Oscar 2 ABPM system, creating a patient-focused solution with unequaled comfort and data reliability.\f28 \par \par \uc2 AtCor's SphygmoCor technology, backed by more than 800 published clinical studies, provides the most detailed data available in the industry, including fully-featured physiological waveforms. SunTech's proprietary motion-tolerance technology and the patented Orbit cuff's patient-focused design helps ensure more accurate readings and fewer repeated studies.\par \par \uc2 Attendees at this year's \uc2 European Society of Hypertension\uc2  (ESH) and \uc2 International Society of Hypertension\uc2  (ISH) Joint Meeting from June 12-16 in Athens, Greece were able to view this new innovative product which will be available to the market in early Fall, 2014.\par \par \uc2 SunTech Medical\uc2 , a \uc2 Halma\uc2  company, has been the preeminent supplier of clinical-grade blood pressure monitoring products and technologies for nearly 30 years. More than 80 companies trust \uc2 SunTech Medical\uc2 's OEM non-invasive blood pressure solutions for their patient monitoring needs. \uc2 SunTech Medical\uc2  produces the leading cardiac stress test blood pressure monitor and is the world's foremost manufacturer of ambulatory blood pressure monitoring \uc2 products.SunTech Medical\uc2  also offers solutions for in-office blood pressure monitoring as well as a complete line of blood pressure cuffs designed for general and specific applications.\par \par \uc2 AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor(R) system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,400 SphygmoCor(R) systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 700 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at {\field{\*\fldinst{HYPERLINK "http://www.atcormedical.com"}}{\fldrslt{\cf2 \uc2 www.atcormedical.com}}}\uc2 .\par \par \uc2 Document BWR0000020140617ea6h0000t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Navidea Biopharm Files 8K - Other Events >NAVB\b0\par\par\uc2 603 \uc2 words\par \uc2 16 June 2014\par 15:52\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Navidea Biopharmaceuticals Inc\uc2 . (NAVB) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 13, 2014.\par \par \uc2 On June 13, 2014, the Company issued a press release announcing \uc2 U.S. Food and Drug Administration\uc2  (FDA) approval of its Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek (R) (technetium Tc 99m tilmanocept) Injection indicated for guiding sentinel lymph node (SLN) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for SLN detection and was first approved in March 2013 for lymphatic mapping in breast cancer and melanoma patients.\par \par \uc2 The expanded approval is supported by data from Navidea's NEO3-06 prospective Phase 3 study that showed with statistical significance the ability of Lymphoseek to correctly identify patients with pathology-positive lymph nodes compared with multiple level lymph node dissection and pathology assessment, which is the current "gold standard." The findings indicate that Lymphoseek accurately identified SLNs in the trial subjects for assessment, and is likely to be predictive of overall node pathology status. Moreover, multiple level nodal dissections of patients in the trial with cancer-positive lymph nodes led to an average removal of 38 lymph nodes per patient, whereas Lymphoseek on average would have led to the removal of approximately 4 lymph nodes, representing a substantial reduction in potential morbidity for patients with head and neck cancer undergoing SLN biopsy.\par \par \uc2 A copy of the complete text of the Company's June 13, 2014 press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/810509/000114420414037851/v381540_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/810509/000114420414037851/v381540_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/810509/000114420414037851/0001144204-14-037851-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/810509/000114420414037851/0001144204-14-037851-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Navidea Biopharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US63937X1037"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US63937X1037}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 16, 2014 15:52 ET (19:52 GMT)\par \par \uc2 Document DJDN000020140616ea6g002ub\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 TG Therapeutics\uc2  Files 8K - Other Events >TGTX\b0\par\par\uc2 281 \uc2 words\par \uc2 13 June 2014\par 08:45\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 TG Therapeutics Inc\uc2 . (TGTX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 13, 2014.\par \par \uc2 On June 13, 2014, \uc2 TG Therapeutics, Inc\uc2 . (the "Company") issued a press release announcing preliminary clinical results from its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib (IMBRUVICA(tm)), the oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19 th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. In addition to the data from the ongoing TG-1101 plus ibrutinib combination study, the Company is also presenting data at the EHA from ongoing single agent studies of TG-1101 and TGR- 1202, the Company's novel, oral PI3K delta inhibitor. A copy of the press release is being filed as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1001316/000114420414037450/v381386_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1001316/000114420414037450/v381386_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1001316/000114420414037450/0001144204-14-037450-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1001316/000114420414037450/0001144204-14-037450-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 TG Therapeutics, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US88322Q1085"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US88322Q1085}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 13, 2014 08:45 ET (12:45 GMT)\par \par \uc2 Document DJDN000020140613ea6d001pj\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Actonel\b0\par\par\uc2 143 \uc2 words\par \uc2 12 June 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan announced that the FDA has granted final approval for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Risedronate Sodium Tablets, the generic version of \uc2 Warner Chilcott\uc2 's Actonel.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-pharmaceuticals/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced that the FDA has granted final approval for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Risedronate Sodium Tablets, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/warner-chilcott-laboratories/manufacturer/11570/"}}{\fldrslt{\cf2 \uc2 Warner Chilcott's}}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/actonel/drug/2039/"}}{\fldrslt{\cf2 \uc2 Actonel}}}\uc2 .\par \par \uc2 Actonel is a bisphosphonate indicated for the treatment and prevention of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/osteoporosis-treatments/article/123840/"}}{\fldrslt{\cf2 \uc2 osteoporosis}}}\uc2  in postmenopausal women. Actonel has an affinity for hydroxyapatite crystals in bone and acts as an antiresoprtive agent. At the cellular level, Actonel inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/osteoporosis-treatments/article/123840/?DCMP=OTC-MPR_Related-Links"}}{\fldrslt{\cf2 \uc2 RELATED: Osteoporosis Treatments}}}\par \par \uc2 Risedronate Tablets are available in a 150mg strength and shipment has begun for this product.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020140613ea6c00002\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Breckenridge Announces Approval for Duloxetine Delayed-release Capsules\b0\par\par\uc2 227 \uc2 words\par \uc2 12 June 2014\par 14:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 BOCA RATON, Fla., June 12, 2014 /PRNewswire/ -- \uc2 Breckenridge Pharmaceutical, Inc\uc2 . announced today the immediate \b \highlight22\uc2 launch\b0 \highlight\uc2  of Duloxetine Delayed-release Capsules. The \uc2 U.S. Food and Drug Administration\uc2  granted final approval for the Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA), which is being manufactured and supplied by its parent company, \uc2 Laboratorios Dr. Esteve, S.A\uc2 . Barcelona, Spain, and will be available in 20mg, 30mg and 60mg strengths. Duloxetine Delayed-release Capsules are AB rated to Cymbalta(R), a drug marketed by \uc2 Eli Lilly\uc2 , for the treatment of (MDD) Major Depressive Disorder. This milestone signifies the first vertically-integrated product developed and commercialized between Breckenridge and Esteve.\par \par \uc2 (The API is sourced from \uc2 Esteve Quimica\uc2 , Esteve's API division.)\par \par \uc2 About Breckenridge:\par \par \uc2 Breckenridge is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products and Medical Foods in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 60 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, and Liquids, and Powders.\par \par \uc2 *Cymbalta(R) is a registered trademark of \uc2 Eli Lilly and Company\par \par \uc2 SOURCE Breckenridge\par \par \uc2 /\par \par \uc2 Document PRN0000020140612ea6c000jt\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Merit Medical receives CFDA approval for Splittable Sheath\b0\par\par\uc2 129 \uc2 words\par \uc2 11 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Merit Medical Systems\uc2  announced several \b \highlight22\uc2 new product\b0 \highlight\uc2  introductions and corporate developments that will be discussed today at its annual meeting of shareholders. Merit reported that it has received approval from the Chinese government, or CFDA, for its Splittable Sheath. Merit also announced plans to \b \highlight22\uc2 introduce\b0 \highlight\uc2  four \b \highlight22\uc2 new products\b0 \highlight\uc2  at its summer European sales meeting. These \b \highlight22\uc2 new products\b0 \highlight\uc2  include the PreludeEASE Hydrophilic Radial Sheath which complements Merit's Think Radial program, the PHD Hemostatis Valve, the HeartSpan Steerable Sheath and the ReSolve Biliary Drainage Catheter. Additionally, Merit announced that product sales through Merit Sensor Systems continue to expand at a rate of 100% year-to-date. This growth is coming from \b \highlight22\uc2 new product\b0 \highlight\uc2  introductions as well as increased demand for existing products.\par \par \uc2 Document FLYWAL0020140611ea6b005v6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Actonel(R) Tablets, 150 mg\b0\par\par\uc2 331 \uc2 words\par \uc2 11 June 2014\par 11:50\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 PITTSBURGH, June 11, 2014 /PRNewswire/ -- \uc2 Mylan Inc\uc2 . (\uc2 Nasdaq\uc2 : MYL) today announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Risedronate Sodium Tablets USP, 150 mg, the generic version of \uc2 Warner Chilcott\uc2 's Actonel(R) Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women.\par \par \uc2 Risedronate Sodium Tablets USP, 150 mg, had U.S. sales of approximately $171.6 million for the 12 months ending March 31, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 303 ANDAs pending FDA approval representing $105.3 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 SOURCE \uc2 Mylan Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020140611ea6b000gl\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Theravance Files 8K - Other Events >THRX\b0\par\par\uc2 270 \uc2 words\par \uc2 11 June 2014\par 08:14\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Theravance Inc\uc2 . (THRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 11, 2014.\par \par \uc2 On June 11, 2014, \uc2 GlaxoSmithKline plc\uc2  (GSK) and \uc2 Theravance, Inc\uc2 . issued a press release announcing positive results from two Phase 3 studies which showed that patients with chronic obstructive pulmonary disease (COPD) who received the anticholinergic, INCRUSE(TM) ELLIPTA(R) (umeclidinium (UMEC) 62.5mcg), or umeclidinium 125mcg (an unlicensed dose) in addition to RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), an inhaled corticosteroid / long-acting beta2-agonist (LABA) combination, achieved an additional improvement in lung function (FEV1) compared to patients receiving FF/VI plus placebo. FF/VI has been developed under the LABA collaboration agreement between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 . A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414000939/theravance8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414000939/theravance8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414000939/0001102624-14-000939-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414000939/0001102624-14-000939-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Theravance, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 11, 2014 08:14 ET (12:14 GMT)\par \par \uc2 Document DJDN000020140611ea6b001so\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Symmetry Medical  \highlight22\uc2 Launches \highlight\uc2  Dual Connection Offset Acetabular Reamer Driver\b0\par\par\uc2 655 \uc2 words\par \uc2 11 June 2014\par 08:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Symmetry Medical \b \highlight22\uc2 Launches\b0 \highlight\uc2  Dual Connection Offset Acetabular Reamer Driver\par \par \uc2 Innovative \b \highlight22\uc2 New Product\b0 \highlight\uc2  Designed to Accommodate Various Surgical Approaches for Total Hip Arthroplasty\par \par \uc2 WARSAW, Ind., June 11, 2014 (GLOBE NEWSWIRE) -- \uc2 Symmetry Medical Inc\uc2 . (NYSE:SMA), a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays, announced today that it has launched the Dual Connection Offset Acetabular Reamer Driver through its OEM Solutions team. The product will be featured in Symmetry Medical's booth #431 at the 10th Annual Orthopedic Manufacturing & Technology Exposition and Conference (OMTEC exhibition) in Chicago on June 11-12, 2014.\par \par \uc2 Symmetry's new Dual Connection Offset Acetabular Reamer Driver is used during Total Hip Arthroplasty ("THA") surgery to easily introduce acetabular reamers to the hip joint and to enhance visibility in minimally invasive procedures such as Direct Anterior Approach THA surgery. The driver features a patented drive shaft assembly designed and tested to meet the demands of THA surgery. The product highlights include: \par \par \uc2 \f2 \par    -- Improved access to the acetabulum due to the low-profile reamer/driver \par       connection \par  \par    -- Innovative design allowing easy disassembly to facilitate the cleaning \par       and sterilization of the internal components \par  \par    -- An ergonomic silicone over-molded stabilization handle \par  \par    -- Compatibility with Symmetry's flagship 420SS Acetabular Reamers as well \par       as the Low-Profile Parabolic Reamers \f28 \par \par \uc2 \f2 Thomas W. Barrett\f28 \uc2 \f2 , Senior Vice President and Chief Commercial Officer, Symmetry Medical OEM Solutions, said, "The launch of the Dual Connection Offset Acetabular Reamer Driver is a significant advancement in our proven line of acetabular preparation products and further enhances our comprehensive offering of instruments for the anterior surgical approach for hip arthroplasty. Our New Product Development team tested this device extensively to validate the mechanical longevity with a focus in optimizing the long term functional performance and the overall ease of use. By providing valuable proprietary product innovation that can be added to our customers' surgical instrument sets, we continue to support our OEM customers, orthopedic surgeons and the patients that they serve."\f28 \par \par \uc2 \f2 Mr. Barrett added, "The product launch is also consistent with our strategy to grow our OEM Solution sales opportunities through use of our own proprietary medical device solutions."\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Symmetry Medical Inc\f28 \uc2 \f2 .\f28 \par \par \uc2 \f2 Symmetry Medical Inc\f28 \uc2 \f2 . is a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company's thousands of Teammates provide design, development and worldwide production capabilities for these products to customers in the orthopedic industry, other medical device markets, and specialized non-healthcare markets. Symmetry's trusted reputation and brands, broad Intellectual Property portfolio and commitment to innovation enable it to collaborate with hundreds of global medical device manufacturers as well as thousands of hospitals to provide solutions for today's needs and tomorrow's growth.\f28 \par \par \uc2 \f2 Forward-Looking Statements\f28 \par \par \uc2 \f2 Statements in the press release regarding \f28 \uc2 \f2 Symmetry Medical Inc\f28 \uc2 \f2 .'s business which are not historical facts may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking-Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at \f28 {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 \f2 . \f28 \par \par \uc2 \f2 \par CONTACT: Investors and Media: \par          The Ruth Group \par          \f28 \uc2 \f2 Zack Kubow\f28 \uc2 \f2  \par          (646) 536-7020 \par          zkubow@theruthgroup.com \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 June 11, 2014 08:01 ET (12:01 GMT)\f28 \par \par \uc2 Document DJDN000020140611ea6b001ry\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Auxilium Pharmaceuticals\uc2  Files 8K - Entry Into Definitive Agreement >AUXL\b0\par\par\uc2 1,212 \uc2 words\par \uc2 11 June 2014\par 07:04\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Auxilium Pharmaceuticals Inc\uc2 . (AUXL) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on June 09, 2014.\par \par \uc2 Distribution and Supply Agreement between \uc2 Auxilium Pharmaceuticals, Inc\uc2 . and Prasco, LLC\par \par \uc2 On June 9, 2014, \uc2 Auxilium Pharmaceuticals, Inc\uc2 . (the "Company" or "Auxilium") provided notice (a "Commencement Notice") to Prasco, LLC ("Prasco," and together with Auxilium, the "Parties," and each individually, a "Party") authorizing Prasco to commence purchasing, distributing and selling an authorized generic version of Testim(R) (testosterone gel) ("Testim") in 5 gram tubes which contain 50mg of testosterone (the "Generic Testosterone Product") in the United States of America and its territories and possessions (the "Territory") pursuant to a Distribution and Supply Agreement (the "Agreement") entered into by the Parties. Prasco commenced initial commercialization activities for the Generic Testosterone Product on June 9, 2014 and commenced shipping the Generic Testosterone Product on June 10, 2014.\par \par \uc2 The Agreement also provides general terms and conditions for the potential future distribution and supply of generic versions of other Auxilium branded products (such branded products, together with Testim, the "Branded Products," and such generic versions, together with the Generic Testosterone Product, the "Generic Products"), should the Company (i) decide to pursue such efforts during the term of the Agreement and (ii) agree to economic terms with Prasco relating to any such potential future product. The Company does not have any current plans to distribute generic versions of any of its Branded Products other than Testim. A summary of certain terms of the Agreement is set forth below.\par \par \uc2 Supply of Product:\par \par \uc2 Auxilium will provide Commencement Notices to Prasco authorizing Prasco to commence selling a given package configuration of a given dosage strength of a Generic Product (each, a "SKU") under the Agreement. Auxilium will provide individual Commencement Notices to Prasco for a particular SKU of a Generic Product.\par \par \uc2 Auxilium will grant to Prasco, on the commencement date set forth in each Commencement Notice (the "Commencement Date"), a non-sublicensable, nontransferable license to distribute, promote, market and sell a particular SKU of a Generic Product in the Territory as an authorized generic version of the applicable Auxilium Branded Product.\par \par \uc2 On the Commencement Date for each SKU, Prasco will provide Auxilium with an order identifying the initial quantities of such SKU of such Generic Product Auxilium is to supply. During the term of the Agreement, Auxilium will supply Prasco with all of Prasco's requirements for any Generic Product for marketing, distribution and sale as a Generic Product in the Territory.\par \par \uc2 Price of Product:\par \par \uc2 During the term of the Agreement, Prasco will pay Auxilium a price agreed to by the parties for each Generic Product on a SKU-by-SKU basis. Any such price will remain unchanged for an initial period of time and may thereafter be adjusted based on changes to costs and materials.\par \par \uc2 Royalty Payments:\par \par \uc2 During the term of the Agreement beginning on the first Commencement Date, Prasco will pay Auxilium, for each Generic Product, the percentage of net sales of such Generic Product that Auxilium owes to any licensor of the applicable Branded Product and a percentage of certain net distributable profits per quarter for each applicable SKU of such Generic Product.\par \par \uc2 Forecasts and Purchase Orders\par \par \uc2 For each calendar month following the first Commencement Date, Prasco will provide a forecast to Auxilium for each Generic Product that covers a twelve (12) month period starting with the calendar month after which Prasco provides such forecast (a "Rolling Forecast"). At the time of each Rolling Forecast, Prasco will provide Auxilium with a binding purchase order for Generic Products to be received by Prasco during a firm period of the Rolling Forecast.\par \par \uc2 Regulatory Matters:\par \par \uc2 Auxilium will have control over, and authority and responsibility for monitoring and coordinating all maintenance of, regulatory actions with respect to, and communications and filings with, the Food and Drug Administration with respect to any Generic Products and the distribution and sale of any Generic Products under the Agreement. Prasco shall be solely responsible for communications and filings with, and submissions to, regulatory agencies specifically and solely related to Generic Product sales, prices, discounts, rebates, fees, charge-backs and other payments associated with Prasco's distribution and sale of Generic Products under the Agreement.\par \par \uc2 Prasco is solely responsible for all federal, state and local government and private purchasing, pricing or reimbursement programs with respect to any Generic Products sold by Prasco.\par \par \uc2 Term:\par \par \uc2 Subject to each Party's termination rights, the term of the Agreement will continue, on a Generic Product-by- Generic Product basis, for a period of three years after the first commercial sale of each such Generic Product. The Agreement will automatically renew on a Generic Product-by- Generic Product basis, for an additional one-year term unless either Party elects not to renew the Agreement by providing written notice to the other Party within a specified period of time prior to the expiration of the applicable term.\par \par \uc2 Auxilium may terminate the Agreement at any time, for any reason, after having given prior written notice to Prasco within a specified period of time in advance of the termination. Auxilium may also terminate the Agreement in the event of delays in the first commercial sale of a particular SKU for any Generic Product, if there is a Prasco change in control, or in certain instances involving settlements of patent infringement lawsuits.\par \par \uc2 Prasco may terminate the Agreement in the event of delays with respect to a particular SKU for any Generic Product launch and the receipt of a Commencement Notice and/or for certain significant selling price decreases.\par \par \uc2 Either Party may terminate the Agreement as a result of the other Party's material breach or bankruptcy.\par \par \uc2 The foregoing is a summary description of certain terms of the Agreement and, by its nature, is incomplete. It is qualified in its entirety by the text of the Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2014 ("Form 10-Q"). All readers are encouraged to read the entire text of the Agreement. Certain terms of the Agreement have been omitted from this Current Report on Form 8-K and will be omitted from the version of the Agreement attached as an exhibit to the Company's upcoming Form 10-Q pursuant to a Confidential Treatment Request that the Company plans to file with the Securities and Exchange Commission at the time of the filing of such Form 10-Q.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465914045215/a14-15198_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465914045215/a14-15198_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465914045215/0001104659-14-045215-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465914045215/0001104659-14-045215-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Auxilium Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US05334D1072"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US05334D1072}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 11, 2014 07:04 ET (11:04 GMT)\par \par \uc2 Document DJDN000020140611ea6b001h2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Tonix Pharmaceuticals\uc2  Files 8K - Other Events >TNXP\b0\par\par\uc2 326 \uc2 words\par \uc2 10 June 2014\par 08:37\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Tonix Pharmaceuticals Holding Corp\uc2 . (TNXP) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 09, 2014.\par \par \uc2 On June 10, 2014, the Company issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  cleared the Company's investigational new drug ("IND") application to develop TNX-102 SL for the treatment of post-traumatic stress disorder ("PTSD"). The Company further reported that, as a result of the clearance of the IND, the Company will be able to move forward in the third quarter of this year with its planned U.S.-based Phase 2 clinical trial designed to evaluate the safety and efficacy of TNX-102 SL in patients with PTSD.\par \par \uc2 A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1430306/000114420414036709/v381041_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1430306/000114420414036709/v381041_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1430306/000114420414036709/0001144204-14-036709-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1430306/000114420414036709/0001144204-14-036709-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 10, 2014 08:37 ET (12:37 GMT)\par \par \uc2 Document DJDN000020140610ea6a001y3\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: RECEPTOS FILES CURRENT REPORT\b0\par\par\uc2 1,093 \uc2 words\par \uc2 10 June 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, June 10 -- \uc2 Receptos Inc\uc2 ., San Diego, files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on June 9.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Regulation FD Disclosure.\par \par \uc2 On June 9, 2014, \uc2 Receptos, Inc\uc2 . ("Receptos" or the "Company") issued a press release announcing top-line results for the Phase 2 portion of its RADIANCE trial for RPC1063, as further described in Item 8.01 below. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.\par \par \uc2 The Receptos management team will host a teleconference and webcast on June 9, 2014 at 5:00 p.m. Eastern (2:00 p.m. Pacific) to discuss the information in the press release. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), conference ID 58382320. The webcast can be accessed live on the Investor Relations section of the Receptos website at {\field{\*\fldinst{HYPERLINK "http://www.receptos.com"}}{\fldrslt{\cf2 \uc2 www.receptos.com}}}\uc2 .\par \par \uc2 The information in this Item 7.01 as well as Exhibit 99.1 to this report is being furnished to the \uc2 Securities and Exchange Commission\uc2  and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof.\par \par \uc2 Other Events.\par \par \uc2 On June 9, 2014, Receptos announced top-line results for the Phase 2 portion of RADIANCE, the Company's accelerated design, randomized Phase 2/3 study of its drug candidate RPC1063 for the treatment of relapsing multiple sclerosis ("RMS"). The randomized, double-blind study assessed the efficacy, safety and tolerability of two orally administered doses (0.5mg and 1.0mg) of RPC1063 against placebo in 258 patients with RMS across 77 sites in 13 countries.\par \par \uc2 The primary endpoint of the Phase 2 portion of RADIANCE was the reduction in the cumulative number of total gadolinium-enhancing ("GdE") lesions determined by magnetic resonance imaging ("MRI") from week 12 to week 24 of study treatment. Patients on RPC1063 experienced a statistically significant reduction in GdE lesions of 86% at both 0.5mg and 1.0mg doses compared to patients on placebo (p-values <0.0001 for each dose group compared to placebo). Secondary endpoints measuring effects on other MRI parameters were also positive and statistically significant (p<0.0001 for each dose group compared to placebo). Although the Phase 2 portion of RADIANCE was not powered to detect a statistically significant difference between RPC1063 treatment arms and placebo on annualized relapse rate ("ARR"), there was a favorable trend for both RPC1063 dose groups.\par \par \uc2 The Company believes that safety and tolerability data from the Phase 2 portion of RADIANCE provide support for a differentiated, potential best-in-class profile, including (i) an overall adverse event profile which appeared relatively similar between the RPC1063 dose groups and placebo with no concerning safety signals for patients receiving RPC1063; (ii) first dose changes in heart rate in patients receiving RPC1063 that were generally modest (maximum mean reduction <2 beats per minute compared to baseline) with no patients dropping below 45 beats per minute during the first six hours after administration, which is consistent with the findings of the Company's earlier thorough QT study; and (iii) rates of liver transaminase elevations observed in patients receiving RPC1063 that were low relative to agents with similar mechanisms of action on the market or in clinical development, and supportive of a favorable hepatic safety profile.\par \par \uc2 Receptos initiated the Phase 3 portion of RADIANCE under a Special Protocol Assessment (SPA) with the FDA in December 2013. The Phase 3 portion of RADIANCE, which is currently enrolling patients, is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex(R)) in 1,200 patients with RMS.\par \par \uc2 Financial Statements and Exhibits.\par \par \uc2 (d) Exhibits.\par \par \uc2 Exhibit No. - Description\par \par \uc2 99.1 - Press release issued by \uc2 Receptos, Inc\uc2 . on June 9, 2014.\par \par \uc2 Exhibit 99.1 to this report is being furnished to the \uc2 Securities and Exchange Commission\uc2  and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof.\par \par \uc2 Forward-Looking Statements\par \par \uc2 The statement in this Current Report on Form 8-K, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The word "believes" as well as similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of RPC1063, constitute forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation consistency of trial results to date with further trial results, the Company's ability to adequately and timely recruit and enroll patients in its clinical trials, as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company's \uc2 SEC\uc2  filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2013 and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. All forward-looking statements contained in this report speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/d740435d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/d740435d8k.htm}}}\par \par \uc2 Document INDFED0020140610ea6a000hb\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 BioDelivery Sciences Files 8K - Other Events >BDSI\b0\par\par\uc2 216 \uc2 words\par \uc2 9 June 2014\par 16:32\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 BioDelivery Sciences International Inc\uc2 . (BDSI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 09, 2014.\par \par \uc2 On June 6, 2014, \uc2 BioDelivery Sciences International, Inc\uc2 . (the "Company") issued a press release announcing that the Company received approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) on its New Drug Application (NDA) for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII), a drug delivery technology used for the maintenance treatment of opioid dependence. A copy of such press release is attached as Exhibit 99.1 hereto.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312514230426/d740613d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312514230426/d740613d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1103021/000119312514230426/0001193125-14-230426-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1103021/000119312514230426/0001193125-14-230426-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 BioDelivery Sciences International, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US09060J1060"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US09060J1060}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 09, 2014 16:32 ET (20:32 GMT)\par \par \uc2 Document DJDN000020140609ea690037c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Novavax\uc2  Files 8K - Other Events >NVAX\b0\par\par\uc2 200 \uc2 words\par \uc2 9 June 2014\par 16:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Novavax Inc\uc2 . (NVAX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 05, 2014.\par \par \uc2 On June 4, 2014, the Company issued a press release announcing the launch of the Offering. On June 5, 2014, the Company issued a press release announcing the pricing of the Offering A copy of the Company's press releases are attached hereto as Exhibit 99.1 and 99.2 and are incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1000694/000114420414036569/v380988_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1000694/000114420414036569/v380988_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1000694/000114420414036569/0001144204-14-036569-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1000694/000114420414036569/0001144204-14-036569-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Novavax, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US6700021040"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US6700021040}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 09, 2014 16:16 ET (20:16 GMT)\par \par \uc2 Document DJDN000020140609ea6900317\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Receptos Files 8K - Other Events >RCPT\b0\par\par\uc2 542 \uc2 words\par \uc2 9 June 2014\par 16:10\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Receptos Inc\uc2 . (RCPT) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 09, 2014.\par \par \uc2 On June 9, 2014, Receptos announced top-line results for the Phase 2 portion of RADIANCE, the Company's accelerated design, randomized Phase 2/3 study of its drug candidate RPC1063 for the treatment of relapsing multiple sclerosis ("RMS"). The randomized, double-blind study assessed the efficacy, safety and tolerability of two orally administered doses (0.5mg and 1.0mg) of RPC1063 against placebo in 258 patients with RMS across 77 sites in 13 countries.\par \par \uc2 The primary endpoint of the Phase 2 portion of RADIANCE was the reduction in the cumulative number of total gadolinium-enhancing ("GdE") lesions determined by magnetic resonance imaging ("MRI") from week 12 to week 24 of study treatment. Patients on RPC1063 experienced a statistically significant reduction in GdE lesions of 86% at both 0.5mg and 1.0mg doses compared to patients on placebo (p-values <0.0001 for each dose group compared to placebo). Secondary endpoints measuring effects on other MRI parameters were also positive and statistically significant (p<0.0001 for each dose group compared to placebo). Although the Phase 2 portion of RADIANCE was not powered to detect a statistically significant difference between RPC1063 treatment arms and placebo on annualized relapse rate ("ARR"), there was a favorable trend for both RPC1063 dose groups.\par \par \uc2 The Company believes that safety and tolerability data from the Phase 2 portion of RADIANCE provide support for a differentiated, potential best-in-class profile, including (i) an overall adverse event profile which appeared relatively similar between the RPC1063 dose groups and placebo with no concerning safety signals for patients receiving RPC1063; (ii) first dose changes in heart rate in patients receiving RPC1063 that were generally modest (maximum mean reduction <2 beats per minute compared to baseline) with no patients dropping below 45 beats per minute during the first six hours after administration, which is consistent with the findings of the Company's earlier thorough QT study; and (iii) rates of liver transaminase elevations observed in patients receiving RPC1063 that were low relative to agents with similar mechanisms of action on the market or in clinical development, and supportive of a favorable hepatic safety profile.\par \par \uc2 Receptos initiated the Phase 3 portion of RADIANCE under a Special Protocol Assessment (SPA) with the FDA in December 2013. The Phase 3 portion of RADIANCE, which is currently enrolling patients, is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex (R)) in 1,200 patients with RMS.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/d740435d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/d740435d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/0001193125-14-230349-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1463729/000119312514230349/0001193125-14-230349-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 09, 2014 16:10 ET (20:10 GMT)\par \par \uc2 Document DJDN000020140609ea690030l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Rockwell Medical\uc2  Files 8K - Other Events >RMTI\b0\par\par\uc2 261 \uc2 words\par \uc2 9 June 2014\par 08:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Rockwell Medical Inc\uc2 . (RMTI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 09, 2014.\par \par \uc2 On June 9, 2014, \uc2 Rockwell Medical, Inc\uc2 . (the "Company") issued a press release that announced it has won its appeal for size determination as a small business and is now working with the \uc2 U.S. Food & Drug Administration\uc2  (FDA) to have its $2.2 million PDUFA User Fee for filing its New Drug Application for Triferic refunded. The Company expects to receive a refund for $2.2 million from the U.S. Department of Treasury. Triferic is the Company's iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.\par \par \uc2 A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000117184314002729/f8k_060914.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000117184314002729/f8k_060914.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1041024/000117184314002729/0001171843-14-002729-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1041024/000117184314002729/0001171843-14-002729-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Rockwell Medical, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US7743741024"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US7743741024}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 09, 2014 08:01 ET (12:01 GMT)\par \par \uc2 Document DJDN000020140609ea690018e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 BioDelivery receives FDA approval for Bunavail\b0\par\par\uc2 58 \uc2 words\par \uc2 6 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 BioDelivery Sciences International\uc2  received approval of the \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for Bunavail buccal film from the FDA. Bunavail is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. BDSI expects to \b \highlight22\uc2 launch\b0 \highlight\uc2  Bunavail late in Q3.\par \par \uc2 Document FLYWAL0020140606ea66008q4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Ariad Pharmaceuticals\uc2  Files 8K - Other Events >ARIA\b0\par\par\uc2 659 \uc2 words\par \uc2 5 June 2014\par 16:06\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Ariad Pharmaceuticals Inc\uc2 . (ARIA) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 31, 2014.\par \par \uc2 On May 31, 2014, \uc2 ARIAD Pharmaceuticals, Inc\uc2 . (the "Company") issued the first of four press releases announcing data presented at the 2014 \uc2 American Society of Clinical Oncology\uc2  (ASCO) Annual Meeting in Chicago, Illinois. This press release detailed preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig (R) (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01of this Current Report on Form 8-K.\par \par \uc2 On May 31, 2014, the Company issued a second press release announcing updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show anti-tumor activity of AP26113 in patients with crizotinib-resistant anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with brain metastases. Crizotinib is approved for ALK-positive NSCLC patients. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01of this Current Report on Form 8-K.\par \par \uc2 On June 1, 2014, the Company issued a press release announcing data, for the first time, from its Phase 2 trial of Iclusig in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The initial data show that ponatinib has anti-tumor activity in patients with advanced GIST, particularly in patients with KIT exon 11 mutations, after failure of at least one prior TKI. The primary endpoint for the trial, clinical benefit rate (CBR) at 16 weeks for patients with KIT exon 11 mutations, was 50 percent, with a median follow-up of six months. A copy of the press release is attached hereto as Exhibit 99.3 and is incorporated by reference into this Item 8.01of this Current Report on Form 8-K.\par \par \uc2 On June 2, 2014, the Company issued its fourth and final press release from ASCO announcing longer-term follow up from its Phase 1 and pivotal Phase 2 PACE trials of Iclusig in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The studies now show that, with a median follow-up of 42.5 months for chronic-phase CML (CP-CML) patients in the Phase 1 trial, Iclusig continues to demonstrate anti-leukemic activity in those who had limited treatment options, and that deep and durable responses have been maintained in CP-CML patients in the PACE trial with 87 percent estimated to remain in major cytogenetic response (MCyR) at two years. Longer-term safety data show that careful benefit/risk evaluation should guide the decision to use ponatinib therapy, particularly in patients who may be at increased risk for vascular occlusive events. A copy of the press release is attached hereto as Exhibit 99.4 and is incorporated by reference into this Item 8.01of this Current Report on Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752314002473/a50880934.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752314002473/a50880934.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/884731/000115752314002473/0001157523-14-002473-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/884731/000115752314002473/0001157523-14-002473-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 ARIAD Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US04033A1007"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US04033A1007}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 05, 2014 16:06 ET (20:06 GMT)\par \par \uc2 Document DJDN000020140605ea65003oc\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 CorePharma, LLC \highlight22\uc2 Announces the Launch \highlight\uc2  of Dextroamphetamine Sulfate Tablets, USP\b0\par\par\uc2 230 \uc2 words\par \uc2 4 June 2014\par 12:47\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.  \par \par \uc2 MIDDLESEX, N.J., June 4, 2014 /PRNewswire/ -- \uc2 CorePharma, LLC\uc2  ("\uc2 CorePharma\uc2 "), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Dextroamphetamine Sulfate Tablets, USP ("Dextroamphetamine"), the generic version of Shire's Dextrostat(R). Dextroamphetamine is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. \uc2 CorePharma\uc2  received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) on March 7, 2014. The product is available in the 5 and 10mg strengths and has begun shipping.\par \par \uc2 The dextroamphetamine immediate release tablet market had U.S. sales of approximately $41 million according to IMS data as of April 2014.\par \par \uc2 About \uc2 CorePharma\par \par \uc2 CorePharma\uc2 , Middlesex, NJ, is a developer, manufacturer and marketer of targeted generic prescription pharmaceuticals across a variety of dosage forms and therapeutic categories. \uc2 CorePharma\uc2  operates a state-of-the-art facility, totaling 112,000 square feet of space, in Middlesex, NJ. The company actively seeks partnerships, licensing and acquisition opportunities to complement and expand its product portfolio. \uc2 CorePharma\uc2  is a wholly owned subsidiary of Tower Holdings, Inc. \uc2 RoundTable Healthcare Partners\uc2 , an operating-oriented private equity firm focused exclusively on the healthcare industry, owns a majority share of Tower Holdings.\par \par \uc2 SOURCE \uc2 CorePharma, LLC\par \par \uc2 /\par \par \uc2 Document PRN0000020140604ea64000j4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 ImmunoCellular Files 8K - Regulation FD >IMUC\b0\par\par\uc2 316 \uc2 words\par \uc2 4 June 2014\par 17:11\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 ImmunoCellular Therapeutics Ltd\uc2 . (IMUC) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on June 01, 2014.\par \par \uc2 99.1 \uc2 ImmunoCellular Therapeutics, Ltd\uc2 . posted slides presented by Patrick Y. Wen, MD, Director of the Center for Neuro-Oncology at The \uc2 Dana Farber Cancer Institute\uc2  and Professor of Neurology at \uc2 Harvard Medical School\uc2 , and principal investigator on the Phase II clinical trial of ICT-107 in an oral presentation made at the \uc2 American Society of Clinical Oncology\uc2  (ASCO) on June 1, 2014 titled, "A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients," a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The information included in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under this Securities Act of 1933, as amended, except as may expressly set forth by specific reference to this Item 7.01 in such a filing.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/822411/000119312514225881/d737200d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/822411/000119312514225881/d737200d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/822411/000119312514225881/0001193125-14-225881-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/822411/000119312514225881/0001193125-14-225881-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 ImmunoCellular Therapeutics Ltd\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US4525361055"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US4525361055}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 04, 2014 17:11 ET (21:11 GMT)\par \par \uc2 Document DJDN000020140604ea64003ts\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Upsher-Smith Receives Final NDA Approval For Vogelxo(TM) (Testosterone) Gel CIII\b0\par\par\uc2 237 \uc2 words\par \uc2 4 June 2014\par 14:53\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 MAPLE GROVE, Minn., June 4, 2014 /PRNewswire/ -- \uc2 Upsher-Smith Laboratories, Inc\uc2 ., today announced that it has received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (NDA) for Vogelxo(TM) (testosterone) gel for topical use CIII. The company is preparing to \b \highlight22\uc2 launch\b0 \highlight\uc2  Vogelxo(TM) in the near future.\par \par \uc2 About Upsher-Smith\par \par \uc2 Upsher-Smith Laboratories, Inc\uc2 ., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life(TM). With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to offering quality products that enable people to live life to its greatest potential. Upsher-Smith's approach to product development and partnering has resulted in a broad range of both branded and generic therapeutic solutions to address patients' needs. The Company has a particular focus on developing therapies for people living with central nervous system (\uc2 CNS\uc2 ) conditions, such as seizure disorders, and has a robust pipeline of promising \uc2 CNS\uc2  compounds in various stages of development. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.upsher-smith.com"}}{\fldrslt{\cf2 \uc2 www.upsher-smith.com}}}\uc2 .\par \par \uc2 Please see Full Prescribing Information, including Boxed Warning, at {\field{\*\fldinst{HYPERLINK "http://tinyurl.com/mc7baos"}}{\fldrslt{\cf2 \uc2 http://tinyurl.com/mc7baos}}}\uc2 .\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20130520/NY17281LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20130520/NY17281LOGO}}}\par \par \uc2 SOURCE \uc2 Upsher-Smith Laboratories, Inc\uc2 .\par \par \uc2 /\par \par \uc2 Document PRN0000020140604ea64000m3\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 ARENA PHARMACEUTICALS\uc2  FILES CURRENT REPORT\b0\par\par\uc2 836 \uc2 words\par \uc2 4 June 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, June 4 -- \uc2 Arena Pharmaceuticals Inc\uc2 ., San Diego, files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on June 3.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 In this report, "\uc2 Arena Pharmaceuticals\uc2 ," "Arena," "Company," "we," "us" and "our" refer to \uc2 Arena Pharmaceuticals, Inc\uc2 ., and/or one or more of our wholly owned subsidiaries, unless the context otherwise provides. \uc2 Arena Pharmaceuticals\uc2 (R) and Arena(R) are registered service marks of \uc2 Arena Pharmaceuticals, Inc\uc2 . BELVIQ(R) is a registered trademark of our wholly owned subsidiary, \uc2 Arena Pharmaceuticals GmbH\uc2 .\par \par \uc2 Other Events.\par \par \uc2 As previously announced, we are scheduled to present a corporate overview today at the Jefferies 2014 Global Healthcare Conference. The corporate overview will include certain updates, including the following:\par \par \uc2 We recently initiated dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1, or S1P1, receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.\par \par \uc2 We and Eisai also recently completed enrollment of a 12-week, Phase 2, proof-of-concept trial of approximately 600 active smokers to evaluate lorcaserin as an aid to smoking cessation. The primary outcome measure in this randomized, double-blind, placebo-controlled Phase 2 trial will assess if patients are able to maintain abstinence from cigarette smoking for the last four weeks of treatment, also known as the continuous quit rate. Results for this study are expected around year-end. Lorcaserin is an investigational drug candidate for smoking cessation. The efficacy and safety of lorcaserin for smoking cessation have not been established.\par \par \uc2 Forward-Looking Statements\par \par \uc2 Certain statements in this Form 8-K are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication, use, safety, efficacy, mechanism of action and potential of APD334 and lorcaserin; and the protocol, design, scope, enrollment, results, expectations and other aspects of the trials of APD334 and lorcaserin. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; our revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to our guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and our business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than us or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of our research and development may not meet regulatory requirements or otherwise be sufficient for (or we or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; our ability to obtain and defend patents; the timing, success and cost of our research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in our filings with the \uc2 Securities and Exchange Commission\uc2 . These forward-looking statements represent our judgment as of the time of the filing of this Form 8-K. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080709/000119312514223288/d737212d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080709/000119312514223288/d737212d8k.htm}}}\par \par \uc2 Document INDFED0020140604ea64000u2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Advaxis Files 8K - Regulation FD >ADXS\b0\par\par\uc2 276 \uc2 words\par \uc2 4 June 2014\par 07:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Advaxis Inc\uc2 . (ADXS) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on May 31, 2014.\par \par \uc2 On May 31, 2014, \uc2 Advaxis, Inc\uc2 . (the "Company") issued a press release announcing that the Company presented final results from the Phase 2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in women with recurrent cervical cancer at the 2014 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. A copy of the Company's press release is attached hereto as Exhibit 99.1.\par \par \uc2 The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315214001810/form8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315214001810/form8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1100397/000149315214001810/0001493152-14-001810-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1100397/000149315214001810/0001493152-14-001810-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 04, 2014 07:31 ET (11:31 GMT)\par \par \uc2 Document DJDN000020140604ea64001hh\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 NanoString Technologies\uc2  Files 8K - Other Events >NSTG\b0\par\par\uc2 232 \uc2 words\par \uc2 3 June 2014\par 16:41\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 NanoString Technologies Inc\uc2 . (NSTG) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 03, 2014.\par \par \uc2 On June 3, 2014, \uc2 NanoString Technologies, Inc\uc2 . ("NanoString" or the "Company") issued a press release announcing it had entered into a companion diagnostics collaboration with \uc2 Celgene Corporation\uc2  ("Celgene") under which the Company will support the development of Celgene's Revlimid for the treatment of Diffuse Large B-cell Lymphoma ("DLBCL") by developing an in vitro diagnostic assay that is intended to be used to enroll patients in a Phase III study of Revlimid for the treatment of a specific subtype of DLBCL. A copy of the press release announcing the Celgene collaboration is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401708/000119312514224059/d737057d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401708/000119312514224059/d737057d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401708/000119312514224059/0001193125-14-224059-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401708/000119312514224059/0001193125-14-224059-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 03, 2014 16:41 ET (20:41 GMT)\par \par \uc2 Document DJDN000020140603ea63003rb\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: ONCOTHYREON FILES CURRENT REPORT\b0\par\par\uc2 823 \uc2 words\par \uc2 3 June 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, June 3 -- \uc2 Oncothyreon Inc\uc2 ., Seattle, files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on June 2.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Entry into a Material Definitive Agreement.\par \par \uc2 On May 28, 2014, \uc2 Oncothyreon Inc\uc2 . (the "Company") entered into a Phase I Co-Development Agreement (the "Agreement") with \uc2 Celldex Therapeutics, Inc\uc2 . ("Celldex"). Pursuant to the Agreement, the Company and Celldex agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. The planned trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses and anti-tumor effects.\par \par \uc2 The Agreement provides that the Company will supply ONT-10 and Celldex will supply CDX-1127. The Phase 1b trial will be conducted and funded by the Company. The Company and Celldex will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the Agreement, neither the Company nor Celldex has granted the other a license, or any other rights, to its product candidate.\par \par \uc2 The Agreement will continue until the completion of the Phase 1b trial, but may be terminated earlier upon written notice from either party or breach of the Agreement. The Company and Celldex have also agreed to indemnity the other party for certain of their respective activities under the Agreement.\par \par \uc2 The Company expects to file the Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2014. The foregoing description is qualified in its entirety by reference to the text of the Agreement when filed.\par \par \uc2 Other Events.\par \par \uc2 On May 29, 2014, the Company and Celldex issued a press release announcing their entry into the Agreement.\par \par \uc2 On June 2, 2014, the Company issued a press release announcing the presentation of data from a Phase 1 trial of ONT-10 at the American Association of Clinical Oncology 2014 Annual Meeting in Chicago. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with a variety of cancer types.\par \par \uc2 Copies of these press releases are attached as Exhibit 99.1 and Exhibit 99.2 hereto and are incorporated herein by reference.\par \par \uc2 Financial Statements and Exhibits\par \par \uc2 (d) Exhibits.\par \par \uc2 Exhibit Number - Description\par \par \uc2 99.1 - Press Release issued by \uc2 Oncothyreon Inc\uc2 . and \uc2 Celldex Therapeutics, Inc\uc2 . dated May 29, 2014.\par \par \uc2 99.2 - Press Release issued by \uc2 Oncothyreon Inc\uc2 . dated June 2, 2014.\par \par \uc2 Forward-Looking Statements\par \par \uc2 In order to provide the Company's investors with an understanding of its current results and future prospects, this Current Report on Form 8-K contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include the Company's expectations regarding clinical development activities and potential benefits of its product candidates.\par \par \uc2 Forward-looking statements involve risks and uncertainties related to the Company's business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause the Company's actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of its product candidates and the indications for which its product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the Company's risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. The Company does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1412067/000119312514222227/d734470d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1412067/000119312514222227/d734470d8k.htm}}}\par \par \uc2 Document INDFED0020140603ea63000np\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Threshold Pharmaceuticals Files 8K - Other Events >THLD\b0\par\par\uc2 273 \uc2 words\par \uc2 2 June 2014\par 17:18\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Threshold Pharmaceuticals Inc\uc2 . (THLD) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 30, 2014.\par \par \uc2 On May 30, 2014, \uc2 Threshold Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing new clinical data from an ongoing investigator-sponsored Phase 1/2 trial of the Company's investigational hypoxia-activated prodrug, TH-302, in combination with bevacizumab (Avastin (R)) in patients with recurrent glioblastoma following progression on single-agent bevacizumab.\par \par \uc2 Also on May 30, 2014, the Company issued a press release announcing new preliminary clinical data from an ongoing Company-sponsored Phase 1/2 trial of the Company's investigational hypoxia-activated prodrug, TH-302, in combination with low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.\par \par \uc2 The press releases are attached as Exhibit 99.1 and 99.2, respectively, to this Form 8-K.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1183765/000114420414035099/v380468_8-k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1183765/000114420414035099/v380468_8-k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1183765/000114420414035099/0001144204-14-035099-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1183765/000114420414035099/0001144204-14-035099-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Threshold Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US8858072064"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US8858072064}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 02, 2014 17:18 ET (21:18 GMT)\par \par \uc2 Document DJDN000020140602ea62003p2\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 GTx Files 8K - Other Events >GTXI\b0\par\par\uc2 255 \uc2 words\par \uc2 2 June 2014\par 14:54\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 GTx Inc\uc2 . (GTXI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on June 02, 2014.\par \par \uc2 On June 2, 2014, \uc2 GTx, Inc\uc2 . issued a press release announcing positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented during the Breast Cancer-HER2/ER poster session being held June 2, 2014 during the 50th Annual Meeting of the \uc2 American Society of Clinical Oncology\uc2  (ASCO) in Chicago, Illinois.\par \par \uc2 A copy of the press release is furnished as Exhibit 99.1 to this Current Report.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1260990/000110465914043264/a14-14450_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1260990/000110465914043264/a14-14450_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1260990/000110465914043264/0001104659-14-043264-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1260990/000110465914043264/0001104659-14-043264-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 GTx, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US40052B1089"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US40052B1089}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 02, 2014 14:54 ET (18:54 GMT)\par \par \uc2 Document DJDN000020140602ea620033t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 CareFusion to  \highlight22\uc2 Launch \highlight\uc2  Three New Infection Prevention Products at APIC 2014\b0\par\par\uc2 1,124 \uc2 words\par \uc2 2 June 2014\par 08:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par Data To Be Presented on Improving Cleansing Compliance Through StartClean Cleansing Program \par  \f28 \par \par \uc2 \f2 SAN DIEGO, June 2, 2014 /PRNewswire/ -- At the 41(st) Annual Conference of the \f28 \uc2 \f2 Association for Professionals in Infection Control and Epidemiology\f28 \uc2 \f2  (APIC), CareFusion (\f28 \uc2 \f2 NYSE\f28 \uc2 \f2 :CFN), a leading global medical technology company, will \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  three \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  that are designed to help reduce surface contamination or the presence of microorganisms that can potentially cause infections during hospital stays and procedures.\f28 \par \par \uc2 The ChloraPrep(R) 1mL applicator is a new addition to the ChloraPrep line of preoperative skin preparation products. It provides clinicians with a unique applicator design and the same formulation they know and trust in a new 1 mL size. With its unique delivery system and winged activation design, the 1 mL applicator is easy to use and can help promote aseptic techniques and best practices. ChloraPrep skin prep products have been proven to be more effective than povidone-iodine at eliminating microorganisms on the skin that may cause infection.[1][2][3]\par \par \uc2 The ChloraShield(R) IV dressing with chlorhexidine gluconate (CHG) antimicrobial is a flexible and breathable dressing, that enhances patient care during vascular access procedures. The dressing features BeneHold(TM) CHG, an innovative adhesive technology from Vancive Medical Technologies(TM), an \uc2 Avery Dennison\uc2  business, which comfortably secures the dressing to the skin, absorbs fluid and protects the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth. ChloraShield dressings are designed to be easy for clinicians to apply and remove, and comfortable for patients to wear. CareFusion is the exclusive distributor of the dressing in North America.\par \par \uc2 The MaxZero(TM) needleless connector from CareFusion is a new extension to a proprietary portfolio of needleless connectors and is designed to help improve patient safety and promote nursing best practices. With a solid, sealed surface, the connector provides a barrier to bacteria and contamination and enables effective three second disinfection with an alcohol pad. The design of the MaxZero needleless connector prevents reflux of blood into the catheter at disconnect and also has a smaller profile. A clear fluid path enhances flushing and anti-reflux technology prevents the need for a clamping sequence, helping save nurses time and reducing process steps.\par \par \uc2 In addition to new products, new data is being presented on tools that can improve patient compliance with physician cleansing instructions and how increased compliance can affect the amount of antiseptic present on the skin. A unique reminder system to improve bathing compliance is one of the key features to the StartClean Cleansing Program from CareFusion, where patients receive a 4 percent CHG cleanser with disposable sponges and an individualized service that contacts patients via text, email, or voice message reminding them to use the cleanser in accordance with physician instructions. The data will be presented by Dr. Charles Edmiston from the Medical College of Wisconsin during a poster presentation on Saturday, June 7 from 12:30 to 1:30 p.m.\par \par \uc2 Additional highlights in CareFusion booth #911 at the APIC conference include:\par \par \uc2 \f2 \par    -- CareFusion Focus on Quality Care Initiative: CareFusion is helping \par       facilities on the path to quality improvement by supporting their efforts \par       to standardize and reduce variability. Learn about the tools, training \par       and tactics hospitals need to help reduce variability and improve patient \par       care. \par  \par    -- MedMined(R) Surveillance Advisor: Ranked as the #1 Infection Surveillance \par       tool by KLAS  in 2009, 2010, 2011 and 2013, MedMined services offer \par       infection surveillance and reporting, and is the only surveillance \par       service on the market today with a HFMA peer reviewed ROI model designed \par       to deliver actual costs savings driven by reductions in HAIs. \par  \par    -- Surgical Clippers: The new line of surgical clippers was designed with \par       input from clinicians and offers new features that make them more \par       ergonomic and intuitive to use, as well as easier to clean, stronger and \par       more energy efficient. \par  \par    -- Surgicept(R) Waterless Surgical Hand Scrub: In a blind study, 78 percent \par       of surgical staffers preferred Surgicept Waterless Surgical Hand Scrub \par       over Avagard(R) Surgical Hand Antiseptic.[4] The unique formulation of \par       Surgicept Waterless Surgical Hand Scrub includes emollients that counter \par       the drying effects of alcohol, and because it dries quickly, gloving is \par       faster and easier. \par  \par    -- ChloraPrep preoperative skin preparation: The 2 percent chlorhexidine \par       gluconate and 70 percent isopropyl alcohol formulation provides \par       rapid-acting and persistent antiseptic activity against a broad spectrum \par       of microorganisms.[5] ChloraPrep applicators promote gentle friction \par       scrub to help the solution penetrate the first five layers of the stratum \par       corneum, where 80 percent of microorganisms reside.[6] The proprietary \par       ChloraPrep applicator promotes aseptic technique and reduces the risk of \par       direct hand-to-patient contact, reducing the risk of \par       cross-contamination.[7] \f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 CareFusion Corporation\f28 \par \par \uc2 \f2 CareFusion (\f28 \uc2 \f2 NYSE\f28 \uc2 \f2 : CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops industry-leading technologies including Alaris(R) infusion pumps and IV sets, MaxPlus(R) and MaxZero(TM) IV connectors and sets, Pyxis(R) automated dispensing and patient identification systems, AVEA(R) , LTV(R) series and AirLife(R) ventilation and respiratory products, ChloraPrep(R) products, MedMined(R) services for data mining surveillance, V. Mueller(R) surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs approximately 15,000 people across its global operations. More information may be found at \f28 {\field{\*\fldinst{HYPERLINK "http://www.carefusion.com"}}{\fldrslt{\cf2 \uc2 www.carefusion.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 [1] Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009;91(8):1949--1953.\f28 \par \par \uc2 \f2 [2] Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87(5):980--985.\f28 \par \par \uc2 \f2 [3] Adler MT, Brigger KR, Bishop KD, Mastrobattista JM. Comparison of bactericidal properties of alcohol-based chlorhexidine versus povidone-iodine prior to amniocentesis. Am J Perinatol. 2012;29(6):455--458. Epub 2012 Mar 7.\f28 \par \par \uc2 \f2 [4] Surgical scrub comparison market research. Bernstein-Rein, 2010.\f28 \par \par \uc2 \f2 [5] Denton GW. Chlorhexidine. In: Block SS. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:321-336.\f28 \par \par \uc2 \f2 [6] Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir pf resident skin flora. J Infect Dis. 1989;160(4):644-650.\f28 \par \par \uc2 \f2 [7] \f28 \uc2 \f2 Centers for Disease Control and Prevention\f28 \uc2 \f2 . Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007. Available at: \f28 {\field{\*\fldinst{HYPERLINK "http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf"}}{\fldrslt{\cf2 \uc2 http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Logo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO}}}\par \par \uc2 \f2 SOURCE CareFusion\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020140602ea620007m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Heron Therapeutics\uc2  provides update on SUSTOL program\b0\par\par\uc2 165 \uc2 words\par \uc2 2 June 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Heron Therapeutics\uc2  announced that it has achieved a rapid start-up of its ongoing Phase 3 clinical trial of SUSTOL for the prevention of delayed-onset chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. As a consequence of the rapid start-up, results of the delayed-HEC study are anticipated earlier than previously projected and the company now plans to include these results in its resubmission of the \b \highlight22\uc2 new drug\b0 \highlight\uc2  application for SUSTOL to the \uc2 U.S. Food and Drug Administration\uc2 . To accommodate the inclusion of the delayed-HEC study, Heron plans to resubmit the NDA in the fourth quarter of 2014 versus the company's previous projection of a mid-year 2014 resubmission. Subject to approval by FDA, if the study is successful, it should enable the inclusion of a delayed-HEC indication in the SUSTOL label at the time of \b \highlight22\uc2 launch\b0 \highlight\uc2  of SUSTOL rather than approximately a year following \b \highlight22\uc2 launch\b0 \highlight\uc2 , as previously expected. \par \par \uc2 Document FLYWAL0020140602ea620020d\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Malarone\b0\par\par\uc2 173 \uc2 words\par \uc2 29 May 2014\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2014 Haymarket Media. All Rights Reserved.   \par \par \uc2 Mylan announced it has received final approval for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Atovaquone and Proguanil HCl Tablets, the generic version of \uc2 GlaxoSmithKline\uc2 's Malarone.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-pharmaceuticals/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced it has received final approval for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Atovaquone and Proguanil HCl Tablets, the generic version of {\field{\*\fldinst{HYPERLINK "http://www.empr.com/glaxosmithkline-pharmaceuticals/manufacturer/11397/"}}{\fldrslt{\cf2 \uc2 GlaxoSmithKline's}}}{\field{\*\fldinst{HYPERLINK "http://www.empr.com/malarone/drug/1869/"}}{\fldrslt{\cf2 \uc2 Malarone}}}\uc2 .\par \par \uc2 Malarone is indicated for the prophylaxis of Plasmodium falciparum {\field{\*\fldinst{HYPERLINK "http://www.empr.com/malaria-patient-information-fact-sheet/article/228705/"}}{\fldrslt{\cf2 \uc2 malaria}}}\uc2  and the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone and Proguanil HCl interfere with 2 different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil HCl primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the malaria parasite disrupts deoxythymidylate synthesis.\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/malaria-patient-information-fact-sheet/article/228705/?DCMP=OTC-MPR_Related-Links%22"}}{\fldrslt{\cf2 \uc2 RELATED: Malaria Patient Information Fact Sheet}}}\par \par \uc2 Atovaquone Proguanil HCl is available in 62.5mg/25mg and 250mg/100mg strength tablets. Mylan has started shipping the product.\par \par \uc2 For more information call (800) 796-9526 or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020140530ea5t00004\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw112\pich40\picscaley100\picscalex100\picwgoal1680\pichgoal600
47
494638396170002800E60000004A8E5989B62B66A19BB8D300146DE3ECF3ABC2DA326BA4F5FAFCB8CFE16487B5DAE9F11C5B9A739BC13B73A9A5BAD5D7E3EEFA
FEFE26619EB3C7DD4677AB135193D3DCE9004D900041896792BC013A855475A996A9C9CCDBE9EDF5F9015294002B7B175B99215C9A7AA3C6134D91899CC13658
98193B85E9F0F68BABCB7794BD0B448B17468C83ABCB456CA4F1F6F9BFD3E4E4F4F818539599B0CE386DA600448A013481233A8500478C718CB80D4C9009498E
001F74EDFAFC002F7EE5EFF5CED4E521478D37609C8BB0CE2B5E9C8398BF90A1C544599980A0C54B639E82A5C8CCDFEC07478C1A5998172779234D91C8CFE12B
51931F609CC5DAE80026785B7FAF556AA2093A85C2C6DC3167A26C78AB3B66A1C0D7E7013E8704418920509305448B0D35820B2E7D364D91CAD8E71758973040
890F1D7010559688A5C82D70A7222C7B004088396FA70005625181B191B2D00D40891B5697EEF2F70924772757974B7EAFC9E6F0E8F8FBDFEFF59FC0D903448A
E1E6F0403C84366FA7FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D6536323166353162393836332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A42434235393642363343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A42434235393642353343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222073745265
663A646F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000700028000007FF80026521650C522188884D87898452528388858C9265520C918E94848B8D8E0C8D6522908993A196A0A58F99658B
A9928FA18684026817353A5965350017381812123800C41872073A3817B74C82C3BE35120238CA00181559C9BD354C590CBCC4350C124CBDD6150715BCBECDDF
CBD622593BD5B85915CAB7350222CF00354D02983CC3A0E3009A616842D4D87140C43A006C24C81B664D461B19EBB86511D6EB978403F32E9CA3212723930302
6A54C3C000D9CA0A6D9AACC3D18CA32F0C22DAE800878B64C63D02048059D9C4A54882341C12235450049B8E110F300187C1620536CBB81D9080A163341A606A
2CBBE60063D69302BA8A6423C2CF0EB1E7FF1CC8E9D2114C16017BA0E6DC9955871F3918B2DA15E0852832B117083A1041576488261B9FFA8AE867EA51AB586F
813940C44B470C52A43E05D08544D92EC3306C16D0A5711711A2C75638BDCDCB5D2F544538D08141250EBF7224D7F022200B866A6C9AF8E10B51C7E2C6D44230
403393F2D45E55DB54089C588784153CA880C0C0A48C8E3D357C80A062034D05F5EB41A03960833D081F521C84E1E1838A0F190EB0C0C3051FD440451D6AD4D7
1F154DEC660308F5D9E0871436F850CC0E6558465A133A21C686732268E095250A41254165DC5D43830CDC71F3110523B4E0021568BCF1461732B4D0C01B030C
E05C0B1928F0801220D091010C2AACC0C0FF0E4264D0420E41348106116F5CA0811719D861431D01B450C4163ABC27460606CCD0461C1A48F106001A1C800411
1A88D4851C0E90C0DD878B89F8010E6C04D5440826B6C1448A30B178961F1A54F187056420A042176FF450C70913F0F1071F09301000141144B004123C341081
012FC0B01F177F60814002E0C1F1030B6EB8F0470604CC906A01085441800D03FC31010A2F3CC1430605A0C186037F703060170DDA39168874EDD9C547E501EA
118AB25DA4163734084040117F1CE186AA363880C016E1A9F0C706037A4107107C884185097F94E0461A7F5841C012069C4141040AB831C0025EF8E007020D10
F0EB155F2C3105011BFC91030F24F03101FF010AA0E0000651FC31030FCCD69919063BB4C15847D31E101622D69C38E85824B401D836274950030FE08E410012
7380E1800744D8D00505EB125083061AC00004153C2421B11B22E8B105151D4CD04518733CE0C6100550A8C30F09CFF0830EC32E00420E7F4CCD430E23D04101
0A6D50D1B11104349BD9427E9C3C19B56211B207DFB2AD080E4D5B754585BA148010C00F4C383087411A58F1870220E8A383011660A041184B2CE1030F1A6060
43070910E0C41F46B8D102024410408207093FF08318048C000115689B00C2075D6860430305784180191194E083C8DB30C4805A7C0A20155C8F496459628532
DF0D57CAACFD870B0A7BE0C3BF5568C043FFC4555021800420180081066CB0F1EF046280DC85051D68318301715031F00A04C8E04106549840019E6082511100
0E08F802847800820B200105346081152200071CD8297907F8C6678A139665E0403A22B845B630420C1CEC200B2238CE3278A0803F00010805A0000FDEF0822D
80000411DBC00EF0E2830958C0062DA1C2113C00812080A00C309803145E900210306102106042FF5090021BA4E1050BC81A0B343080089CE00A70484300E240
0104A0800F28F803122A87410DFA022859408F0775008A7E5C435B1D69865244723425A0AE0A4D0041171A300722A827620D500D0E6C30810E9040003B10DF13
16000111F8A003067042107EF0002AA4A0FF00FC23C10F52C083194060031E78830D6AD0803F9C200C5D5CC219EC80020A3CA1854518D02D94373838CA313165
D807A02E834776A07026C0F082BAC6003A1DA021031EC8827A2497032A28C30706E0431976E08530E0800092D355D58A340120F04009A02400111040AB0740C0
0964E8407F94108127F827010B70421582C7832CA08E0A89511EF37C0997AAD0A0028320268B68B611649E487B4200013A86F6822C88076D1B682000B0C907DF
1D20014250670432C0034CD2E10A4AE3C11020F03901BC2076F11A41015840801678F10A1A30000AF45900484601011CA002C9F236D0E2A8102232F0833A5856
95B208E77A79B9890468B0039CFDC1041AFFF0830C7C40432280000019F84315BECA062F58C0021AF081ACECB585C911C0027AF0010B16000502B492086E686B
000820BB0A0801756E68A10278C00328C87203B5A4C218924500BFA4B02340494B35E6E480ED000011D991C1DD362301CF4895062BC0010F8C90363904C70601
F08000481087882940A80CA840070A80341BE821024800420F9E40800EFCE10130F0000508F0D305E4000231E0ED042210073A4C610954A003AA8A6080080C37
033F68020FE8A5ACE74056227B982C9DAEB20C4260E62C28290C34A63A950FD8600B0FB0C35B1223801450000D2010821EB20082B65C210023C00006BAC08007
E0810B51A082064690001818C0053ED843FF17DA00831E4CC09E714082127AE70738D401471C88C102D8C5820CA4C14A3248411544E014007C0000BEC4C18B29
7B958E14421023EB820088102D6B30200B2BE0450D7A538632F4AE2BD70811352054949D54A8062450431C40D71F26A88104E1518F0624A0062A10C07754708E
0E40308CF570D906A0437305A4FCD50F68800A2190401754326011E08518BE2B03052AD0050F7E30046F814A05C04305F6EC410415608F9B41A7063430B04220
78447F6C00001B5CE1033EA046A1652080377B990756C672A1A9A0E303C487003C98CDF2E043EA82B917D55210C0E77CF0010C44387417500F153CD3E737FBC0
0B158803627021011184E01935B001051EFF908614A4400157685C03D240011FD861002920020FA29086090C40013B28D7001AA08127E861008913808EA44001
0DB7000E0D38000682A08404E8C1052B38800FA230002E0C40085F68C280DF900225C0E10133B043170230EE3AD000092978830F4800070334200E2C1881B30D
900209F8E00A2A98000C7220C802AD800612904308B2328F3744E00F308F00192AF00504FC960043F8031E6E208629C0FC0F08D840EDFED083281CE1E53D5883
A2681B809FC3FC085480C1CF3DA0021E08C1E63F7700997D0004A7FF61003630C01FA67006B42D4A7130EF8119CC807598BF810E62FF39127CA00126A0BC0609
255C1C84E0013566E0057F38C009E6803AFF1EE8E10F0B10430B110681450DEB0F1138C209F20073131C00011040FB0BE0908211680F010A20830B55FA8704BC
A1F170A03B1BEC30044B8D720B61FF83010860F60234A1953A37C30D62E02B1534400644F8C3FF52407413F0C00F36FB334DEE62F5BE1FC1060BF8831D4E5080
3FA440030FF803046C00AE39ACC1050998810FC21A831BDC80F27F68801D5EF0C3A67B807BFD81C31F0AE0840D24800339FD3A0B21308238D0650757D02B5C00
026ED030B2B7362F870202807B79700263607301E00685D6740DB80677600026F005C9770184703D3500025BD0772E200269E40771507D1FD3028827065A0073
45400727E503AD547EBB077309F077ED07FF74426720EAE23162400796D62BB3420074B003B7506C62907D53501F02E05B0680807F30076F9073C2570726D077
00F46B4D277B61400057A0065270548F713EBC00827D47492F9006364002D5473739B700611005BC372AC2B202B6428331800073300703800016E0034D17017C
C0077BF505D1277BF6C4553F370361604D41E1055720766480067B000613207B181301C0024508D0296330797FF00316300015C00252B72842100765400D22F1
41527010BD905F7DF7022FF03F54200384E786F3E70754B00196327F5BB0607F40833D600170300780D7013610567F00780DC00336A000D5377F86440245F072
7F400641F048831289DA97053C80527FA0FF075695008D87020FF0023B5783088000301007205007BE0573002416D4800687D00F54E00236B762D517004D9046
BA380734C00304100409007350F07834E88707308F64A00348207C0A100415606C3C700209F90730200257E00644D0785F4702228203DEB80455B5025297001A
002E157729F4D403E6C77B03B022FEC00362602BDAF7043E708402000A75C1066F607349D05BB2F70596622F2A58442BE000271040DA875A7F90072C402F1E40
027117454D170363E0062BA006592078E9337F0CF0050E40079CF3071D700236700B6120765370337120755CA078113002616501ADB48EBC472B3C500321E007
4F60031C00731B4005D19005D522552440FF043FF00749C0034BF00770307880A5820BA00185C90567002E10C0064D870042C002BC770355F0721D807631607C
632676B2A42816000097C801F7F2074B100471A2012420751D205A5790907A407B11D0007EF0072D40033A677E94B757FD11567960037D60983CC03788E01171
73043637032960732A7006A8020169107D30400025007329207A164005618500BA87077F60062BF0982C159A133001091006E5F90745909040000287370501E0
5B7A10061A500315C00009B90452C4023E37013CA02E29200008F0067FB5736CA7963D92056DF5024850983F100571E0071D4408C040553CE002D8087330C002
FB984631F706041007F3287C42B7973740FF3C57A50193C907E3E7755640051B297CBAB20584077335E403C9910594A2965DD04FD1573AEA020375F00314D056
1EF0044EE374231006419A7ED1305F1CD804EC55033520036FD00070A0021B802638000214900270A0045EA50138B0051910A733B202671A002BB0020110004A
950519F0066CC0004AA0040A90011910023CF0052D30004AE00236800120D0064300A975E00304A6131A40010D40014C20014DE0A914B0256274050E80066590
030D40032410008A9AA801C00461A0000330042EB00352C01B1E640912C0AB6E466B6F062100B003120006FEA11E362001FA91AC54B00375C21F2FC6033BB403
EAE10350A603FD711F6C400232A00137E4FF0324F3ABE2711F1AC021242016E22306C8D705CA8A03DB64038B74343E8006C6724385E64C9586AF5EB0ABC3B603
75840FDDAA55742A127B701760206035C016BB41671AE0174DC006BC8003D38217F6382754851AA4B10213D21ABC0006C5C1046CD01B18C02196951827A13747
E33C1D8454CB411710611B2DB6275BE21629C269C6860F18601A02E7158F881CBAA10399F11B7ED0B393C1B288610CCBF1AF26A31630561CE1B50C6C305EDBB2
037923197C0238155159C2C159510B632E43282B3208E10013C1610E3810144371147BC11DBF7100320159503B6C724003CCD1134E510D38200D6BEB0F72A01D
CCD314CC130DCFC347327050D65338D5F0843785EB0F8502986800006F1BB1682B05C7AAB7C7C0AB22B143462BB9D2F04B38800D3BD11127F45825C40001410F
E870B20010AA8FC547F1A021A16B0F6E9BB652A012AD0819D3F3B6248406821002ABE00952D00491300897C00AC12B09E340BCAA400ACA0B099900BCCC9B08C9
8B088610BDD21BBDD56B09D09B08AE80BCA4104C8100003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of malaria drug\b0\par\par\uc2 Paul J. Gough   \par \uc2 98 \uc2 words\par \uc2 29 May 2014\par \uc2 Pittsburgh Business Times Online\par \uc2 PITBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2014 American City Business Journals, Inc. All rights reserved.   \par \par \uc2 Mylan Inc\uc2 . has \b \highlight22\uc2 launched\b0 \highlight\uc2  a generic version of Malarone, a \uc2 GlaxoSmithKline\uc2  medication for malaria.\par \par \uc2 The Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg products were approved by the FDA in its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application process. The drugs had about $89 million in sales over the past 12 months, according to \uc2 IMS Health\uc2 .\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=pittsburgh&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Pittsburgh Business Times for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PITBJO0020140529ea5t0005q\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Dipexium Pharmaceuticals\uc2  Files 8K - Entry Into Definitive Agreement >DPRX\b0\par\par\uc2 288 \uc2 words\par \uc2 29 May 2014\par 08:02\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Dipexium Pharmaceuticals Inc\uc2 . (DPRX) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on May 22, 2014.\par \par \uc2 On May 22, 2014, \uc2 Dipexium Pharmaceuticals, Inc\uc2 . entered into an amendment to its Product Development Agreement, dated January 1, 2014, with RRD International, LLC. (the "Amendment"). Pursuant the Amendment, the parties agreed upon a new scope of services and budget to commence preparation of a New Drug Application ("NDA") to be submitted to the FDA for Pexiganan Cream 0.8% ("Pexiganan") if and to the extent the Company successfully completes its pivotal Phase 3 clinical studies and otherwise successfully completes the Pexiganan drug development program. The Amendment also addresses, among other things, certain medical monitoring (and related) activities, the addition of a new Phase 1 Site Monitor, and the addition of additional fees and pass-through expenses to the development budget.\par \par \uc2 The foregoing description of the Amendment is qualified in its entirety by reference to the provisions of the Amendment filed as Exhibit 10.1 to this Report, which is incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1497504/000110465914042172/a14-13391_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1497504/000110465914042172/a14-13391_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1497504/000110465914042172/0001104659-14-042172-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1497504/000110465914042172/0001104659-14-042172-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 29, 2014 08:02 ET (12:02 GMT)\par \par \uc2 Document DJDN000020140529ea5t001sq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Intercept Pharmaceuticals\uc2  Files 8K - Other Events >ICPT\b0\par\par\uc2 294 \uc2 words\par \uc2 28 May 2014\par 17:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Intercept Pharmaceuticals Inc\uc2 . (ICPT) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 28, 2014.\par \par \uc2 On May 28, 2014, Intercept announced that the FDA had granted Fast Track designation to OCA for the treatment of patients with PBC. OCA is being developed to treat PBC patients with an inadequate therapeutic response to, or who are unable to tolerate, ursodiol, the only drug currently approved to treat the disease. Intercept intends to complete its New Drug Application ("NDA") of OCA for PBC in the first half of 2015. The NDA will include data from the Phase 3 POISE trial and two randomized Phase 2 trials of OCA in PBC, all of which met their primary endpoints with high statistical significance.\par \par \uc2 Established under the FDA Modernization Act of 1997, the Fast Track program is designed to facilitate the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1270073/000114420414033985/v379977_8-k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1270073/000114420414033985/v379977_8-k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1270073/000114420414033985/0001144204-14-033985-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1270073/000114420414033985/0001144204-14-033985-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 28, 2014 17:01 ET (21:01 GMT)\par \par \uc2 Document DJDN000020140528ea5s003ue\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: \uc2 BIOCRYST PHARMACEUTICALS\uc2  FILES CURRENT REPORT\b0\par\par\uc2 1,267 \uc2 words\par \uc2 28 May 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, May 28 -- \uc2 BioCryst Pharmaceuticals Inc\uc2 ., Durham, N.C., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on May 27.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Regulation FD Disclosure.\par \par \uc2 On May 27, 2014, \uc2 BioCryst Pharmaceuticals, Inc\uc2 . ("BioCryst") issued a news release announcing the results of the BCX4161 OPuS-1 trial, as further described in Item 8.01 below. A copy of the news release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.\par \par \uc2 BioCryst's management team will host a conference call and webcast on May 27, 2014 at 8:30 a.m. Eastern Time to discuss the results of the BCX4161 OPuS-1 trial and other aspects of BioCryst's HAE development program. The conference call can be accessed by dialing 1-877-303-8027 (United States) or 1-760-536-5165 (International). The webcast can be accessed by logging onto {\field{\*\fldinst{HYPERLINK "http://www.biocryst.com"}}{\fldrslt{\cf2 \uc2 www.biocryst.com}}}\uc2 , and slides that will be used in connection with the conference call and webcast are available for viewing, downloading and printing on the website.\par \par \uc2 The information in this Item 7.01 is furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.\par \par \uc2 Other Events.\par \par \uc2 On May 27, 2014, BioCryst announced preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema ("HAE"). The trial met the primary efficacy endpoint, several secondary endpoints and all other objectives established for the trial.\par \par \uc2 OPuS-1 evaluated 400 mg of BCX4161 administered three times a day for 28 days in HAE patients with a high attack frequency (1 per week), in a randomized, placebo-controlled, two-period cross-over design. The primary goals for the trial were to estimate the degree of efficacy of BCX4161 in reducing the frequency of angioedema attacks, and to evaluate the safety and tolerability of 28 days of BCX4161 treatment.\par \par \uc2 Twenty four patients received study drug, and all completed the study. The primary efficacy endpoint for the trial was the by-subject difference in mean angioedema attack rate on BCX4161 compared to placebo. Treatment with BCX4161 demonstrated a statistically significant mean attack rate reduction of 0.45 attacks per week versus placebo, p< 0.001. The mean attack rate per week was 0.82 on BCX4161 treatment, compared to 1.27 on placebo.\par \par \uc2 Oral administration of BCX4161 was generally safe and well tolerated, with an adverse event profile similar to that observed for placebo. There was one serious adverse event reported, an abdominal HAE attack during the placebo period. Patient dosing compliance was 98 percent.\par \par \uc2 The mean number of attack-free days during each treatment period improved from 19 for placebo to 22 for BCX4161, p=0.008. Three subjects were attack-free during the BCX4161 period, compared to none during the placebo period. Quality of life was measured by the Angioedema Quality of Life questionnaire, AeQoL, and disease activity by the Angioedema Activity Score, AAS28. For BCX4161, the mean total AeQoL score improved by 8.4 units from baseline compared to 0.5 for placebo, p=0.004, and the AAS28 was 21.4 for BCX4161 compared to 28.2 for placebo, p=0.022.\par \par \uc2 Plasma drug concentrations and the degree of plasma kallikrein inhibition achieved after oral dosing with BCX4161 in OPuS-1 HAE patients were similar to those seen in healthy subjects in the Phase 1 trial. In OPuS-1, higher drug exposure was associated with a better clinical outcome.\par \par \uc2 About BCX4161\par \par \uc2 Discovered by BioCryst, BCX4161 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients.\par \par \uc2 About Hereditary Angioedema\par \par \uc2 HAE is a rare, severely debilitating and potentially fatal genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various locations, including the hands, feet, face, genitalia and airway. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting that are caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation. Further information regarding HAE can be found at {\field{\*\fldinst{HYPERLINK "http://www.haea.org"}}{\fldrslt{\cf2 \uc2 www.haea.org}}}\uc2 .\par \par \uc2 About \uc2 BioCryst Pharmaceuticals\par \par \uc2 BioCryst Pharmaceuticals\uc2  designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst's core development programs include BCX4161 and two next generation oral inhibitors of plasma kallikrein for hereditary angioedema; peramivir, a viral neuraminidase inhibitor for the treatment of influenza; and BCX4430, a broad spectrum antiviral for hemorrhagic fevers. The company has been issued approximately 100 patents on its programs, with approximately 25 of those patents issued in the United States. For more information, please visit the Company's website at {\field{\*\fldinst{HYPERLINK "http://www.BioCryst.com"}}{\fldrslt{\cf2 \uc2 www.BioCryst.com}}}\uc2 .\par \par \uc2 Financial Statements and Exhibits.\par \par \uc2 (d) Exhibits\par \par \uc2 Exhibit No. - Description\par \par \uc2 99.1 - Press release dated May 27, 2014 entitled "BioCryst Announces Positive Results from OPuS-1, a Phase 2 Trial of BCX4161 for the Prophylactic Treatment of Hereditary Angioedema"\par \par \uc2 Forward-Looking Statements\par \par \uc2 This Current Report on Form 8-K contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA or similar regulatory agency may refuse to approve subsequent studies, or delay approval of clinical studies which may result in a delay of planned clinical studies and increase development costs of a product candidate; that the FDA may withhold market approval for product candidates; that ongoing and future preclinical and clinical development of HAE second generation candidates may not have positive results; that the Company or its licensees may not be able to continue future development of current and future development programs; that such development programs may never result in future product, license or royalty payments being received; that the Company may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of product candidates. Please refer to the documents BioCryst files periodically with the \uc2 Securities and Exchange Commission\uc2 , specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/d732795d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/d732795d8k.htm}}}\par \par \uc2 Document INDFED0020140528ea5s000m5\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 BioCryst Pharmaceuticals\uc2  Files 8K - Other Events >BCRX\b0\par\par\uc2 774 \uc2 words\par \uc2 27 May 2014\par 08:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 BioCryst Pharmaceuticals Inc\uc2 . (BCRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 27, 2014.\par \par \uc2 On May 27, 2014, BioCryst announced preliminary results from its OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema ("HAE"). The trial met the primary efficacy endpoint, several secondary endpoints and all other objectives established for the trial.\par \par \uc2 OPuS-1 evaluated 400 mg of BCX4161 administered three times a day for 28 days in HAE patients with a high attack frequency ( 1 per week), in a randomized, placebo-controlled, two-period cross-over design. The primary goals for the trial were to estimate the degree of efficacy of BCX4161 in reducing the frequency of angioedema attacks, and to evaluate the safety and tolerability of 28 days of BCX4161 treatment.\par \par \uc2 Twenty four patients received study drug, and all completed the study. The primary efficacy endpoint for the trial was the by-subject difference in mean angioedema attack rate on BCX4161 compared to placebo. Treatment with BCX4161 demonstrated a statistically significant mean attack rate reduction of 0.45 attacks per week versus placebo, p< 0.001. The mean attack rate per week was 0.82 on BCX4161 treatment, compared to 1.27 on placebo.\par \par \uc2 Oral administration of BCX4161 was generally safe and well tolerated, with an adverse event profile similar to that observed for placebo. There was one serious adverse event reported, an abdominal HAE attack during the placebo period. Patient dosing compliance was 98 percent.\par \par \uc2 The mean number of attack-free days during each treatment period improved from 19 for placebo to 22 for BCX4161, p=0.008. Three subjects were attack-free during the BCX4161 period, compared to none during the placebo period. Quality of life was measured by the Angioedema Quality of Life questionnaire, AeQoL, and disease activity by the Angioedema Activity Score, AAS28. For BCX4161, the mean total AeQoL score improved by 8.4 units from baseline compared to 0.5 for placebo, p=0.004, and the AAS28 was 21.4 for BCX4161 compared to 28.2 for placebo, p=0.022.\par \par \uc2 Plasma drug concentrations and the degree of plasma kallikrein inhibition achieved after oral dosing with BCX4161 in OPuS-1 HAE patients were similar to those seen in healthy subjects in the Phase 1 trial. In OPuS-1, higher drug exposure was associated with a better clinical outcome.\par \par \uc2 About BCX4161\par \par \uc2 Discovered by BioCryst, BCX4161 is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with hereditary angioedema (HAE). By inhibiting plasma kallikrein, BCX4161 suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients.\par \par \uc2 About Hereditary Angioedema\par \par \uc2 HAE is a rare, severely debilitating and potentially fatal genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE symptoms include recurrent episodes of edema in various locations, including the hands, feet, face, genitalia and airway. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting that are caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation. Further information regarding HAE can be found at {\field{\*\fldinst{HYPERLINK "http://www.haea.org"}}{\fldrslt{\cf2 \uc2 www.haea.org}}}\uc2 .\par \par \uc2 About \uc2 BioCryst Pharmaceuticals\par \par \uc2 BioCryst Pharmaceuticals\uc2  designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst's core development programs include BCX4161 and two next generation oral inhibitors of plasma kallikrein for hereditary angioedema; peramivir, a viral neuraminidase inhibitor for the treatment of influenza; and BCX4430, a broad spectrum antiviral for hemorrhagic fevers. The company has been issued approximately 100 patents on its programs, with approximately 25 of those patents issued in the United States. For more information, please visit the Company's website at {\field{\*\fldinst{HYPERLINK "http://www.BioCryst.com"}}{\fldrslt{\cf2 \uc2 www.BioCryst.com}}}\uc2 .\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/d732795d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/d732795d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/0001193125-14-212105-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/882796/000119312514212105/0001193125-14-212105-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 BioCryst Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US09058V1035"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US09058V1035}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 27, 2014 08:16 ET (12:16 GMT)\par \par \uc2 Document DJDN000020140527ea5r001fo\par }\page {\par\fs20\b \uc2 Mylan Inc\uc2 . Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Zyprexa Zydis(R) Tablets\b0\par\par\uc2 472 \uc2 words\par \uc2 26 May 2014\par \uc2 Mental Health Weekly Digest\par \uc2 MHWK\par 39\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Mental Health Weekly Digest via NewsRx.com    \par \par \uc2 2014 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- \uc2 Mylan Inc\uc2 . (Nasdaq: MYL) announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of \uc2 Eli Lilly and Company\uc2 's Zyprexa Zydis((R)) Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for this product, which is indicated for the treatment of schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder.(1)\par \par {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnvar/20140423/77793"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnvar/20140423/77793}}}\par \par \uc2 Olanzapine ODT, 5 mg, 10 mg, 15 mg and 20 mg, had U.S. sales of approximately $120.8 million for the 12 months ending March 31, 2014, according to \uc2 IMS Health\uc2 .\par \par \uc2 Currently, Mylan has 300 ANDAs pending FDA approval representing $105.3 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to \uc2 IMS Health\uc2 .\par \par \uc2 Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com\par \par \uc2 (1) There is an increased risk of death in elderly patients with dementia-related psychosis. Olanzapine is not approved for the treatment of patients with dementia-related psychosis. Close supervision of high-risk patients should accompany drug therapy when using in combination with fluoxetine. Other risks include neuroleptic malignant syndrome, increased blood sugars, increased blood lipids, tardive dyskinesia, low blood pressure, white blood cell abnormalities, seizures, impaired judgment, and elevated prolactin levels.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20140423/77793"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20140423/77793}}}\par \par \uc2 Keywords for this news article include: \uc2 Mylan Inc\uc2 , Government Agencies Offices and Entities.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document MHWK000020140523ea5q0000o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw237\pich40\picscaley100\picscalex100\picwgoal3555\pichgoal600
47
4946383961ED002800F7000095A4CED1D8EA677EB88598C64964AAF0F2F8B3BEDCC2CBE33957A32A4A9CE1E5F1A4B1D5768BBF5871B1F2F4F9F9FAFCFAFBFDEA
EDF5E9ECF5F3F5FAFDFDFEDDE2EFFBFBFDF1F3F8F5F7FAFCFDFEA5B2D5E6E9F3F4F6FAE7EAF4E2E6F2FEFEFFF8F9FCF6F7FBD2D9EAECEFF6F7F8FBE6EAF38597
C6C1CAE2D9DFEECCD3E7DADFEEDEE3F0F3F5F9D3D9EAC9D1E6CFD6E9C3CCE3EFF1F86077B5CED5E8EEF0F7EEF1F7E8EBF4FBFCFDFDFEFEDAE0EEC0C9E2D4DAEB
FCFCFDA9B6D85F76B5B7C2DEB0BCDBCDD4E7D4D9EA9CAAD1F6F7FA697FB9697FB85E75B5D0D6E9C6CEE4C5CDE4E3E7F2D4DAEAD9DFEDBCC6E0BEC8E1BFC8E162
79B7FAFAFDC6CEE5677EB9EFF1F7E4E8F2D1D7E9A0AED3ACB8D9EDEFF6B7C1DDCBD3E78597C7B1BCDBB5C0DDE5E8F29BAAD0788CC08C9DC9DFE4F0FEFEFED3DA
EBD8DEEDAAB7D86F84BDE2E7F2E3E7F1E0E5F19BA9D0FAFAFCA6B3D5D9DEECF3F4F9B6C1DDBAC4DF657BB79AA9D0EBEEF68394C5BEC7E1E0E4F092A1CCC8D0E5
D7DDED8496C6DEE3EF97A7CF4F69AEA6B3D6CAD2E6B2BDDB7387BEC4CCE3C5CEE4DBE1EF1B3D95FFFFFF00000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000ED0028000008FF0013091C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2434418336ADC88
9180018B20438A1C49B2A4C98B1C536EFC78B2A5CB97306356544913A300993873EADC4932E381850508606CC0B3A8D1A34805FA6408002302824D392E10B840
E5D4444237264834206500810D38DE14D875E3538109080CCCBA516DA20088880E2C8068ECC0A6080A10EC0AA0A101AF6401C3E5C820D10144670722C89B4800
22BD5839BAFDCBB12F578E891B2E5D18357353968914D415E8F8EB40B885239BDE8BC87241D103A0BA46E056A0810190D30A846B973422056F3B024F44B77701
048E630FE4DB90C1E3D3034C33370857B940045B2FBB6E7AD5B15EDE0485EAFFFDDB9B206D82B7216BC6F893B353A888408B1E5B9A2078D506A7BF4E993A1102
C903E9165C79F5C115560253154710030914D0D56AFA29E49C56C345781A22D6F9979D867A15206063CFDD67DB40E421F45F5B106DA65067F049E5DB6A030AC4
1622106A541B581C6D58D646A60928E28BC10110C07F0C28B85B6BC49D17986B0A51B691653B2272E3601BF557A273AB7917E35D2C3989917A977104E3422A22
14D450F07DE4587F20C2789F50636A77500002C0A8A5834C7E86965B3FB6192471610965D78C18418924531956B7E49C1826D254036082D854865AFE285E2225
1A84679A0FD544536F7A82281788FCC948637E871654558E02890658223ED2FF041C5CAE953556533012C0988526A6642893172AD71401C309E421626056AAD2
78A319E4AA989D7A9A12688EC63790630D7CB52A47EDC1892A471F9D59E5B500EEB9564A72D18A5E02372990C0A8B68D1625461B161495460954386D70D6E175
95404D01AB6564E3629A92728EA118ADB41979945444197C9088044008B447060F67ACB152EC6D5C9206122412410F89E0B0000F1EA76C54992A5784C6082304
92C8066D2472430D5B60DCF2CE2FB1CC734312D49188204D2472081B6468108708737C81C1CF509BE473D409451046222FB4F080098984B0C1CC1780E042000A
A040F5D9144D8D76412CA49008160E20F4801A0E4C40C2DA78A384487B7917FF5404173688914810712B9482191D4CD0F7E206A98DF7090E5050881B0E718001
058C67AE794249B04088160505302122091499881D397420C5E6AC6F1EC11128DB5B97690B1090C04F17385078EBBCAFDD0715893CA082EC7C0FC440612358D0
FBF2689F8144224CF840908719326FFDE255C84044417F157BD061FF56BBD15487695458F919C15BED704D01179646E15F2F7F225618B13BC0F57E8F48F8CE11
846455C359405FC057908C28A07D00FB4D221A901804006B7ECC03041C1271872140257F0621A0F110E1BF016E8428E8CBCC5D14B8BE058E0F82F34B43051261
0830A0E73909D1A040FA3790FFB986014F91A14110584206A2F0870389C209ED0AE2A10712047D85BA5746A6A2C4B818E683DC330B58440844F979A10230F000
7C8A37C3D4604079550CA34E0661B637CC40760208A0ED0E70831C948003628CA34CBAE0841AF8E17B09239DE91211031AC0518E807C8910E85086315C80210F
A8800226F080403AF22410800005B20001857CC0011798C0D31EC94992FC410E8930010D9E3005835040793B78410942D6C9568224040FC0811220B0060F64C0
051D48041F1261831F8820046074A5304182871D2442061158420B40A003155452042B88C030A75911287C250F2B488406B4A883195C819AE004C907F4008244
C0608524884138D7C9CEA80504003B}}
\par\par \b \uc2 Cumberland Pharmaceuticals\uc2  Posts 1Q 2014 Results\b0\par\par\uc2 1,207 \uc2 words\par \uc2 24 May 2014\par \uc2 Professional Services Close-Up\par \uc2 PSVCLU\par \uc2 English\par \uc2 (c) 2014. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Cumberland Pharmaceuticals Inc\uc2 ., a specialty pharmaceutical company focused on hospital acute care and gastroenterology, has announced first quarter 2014 financial results.\par \par \uc2 In a release on May 13, the Company noted that during the quarter the Company returned to profitability, \b \highlight22\uc2 launched\b0 \highlight\uc2  two \b \highlight22\uc2 new products\b0 \highlight\uc2 , and continued to maintain positive cash flow from operations.\par \par \uc2 Net Revenue: For the three months ended March 31, net revenues were $8.1 million, compared to $10.3 million for the prior year period. The change in net revenues was driven by a decrease in Acetadote revenues, partially offset by increased revenues from Kristalose and Caldolor and the addition of new revenues from Omeclamox-Pak and Vaprisol.\par \par \uc2 Net revenue was $3.4 million for Kristalose, $2.7 million for Acetadote, including $1.3 million of authorized generic, $1.1 million for Omeclamox, $0.5 million for Caldolor and $0.3 million for Vaprisol. Net revenue for Vaprisol represents one month of sales following the acquisition of the product at the end of February 2014.\par \par \uc2 Operating Expenses: Total operating expenses for the three months ended March 31, were $7.7 million, compared to $8.9 million during the prior year period. The decrease in total operating expenses was driven primarily by decreases in research and development expenses following the conclusion of clinical studies related to Caldolor and a decrease in general & administrative expenses as the Company focuses on managing expenses in line with revenues.\par \par \uc2 Net Income: Net income attributable to common shareholders for the three months ended March 31, was $0.3 million, or $0.02 per diluted share, compared to $0.9 million or $0.05 per diluted share during the prior period. However, first quarter net income represented a return to profitability for the Company and an increase from a net loss of $(1.5) million or $(0.08) per diluted share in the fourth quarter of 2013.\par \par \uc2 Operating Cash Flow: Operating cash flows for the three months ended March 31, were $1.0 million, compared to $1.7 million, for the prior year period.\par \par \uc2 Balance Sheet: As of March 31, Cumberland had $52.6 million in cash and marketable securities, with approximately $39.0 million in cash and equivalents and $13.5 million in marketable securities. Total assets at March 31, were $91.1 million and the Company had no debt at the end of the first quarter.\par \par \uc2 "We are very optimistic about the opportunities that Vaprisol and Omeclamox-Pak will offer Cumberland. We continue to build a diversified product portfolio while deploying our resources to sustain long-term growth," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "The joint investment with Gloria will allow us to continue to both accelerate the development of existing CET projects and pursue new product candidates."\par \par \uc2 Quarter Highlights\par \par \uc2 Acquisition and Launch of Vaprisol\par \par \uc2 In February 2014, Cumberland acquired certain product rights, intellectual property and related assets for Vaprisol from \uc2 Astellas Pharma US, Inc\uc2 . Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the first and only intravenously administered treatment.\par \par \uc2 Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion.\par \par \uc2 Cumberland believes that Vaprisol, an injectable hospital product, used in the critical care setting, is an excellent strategic fit for the Company as it overlays well with the existing efforts of its sales organization. The Company began shipping Vaprisol in early March 2014 and launched active promotional efforts in early May 2014 by its hospital sales force, which also features Caldolor and Acetadote.\par \par \uc2 Launch of Omeclamox-Pak\par \par \uc2 Cumberland launched promotion and distribution efforts to support Omeclamox-Pak in January 2014. The Company's field sales force promotes Omeclamox-Pak to the gastroenterologist segment, which accounts for the largest component of the prescriber base for this product. Omeclamox-Pak is a branded prescription product used for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. This product combines three widely prescribed medications: omeprazole, clarithromycin, and amoxicillin. Omeclamox-Pak contains omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Clarithromycin and amoxicillin are both antibiotic agents which hinder the growth of H. pylori. Interaction of these agents allows the stomach lining to heal effectively. The medications are packaged together on convenient daily dosing cards, making it simple to follow the twice a day dosing before meals.\par \par \uc2 While there are competing products, Omeclamox-Pak is one of the few actively marketed products for this condition. In addition, compared to the competing branded products, Omeclamox-Pak has the lowest pill burden, fewest days of therapy and the lowest cost. Cumberland's involvement with Omeclamox-Pak was effective October 2013, through an agreement with \uc2 Pernix Therapeutics\uc2 . \uc2 Pernix Therapeutics\uc2  continues to promote the product through its specialty sales force focusing on select primary care physicians. Cumberland is responsible for the marketing, sale and distribution of the product.\par \par \uc2 Caldolor Pediatric Presentation\par \par \uc2 Data from the Company's Caldolor pediatric fever study was presented at the Society of Pediatric Anesthesiology meeting in Ft. Lauderdale in March 2014. The presentation entitled "A Multi-Center, Open-Label, Parallel, Active-Comparator, Multiple Dose Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Pediatric Patients" was presented by Dr. Samia N. Khalil, M.D., Department of Anesthesiology, the \uc2 University of Texas Medical School\uc2  at Houston. The meeting was co-sponsored by the \uc2 Society for Pediatric Anesthesia\uc2  and the American Academy of Pediatrics Section on Anesthesiology and Pain Medicine.\par \par \uc2 The pediatric study met its primary endpoint demonstrating that Caldolor was associated with a statistically significant reduction in temperature within the first 2 hours of dosing when compared to acetaminophen. Equally important, no safety concerns were observed during the study. During the study, febrile hospitalized children ranging in age from less than 1 year to 16 years, were administered Caldolor (ibuprofen) injection or oral or rectal acetaminophen as a single or multiple dose therapy for up to five days. One hundred and three patients were enrolled in this multi-center, randomized, open-label active comparator study. The pediatric patients received either 10 mg/kg intravenous ibuprofen (not to exceed 400 mg per dose) or 10 mg/kg acetaminophen (not to exceed 650 mg per dose).\par \par \uc2 International Agreement\par \par \uc2 As announced last week, Cumberland received approximately $1 million from \uc2 Harbin Gloria Pharmaceuticals\uc2  ("Gloria") for their participation in Cumberland Emerging Technologies Inc. ("CET"). As part of this transaction Gloria will have the first right to negotiate a license to CET products for the Chinese market. The funds from this new investment will be used to accelerate the development of CET product candidates. CET was founded through a partnership between Cumberland, \uc2 Vanderbilt University\uc2  and the state of Tennessee.\par \par \uc2 ((Comments on this story may be sent to health@closeupmedia.com))\par \par \uc2 Document PSVCLU0020140524ea5o00004\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw171\pich40\picscaley100\picscalex100\picwgoal2565\pichgoal600
47
4946383961AB002800F7FF00DACBCB9624288F6B6BBDA3A4C2999AD3C4C4CCBBBBF1F1F1BA151BA78687712023C11E24EEEDEDD1B9BAE5DEDEA71E22A43E42C4
ABABFCFCFCDDDBDBCDC4C4ECE9E9F1EDEDCBB3B4FAFAFAC4A4A5B81E24E9E6E6BD1E24BE9293AB0C12B37A7CAE8081CAAAABE5E1E1A62C30AB1419E1D4D5BCB7
B7B16769E2DDDDC6B3B3B59293B91A20B3898BB28485EAE8E8A30C12BA181EB91C229C0D12E0D9D9F4F2F2A26163BA2026BC9B9BAA696CBE1C22B62025DDD5D5
9D8B8BF6F6F6A13135981E22BD1920B10D14BD2026D2C9C9A35A5DB720269A5254BA8B8DA97375F8F7F7E6E5E5B6161CF4F4F4B5181EA44144D4D1D184191CA1
9FA0C6C3C3AB242ABB1E249C595AB2141AAD9A9BA25255A56C6DA05F61982B2FAA7B7CCCCBCBADACACA3292DAB595CA31419DAD1D19A313596080D885B5CD5CD
CDD7C4C5B21016E2E1E1A34649A21016A27476B5141AF0EAEAB51218DED1D29A14199D4A4DA74D50AB1016AC2126F8F6F69B4143A27C7DAC4A4E96393CDAD6D6
A3050A9B4E51B38E8FB9818296151AB12025C7AFAF8437399B1016A23438F6F4F4B87B7EA45558AD5D6093191EFBFCFC9C3B3FB012188C0204AC181E9C353899
5F61A4393CAC6163EAE3E3B47779B31F24954A4DA4252AE7DDDDB46D70B2161CAA34397D4749AA6E70F4F7F69C191EA34B4EAB292DAB5356A84549F8FAFAAC56
59DCCFCFA84246B05256BA8688ECE6E6B27274955052D5C8C9B01D23A4191EEDECEBA93135B15F62AD6668963134A12125AA3B3FBA1F25B41F24B61C22882528
B61A20FCFAFAF2F4F4B11A20B12E33AB7678B996979B4649B81F25943639F9F9F99C5658F6F8F8BA1017E6E3E3935B5CD9D3D4961217933F42BC2127C2BABAB6
8688ECE3E3E8E3E4B92025A67778BA1D23B81D23A56668B71F25BB2025FEFEFEB61F25FFFFFFFEFFFFFDFEFEB61F24B71E24FCFCFBF8F9F9B71F26B61E24FBFB
FBFDFDFDBFA8A9900D12E3D9D9B99FA0D8CFCFE5DFDFD0BFBFDFCDCDB23C3FC09F9FE3E3E3D2C7C78E474AD8C7C8EFEFEFDFD3D3F5F8F7B87577DDD8D8D9C9C9
D2CDCCE7E7E7D8CCCCFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A32313636333832333530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3231
363633383234353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3231363633383231353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3231363633383232353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AB00280040
08FF00FF091CF8CF98190A43120E993744998481C64420543884C21E0C04336ADCC8B1A3C78F2039764BC26FA2427E6652326BB7A1021373C642CA14D88DC981
0349CC6DFBB7CD5CC61E82C2F0A296AD68B6222B7E05A3F40F052318C48C0A91D16111C124FAB8DC193125D0AB5796024DF161045D8F810ED86CF1C1966D002E
18FFB5AB62ABAD8F11BB0074FB87CCCF962F76035489F5EF80811A92BED4F90A36509D2F7754F43B37904686472B8A18CDC641571F754C6E84E1B0391B104E82
28FC0D9CE58040667D02D8F5114005E19915882CD150DA282E0ECE3A895A609418902D3BFE9500B4C286D122401EB190D08D800CD29B81485AF92306AEA24510
70FF72652EDE03189A8DC6B0F2A1C73D4039A216CD218A4D825FD6E44387754360BC30C9AC00C3800890E1CE3F15C801036F9B5111C8187214620915C454488C
3540C81001466EB0F04A66D9D8B0C2303C1462CD77D93CD3860F62EC359340EE3493C366391452C625F1F576D47A2D5850C1218D3008DE0A3EF851403DFB00A0
E49200D4730F133D6440470CE9091188020A08A14D3642FC00C503B8E0A28D220A80B200374569B0422D0E0CF44D3F6C00B20407159656042E40D0D1870B025D
4008719B69E3C12C1BFCA38C136838075E0C6B444083403DA880597ABDE510C7052F12C484261E0861D4356DD460C13F1638B36069362C818918DBE8430B1AF2
15FF25C40B7F9CE502048D785A9488A0F8F3D03E889CDA9B354BF461813273B4A123528F7091C43F06E481C066B8BCD00132FFD873C7261CA0998D3656F8A00C
13F9745A1A073284B04D1282D4B104A5DA2C61CB0CFFE8A3461BF269F0C60752A882869045C0F08501996E644E165680980D37DA34B18532026D734633F915C5
0D0C234450F0C61C773C10325A58416569DC94ECADC5452CC0C707B7792C1049C618F384175E48214546EAFCB00215BDE1B2421C25F8A28A072866434D109AB4
F38F39C2AC01C333DEE2A2C117A14858F4B71E7C70402677AC608D51408491814029C88200A51AC0A0871BFF6C7087B09CE910090FB6E46083B736E882892910
04FF5274111A34E209612528B2C2D5365851483BDB1C5089B946D9E0C121E318A24713280A3ACB4BC1909083B7542C714705993241C00BB8C47A940ED45E7D21
210D20580B0C571F458C151EFC4B6951D512F00900841CBE2B1A9A3CD1422E0A17454C0C8F0CE0C714331A9543AF9FFCD18835BB17C1C1123260E38E123B6564
4F0744AB7E271008E4F01D31D4BCA2C8250380EFE60E982CA12837B9500A1D2803849FA9187378437A8841851784001F0D9041C54A133A3D58A01B21B88EEA80
000A4108A400F048C60236C8415094E01F22388415AE41296A50232AC4C88124AEC0057C29AF34D668421F68D08D76C4230438CCA13BD28002157C411744314A
0CFFB160811D90E26CA541800F0AF08F45742E079422D6305C738E7DC027884278C00FB8112B217840137CCAD4396E000B20B02E1B3E0B409BFE41830808457F
3078851F9EF50F1718C1030B700EE872A0BE92154108C95843300A3590120420479B418A1CCFE28E42C0A0373A80C10332E0A21E08830C0B784611D0C40D5CF0
F16EDC28820D16108400B8A31BDEF04318A2571C3A7C8001200C4013147594254C4110F6F840A74A468D1510C21DE670C311E8A0812EBEA01231F1580F52B086
202CC10A56D8C41B3C60844F0CC402C508421BA0690504F0C11371719938C7A91143A0230CCEE4A63AB9D90812B87304443000B6C6D90D1A4881014C8882148C
E1FF85286884125BC0DC66A8D1840718E0592E18663177158459A0802312308405DC40510BF4C07F19D9864637BA0D170D84A31BCD284835EA8D8C60800613AD
A8211EA2916E644296B58B4A201EC18BDA99C61604E309483532D29046CC1CDDE8C639CC618EA166A4023568420C7AD684628CEA021204DB1698281076E0009D
4010820D8AC0D5AE5243080B40800CB8004B386021071CB0C1339EB100121CE11B4BFBC30BF2B856B006401D4DDC471C72F00CB53E0301F04881AB5EF0861C68
B5AB5E7D861010E0814B40EC1F86C0C26E1229C90158C54FAC2C0A0248B10711FC20AB7545C32C46150B53A041AB6BE5000C6A00CB173121036B18999D624082
01FF40C314D3320ABA32E00D090883042B082297AC3006D2D5E3B3A5014221F451812D08EF2830C084C67A80083A08E164D7580211A691840ED06181C6518300
18A10D9E1585037420826B869007012AEF1A7438023EE331A5DDE580044858C439063002F4D0081000F84726B4A08BA572A9A169B880289610440E580112D3C0
A84CDEA1083AE9281BC4E8D20F2C81226268000D7FD8801BA221B2122EE10B2938C01EB090A8CD10E30D89E84726E2F05C6AA0211528A88024ACB0A5E7D03603
13384410FE86864350E00F6D902D1A37510803942216997043055CB00A2AAF02A8FB9091EA94A70D0E68A34E5A84042D042102CAFCA30717780083D1A8034540
21FF1CBA0ACFC04A5A303180E10D9BC922141421842D1B256DB57860024F94489FB5E1D0884E74814EF18D06C43688B8E0C53178F0054213A36468D40626CAE0
0C446643037488866B62710C0F0061ABBDB1410E1AA108166CC0CCFF70C51C729B9D11E0011D59A8430CE4D3492028E21EFE8B0524AC705D1D718010F1B0CAC6
98A08A17E8EAD36DC847173A703D3F8B280EF5F00600C60004D579511367C1C0055AD0817297FB082D6086396271844690B028DAD022982AA48D41282017A923
C657B858945E364AD904C18032E2B1053A2C40B8426C82162CFA07C81965013220C0363050B635F36E058080C34ECC718135049777B59BD511C6B13108EEB538
39FF50C40797E31D3B25850507B0C7213C404BA3DDD80CFFF8860ACA18C525B0F61FF7C0C1647B538418D0E102410E829F43242F769C6303F9088297B5D1E564
CC821DFF48420B7EA13066A9401C0D20446643F445D25560D8CF66963046358F2D745B568118C4203850341BA7C2150593802BDA1B447F0BE22C1508C62694CC
192BC8E1510C68F8B3D1D8045280C01385B88679B9F18C2580C21DE1ABC0538414B926D86207E768C011752484464060033B8916AD31CC0B527021186AD0C5D7
C0038329AC23090540451B76970D188C610FFFE80536AC30FBF35A81083DB0472282F08C34E5600B28F0C50782442364D37926FD200209741088EEBFE211AD89
D8FF3D14F10BEE775F07242804E807328E21D4401681C805A6B3018E72E42210C040440AECA19153284217DD178081C00D24D007AEF10FFBF003BC2080DD5704
6B400B4C4010DE2002D52009756009E5500E9C647F96300592E0093BA06CB180056B607E01080ECDD000DBC004E7F40B02A8039BE00452500D0F0080DDF70BB0
A0026761011DB0066111803AB0066010461D730E33D00792800A4AA8848CE00724271034000292E0044B880A63C0058F424E5A484EE2B00372908455880AA430
86A1300A603009ACC002EBA0042C454FFD000D4FA00452003E287033196107C2F00A40F00C54870B0B203A07286087A425DAE087614000D7B7858AC83134B075
7BFF487590088961D2651C90038CA507EC20611D23017B600E12600226200F5E000DE5340C9B605EBBE2796240194910026BB04045F0067970208B588B1B6301
8CB004A8E81B7C840BE4602708E004B4284EE6200FE68001B1C00F5DD00F139011E7E00FA0304B8994146BF70F3380036D100E52E10195108802710E867000EC
10012C0002E6A80229800234904C02B16E28E000ED108FED8002B1E02212500128208FF188023DB0172B388FFA8802CA904CC64003B1300F03508EE6E807E860
0607006B02810167108D3527355F1009913002BA503B40800917D00322008FF2986366660E2E908F01B90174841B47005CBC1743C7C03670A0089E9603841002
1EFF85027E00018FD0086DB0042B109441B9046FD0085F500DA4A31C4610046FC04DDE9405CA7601E9900CDCD406C9900EFB2010B1904DDB044DC9F04D58810D
B2D0936D000342199430D0068D000B7D3004CA6608205062CFB102CD821105000840501A30700B0630043280065DE94D73C07FE7E007644095D06495E9500010
1912B1A00730B08B17F70394700EA75334E4800073E00F02B101D8B00608A049DCA003BDF4061F071EDA0004E99002E7F00E72E035D2B30604B01769600A41D0
639FB6025BC01407C0028D60604C370A2690058DB08725439A2B8006B4931EDCA06A6490013E5101B5F05CBB72628C790E1DE06C89840689500116105028E245
B3FFF090293002481422BE6400002713E7500084D072A5E16FEE80029A002B462128AA800C13B8056D506C46B3020FA00213A0020F307608A0064AC00090B033
E001040FA031DBD002AB74469F060372B00ADD9065EA233D9C200091400DD8F19FA2200CCCB00E9C00157F66059EE002DB1076F0292B8D100A8FB20760D06252
F10219B00D6E20074D307B9A630FB1400AA78526D40003B0707B05E3022DE06E4B1743D59000B79097CA9303CDC04434300C4B507C9C41024480110D2023C9A5
7E1BE05C0C121E9C7001E6C00C9260A345710D56800334E0027D800042126955800753400545930361E007702508B7800052A301B8600D389A04ABF00123541A
39FFF008D5C000FA800824B078B8F00658D00FFF400948C0759A61036D900814E009E0307BD0410220D09832210DDCC679D4220450000575F06CE1B004888002
E610011EA73F4B200AAC390E1FA09D9BB159138002868322B1880A33600CD8D008DDE2638DD001F61002C05A1430900757D0024A45236170AADD200C50E00390
10AE3EB005838057D210006FD71BBA6005494614B8005662850461440303F00A4DD0A9DAB00B0A10AB51C10D3940079E500A1B730E506561CA933AC5610996C0
6F185640048001ABA01B5ABA3C7580087F3009A2B06B2E5664F6500234862236D05013E00E0B8670CB430282000DD2422D06A404959064FA830B9BB005C2200F
1DFF610E1164B02EB64968820B45000A0A5006CCC08E4B330FB6603F68940B0F0026E1E90193E08D2FA20C42162BB860094B6B53BE610D2AA71C346953D4B056
7D6542626B0353D1008B70068FB62B6D400B26100A31C033C480B0045407095003BC809BC470A065760164706A27D36F0B8006E9800DA7B092023103AC609F9B
61039630029CF008D7804561450620108103B10163C063C5513436800660A0341C730A63F04852610B0AB00B0B80B5D9905D88400396F9020B6514D4900B7520
0A533005A290BBBA2B0A75500C0E700EAE285BB8500E83D00913824681600B7510265DA200017026BC832E0DF010DFA00F97E0341C8070CA430540B00646A00F
66FFE60AE86A27B2380FE6B00788424BD4C028117016FFE00D33B0054B809B8C0A08C35830E7100F32B07830300A57100C43179FB4150176E00F6040A78B8B06
A6800218B00D434554107C8CE7B00D164000F5252B0FB06742F01D0B00050AF00A6162038AA008AF1067EBE109FC47109F90027AF00259D51B9487006B3000C6
6099FB5B1AB352093D700E3B700B6C2A9F71B101C5A08B17C619C886AA3221029CA2281EE6011DD00F21F05D7EA60D2BF0034A530FF0A13A0BB0064740192250
0C8EF0023230C632F0028E2008F7180DEE961E553B80F4560702B00C350572545BC5EAD00D138701C75854DBE00BEE5003C1430DBB630DBC70A11B700241A0BD
14FF644118A00275E05FBC030301300D02C100C790A59A410C45A0037F3B2B87E00B1C73065F00C9C4802E67F00DF5F09E3615034D500307600ED97935E1D164
FF700EE8609E94E233B5403A33E0096D700D2E261FD9C50A52F0078AEB728FA0024980012D10C62FF0CC2FC007BB90028551039B9059D6B00938600EA7600B52
FA1C6F3007F4D203586005219A0D31B00928DC36D3E7B318860B1E6C039C2BB2037B046B0028B9A9074CF152D4D96F05250849A00C9A1004BB232827004BE680
0D7410A2484102C2C07F7030094B00CC3DB3028A8002FD30096FE0670C630577C07FEC90086F906F713B397C920459B009C557044B50074E763AE7CC252F7004
49FF700E70F0056DA0BE05650018D05DCE86423900013C8004015C046D800A399529CA000641A02845D70847403A8650056DA0A55CB209635028F4890608372B
20400376B00E530003C2650D56D0078620105C033773F908376008A7902C3A420DBBCAD3FF207AAB870B1E7004078001EE600BD2B8300E867CFD609B35970D39
00084C640C7E3029F7F960F6E00DF1F027CA63A80DD00FC6CC798B9C7765739ED7560F7055012AE092CF715FE054CB828049A882830F80399A11C361C002962B
60B590AECFC1019B2007AE11011040BAE74202DB5C55CB577336C0DA9B80B00BE345A1C000DB300098F0CD46F1068860B3347007443C24BFD002E36000DE8C26
45FF670548C000B91424B1B2C5D180C41E9104D3B7001CD0DE967807AD650CEEB00640C0DEED1D56BC4A471240017AE0016D6058856821BF61891EF0052DF050
045102A0000468D5DEF79D0C5F60060F5102B680000EEEE00B900C92B003FEA3045520036F00041CB0C102DE6540F0062FC008291013E370027874E139B0001E
4000355D0F618000F6CD01190E0C05600019C4DE7C84007AC0270CD00141C04718EE0127908533910678D00A5A10E55A5005651188151009C720E55A500397C0
06293C1012600F82A00590F005C070E6C0300290500503100B6D481033D00A44A0E5517E0CC730003EF10F3BB00C594EE744D00A112061DE900414C006CEF005
A23E80E6A23002C3C0051490042EB20D1BC0069750037EBE0C6D720011D00AC760E9525E052020057860049E5E03461009334019CB440F74CEE55C4084321110
003B}}
\par\par \b \uc2 Actavis plc\uc2 ; \uc2 Actavis \highlight22\uc2 Launches \highlight\uc2  Generic Version of Catapres-TTS(R)\b0\par\par\uc2 151 \uc2 words\par \uc2 23 May 2014\par \uc2 Health & Medicine Week\par \uc2 HAMW\par 1356\par \uc2 English\par \uc2 (c) Copyright 2014 Health & Medicine Week via NewsRx.com   \par \par \uc2 2014 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- \uc2 Actavis plc\uc2  (NYSE: ACT) announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  a generic version of \uc2 Boehringer Ingelheim\uc2 's Catapres-TTS((R)) (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application from the \uc2 U.S. Food and Drug Administration\uc2 .\par \par \uc2 Catapres-TTS((R)) is a transdermal therapeutic system indicated for the treatment of hypertension. For the 12 months ending February 28, 2014, Catapres-TTS((R)) had total U.S. sales of approximately $180 million, according to \uc2 IMS Health\uc2  data.\par \par \uc2 Keywords for this news article include: Generics, \uc2 Actavis plc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document HAMW000020140516ea5n000z6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw171\pich40\picscaley100\picscalex100\picwgoal2565\pichgoal600
47
4946383961AB002800F7FF00DACBCB9624288F6B6BBDA3A4C2999AD3C4C4CCBBBBF1F1F1BA151BA78687712023C11E24EEEDEDD1B9BAE5DEDEA71E22A43E42C4
ABABFCFCFCDDDBDBCDC4C4ECE9E9F1EDEDCBB3B4FAFAFAC4A4A5B81E24E9E6E6BD1E24BE9293AB0C12B37A7CAE8081CAAAABE5E1E1A62C30AB1419E1D4D5BCB7
B7B16769E2DDDDC6B3B3B59293B91A20B3898BB28485EAE8E8A30C12BA181EB91C229C0D12E0D9D9F4F2F2A26163BA2026BC9B9BAA696CBE1C22B62025DDD5D5
9D8B8BF6F6F6A13135981E22BD1920B10D14BD2026D2C9C9A35A5DB720269A5254BA8B8DA97375F8F7F7E6E5E5B6161CF4F4F4B5181EA44144D4D1D184191CA1
9FA0C6C3C3AB242ABB1E249C595AB2141AAD9A9BA25255A56C6DA05F61982B2FAA7B7CCCCBCBADACACA3292DAB595CA31419DAD1D19A313596080D885B5CD5CD
CDD7C4C5B21016E2E1E1A34649A21016A27476B5141AF0EAEAB51218DED1D29A14199D4A4DA74D50AB1016AC2126F8F6F69B4143A27C7DAC4A4E96393CDAD6D6
A3050A9B4E51B38E8FB9818296151AB12025C7AFAF8437399B1016A23438F6F4F4B87B7EA45558AD5D6093191EFBFCFC9C3B3FB012188C0204AC181E9C353899
5F61A4393CAC6163EAE3E3B47779B31F24954A4DA4252AE7DDDDB46D70B2161CAA34397D4749AA6E70F4F7F69C191EA34B4EAB292DAB5356A84549F8FAFAAC56
59DCCFCFA84246B05256BA8688ECE6E6B27274955052D5C8C9B01D23A4191EEDECEBA93135B15F62AD6668963134A12125AA3B3FBA1F25B41F24B61C22882528
B61A20FCFAFAF2F4F4B11A20B12E33AB7678B996979B4649B81F25943639F9F9F99C5658F6F8F8BA1017E6E3E3935B5CD9D3D4961217933F42BC2127C2BABAB6
8688ECE3E3E8E3E4B92025A67778BA1D23B81D23A56668B71F25BB2025FEFEFEB61F25FFFFFFFEFFFFFDFEFEB61F24B71E24FCFCFBF8F9F9B71F26B61E24FBFB
FBFDFDFDBFA8A9900D12E3D9D9B99FA0D8CFCFE5DFDFD0BFBFDFCDCDB23C3FC09F9FE3E3E3D2C7C78E474AD8C7C8EFEFEFDFD3D3F5F8F7B87577DDD8D8D9C9C9
D2CDCCE7E7E7D8CCCCFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A31453036373638353530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3145
303637363836353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3145303637363833353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3145303637363834353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AB00280040
08FF00FF091CF8CF98190A43120E993744998481C64420543884C21E0C04336ADCC8B1A3C78F2039764BC26FA2427E6652326BB7A1021373C642CA14D88DC981
0349CC6DFBB7CD5CC61E82C2F0A296AD68B6222B7E05A3F40F052318C48C0A91D16111C124FAB8DC193125D0AB5796024DF161045D8F810ED86CF1C1966D002E
18FFB5AB62ABAD8F11BB0074FB87CCCF962F76035489F5EF80811A92BED4F90A36509D2F7754F43B37904686472B8A18CDC641571F754C6E84E1B0391B104E82
28FC0D9CE58040667D02D8F5114005E19915882CD150DA282E0ECE3A895A609418902D3BFE9500B4C286D122401EB190D08D800CD29B81485AF92306AEA24510
70FF72652EDE03189A8DC6B0F2A1C73D4039A216CD218A4D825FD6E44387754360BC30C9AC00C3800890E1CE3F15C801036F9B5111C8187214620915C454488C
3540C81001466EB0F04A66D9D8B0C2303C1462CD77D93CD3860F62EC359340EE3493C366391452C625F1F576D47A2D5850C1218D3008DE0A3EF851403DFB00A0
E49200D4730F133D6440470CE9091188020A08A14D3642FC00C503B8E0A28D220A80B200374569B0422D0E0CF44D3F6C00B20407159656042E40D0D1870B025D
4008719B69E3C12C1BFCA38C136838075E0C6B444083403DA880597ABDE510C7052F12C484261E0861D4356DD460C13F1638B36069362C818918DBE8430B1AF2
15FF25C40B7F9CE502048D785A9488A0F8F3D03E889CDA9B354BF461813273B4A123528F7091C43F06E481C066B8BCD00132FFD873C7261CA0998D3656F8A00C
13F9745A1A073284B04D1282D4B104A5DA2C61CB0CFFE8A3461BF269F0C60752A882869045C0F08501996E644E165680980D37DA34B18532026D734633F915C5
0D0C234450F0C61C773C10325A58416569DC94ECADC5452CC0C707B7792C1049C618F384175E48214546EAFCB00215BDE1B2421C25F8A28A072866434D109AB4
F38F39C2AC01C333DEE2A2C117A14858F4B71E7C70402677AC608D51408491814029C88200A51AC0A0871BFF6C7087B09CE910090FB6E46083B736E882892910
04FF5274111A34E209612528B2C2D5365851483BDB1C5089B946D9E0C121E318A24713280A3ACB4BC1909083B7542C714705993241C00BB8C47A940ED45E7D21
210D20580B0C571F458C151EFC4B6951D512F00900841CBE2B1A9A3CD1422E0A17454C0C8F0CE0C714331A9543AF9FFCD18835BB17C1C1123260E38E123B6564
4F0744AB7E271008E4F01D31D4BCA2C8250380EFE60E982CA12837B9500A1D2803849FA9187378437A8841851784001F0D9041C54A133A3D58A01B21B88EEA80
000A4108A400F048C60236C8415094E01F22388415AE41296A50232AC4C88124AEC0057C29AF34D668421F68D08D76C4230438CCA13BD28002157C411744314A
0CFFB160811D90E26CA541800F0AF08F45742E079422D6305C738E7DC027884278C00FB8112B217840137CCAD4396E000B20B02E1B3E0B409BFE41830808457F
3078851F9EF50F1718C1030B700EE872A0BE92154108C95843300A3590120420479B418A1CCFE28E42C0A0373A80C10332E0A21E08830C0B784611D0C40D5CF0
F16EDC28820D16108400B8A31BDEF04318A2571C3A7C8001200C4013147594254C4110F6F840A74A468D1510C21DE670C311E8A0812EBEA01231F1580F52B086
202CC10A56D8C41B3C60844F0CC402C508421BA0690504F0C11371719938C7A91143A0230CCEE4A63AB9D90812B87304443000B6C6D90D1A4881014C8882148C
E1FF85286884125BC0DC66A8D1840718E0592E18663177158459A0802312308405DC40510BF4C07F19D9864637BA0D170D84A31BCD284835EA8D8C60800613AD
A8211EA2916E644296B58B4A201EC18BDA99C61604E309483532D29046CC1CDDE8C639CC618EA166A4023568420C7AD684628CEA021204DB1698281076E0009D
4010820D8AC0D5AE5243080B40800CB8004B386021071CB0C1339EB100121CE11B4BFBC30BF2B856B006401D4DDC471C72F00CB53E0301F04881AB5EF0861C68
B5AB5E7D861010E0814B40EC1F86C0C26E1229C90158C54FAC2C0A0248B10711FC20AB7545C32C46150B53A041AB6BE5000C6A00CB173121036B18999D624082
01FF40C314D3320ABA32E00D090883042B082297AC3006D2D5E3B3A5014221F451812D08EF2830C084C67A80083A08E164D7580211A691840ED06181C6518300
18A10D9E1585037420826B869007012AEF1A7438023EE331A5DDE580044858C439063002F4D0081000F84726B4A08BA572A9A169B880289610440E580112D3C0
A84CDEA1083AE9281BC4E8D20F2C81226268000D7FD8801BA221B2122EE10B2938C01EB090A8CD10E30D89E84726E2F05C6AA0211528A88024ACB0A5E7D03603
13384410FE86864350E00F6D902D1A37510803942216997043055CB00A2AAF02A8FB9091EA94A70D0E68A34E5A84042D042102CAFCA30717780083D1A8034540
21FF1CBA0ACFC04A5A303180E10D9BC922141421842D1B256DB57860024F94489FB5E1D0884E74814EF18D06C43688B8E0C53178F0054213A36468D40626CAE0
0C446643037488866B62710C0F0061ABBDB1410E1AA108166CC0CCFF70C51C729B9D11E0011D59A8430CE4D3492028E21EFE8B0524AC705D1D718010F1B0CAC6
98A08A17E8EAD36DC847173A703D3F8B280EF5F00600C60004D579511367C1C0055AD0817297FB082D6086396271844690B028DAD022982AA48D41282017A923
C657B858945E364AD904C18032E2B1053A2C40B8426C82162CFA07C81965013220C0363050B635F36E058080C34ECC718135049777B59BD511C6B13108EEB538
39FF50C40797E31D3B25850507B0C7213C404BA3DDD80CFFF8860ACA18C525B0F61FF7C0C1647B538418D0E102410E829F43242F769C6303F9088297B5D1E564
CC821DFF48420B7EA13066A9401C0D20446643F445D25560D8CF66963046358F2D745B568118C4203850341BA7C2150593802BDA1B447F0BE22C1508C62694CC
192BC8E1510C68F8B3D1D8045280C01385B88679B9F18C2580C21DE1ABC0538414B926D86207E768C011752484464060033B8916AD31CC0B527021186AD0C5D7
C0038329AC23090540451B76970D188C610FFFE80536AC30FBF35A81083DB0472282F08C34E5600B28F0C50782442364D37926FD200209741088EEBFE211AD89
D8FF3D14F10BEE775F07242804E807328E21D4401681C805A6B3018E72E42210C040440AECA19153284217DD178081C00D24D007AEF10FFBF003BC2080DD5704
6B400B4C4010DE2002D52009756009E5500E9C647F96300592E0093BA06CB180056B607E01080ECDD000DBC004E7F40B02A8039BE00452500D0F0080DDF70BB0
A0026761011DB0066111803AB0066010461D730E33D00792800A4AA8848CE00724271034000292E0044B880A63C0058F424E5A484EE2B00372908455880AA430
86A1300A603009ACC002EBA0042C454FFD000D4FA00452003E287033196107C2F00A40F00C54870B0B203A07286087A425DAE087614000D7B7858AC83134B075
7BFF487590088961D2651C90038CA507EC20611D23017B600E12600226200F5E000DE5340C9B605EBBE2796240194910026BB04045F0067970208B588B1B6301
8CB004A8E81B7C840BE4602708E004B4284EE6200FE68001B1C00F5DD00F139011E7E00FA0304B8994146BF70F3380036D100E52E10195108802710E867000EC
10012C0002E6A80229800234904C02B16E28E000ED108FED8002B1E02212500128208FF188023DB0172B388FFA8802CA904CC64003B1300F03508EE6E807E860
0607006B02810167108D3527355F1009913002BA503B40800917D00322008FF2986366660E2E908F01B90174841B47005CBC1743C7C03670A0089E9603841002
1EFF85027E00018FD0086DB0042B109441B9046FD0085F500DA4A31C4610046FC04DDE9405CA7601E9900CDCD406C9900EFB2010B1904DDB044DC9F04D58810D
B2D0936D000342199430D0068D000B7D3004CA6608205062CFB102CD821105000840501A30700B0630043280065DE94D73C07FE7E007644095D06495E9500010
1912B1A00730B08B17F70394700EA75334E4800073E00F02B101D8B00608A049DCA003BDF4061F071EDA0004E99002E7F00E72E035D2B30604B01769600A41D0
639FB6025BC01407C0028D60604C370A2690058DB08725439A2B8006B4931EDCA06A6490013E5101B5F05CBB72628C790E1DE06C89840689500116105028E245
B3FFF090293002481422BE6400002713E7500084D072A5E16FEE80029A002B462128AA800C13B8056D506C46B3020FA00213A0020F307608A0064AC00090B033
E001040FA031DBD002AB74469F060372B00ADD9065EA233D9C200091400DD8F19FA2200CCCB00E9C00157F66059EE002DB1076F0292B8D100A8FB20760D06252
F10219B00D6E20074D307B9A630FB1400AA78526D40003B0707B05E3022DE06E4B1743D59000B79097CA9303CDC04434300C4B507C9C41024480110D2023C9A5
7E1BE05C0C121E9C7001E6C00C9260A345710D56800334E0027D800042126955800753400545930361E007702508B7800052A301B8600D389A04ABF00123541A
39FFF008D5C000FA800824B078B8F00658D00FFF400948C0759A61036D900814E009E0307BD0410220D09832210DDCC679D4220450000575F06CE1B004888002
E610011EA73F4B200AAC390E1FA09D9BB159138002868322B1880A33600CD8D008DDE2638DD001F61002C05A1430900757D0024A45236170AADD200C50E00390
10AE3EB005838057D210006FD71BBA6005494614B8005662850461440303F00A4DD0A9DAB00B0A10AB51C10D3940079E500A1B730E506561CA933AC5610996C0
6F185640048001ABA01B5ABA3C7580087F3009A2B06B2E5664F6500234862236D05013E00E0B8670CB430282000DD2422D06A404959064FA830B9BB005C2200F
1DFF610E1164B02EB64968820B45000A0A5006CCC08E4B330FB6603F68940B0F0026E1E90193E08D2FA20C42162BB860094B6B53BE610D2AA71C346953D4B056
7D6542626B0353D1008B70068FB62B6D400B26100A31C033C480B0045407095003BC809BC470A065760164706A27D36F0B8006E9800DA7B092023103AC609F9B
61039630029CF008D7804561450620108103B10163C063C5513436800660A0341C730A63F04852610B0AB00B0B80B5D9905D88400396F9020B6514D4900B7520
0A533005A290BBBA2B0A75500C0E700EAE285BB8500E83D00913824681600B7510265DA200017026BC832E0DF010DFA00F97E0341C8070CA430540B00646A00F
66FFE60AE86A27B2380FE6B00788424BD4C028117016FFE00D33B0054B809B8C0A08C35830E7100F32B07830300A57100C43179FB4150176E00F6040A78B8B06
A6800218B00D434554107C8CE7B00D164000F5252B0FB06742F01D0B00050AF00A6162038AA008AF1067EBE109FC47109F90027AF00259D51B9487006B3000C6
6099FB5B1AB352093D700E3B700B6C2A9F71B101C5A08B17C619C886AA3221029CA2281EE6011DD00F21F05D7EA60D2BF0034A530FF0A13A0BB0064740192250
0C8EF0023230C632F0028E2008F7180DEE961E553B80F4560702B00C350572545BC5EAD00D138701C75854DBE00BEE5003C1430DBB630DBC70A11B700241A0BD
14FF644118A00275E05FBC030301300D02C100C790A59A410C45A0037F3B2B87E00B1C73065F00C9C4802E67F00DF5F09E3615034D500307600ED97935E1D164
FF700EE8609E94E233B5403A33E0096D700D2E261FD9C50A52F0078AEB728FA0024980012D10C62FF0CC2FC007BB90028551039B9059D6B00938600EA7600B52
FA1C6F3007F4D203586005219A0D31B00928DC36D3E7B318860B1E6C039C2BB2037B046B0028B9A9074CF152D4D96F05250849A00C9A1004BB232827004BE680
0D7410A2484102C2C07F7030094B00CC3DB3028A8002FD30096FE0670C630577C07FEC90086F906F713B397C920459B009C557044B50074E763AE7CC252F7004
49FF700E70F0056DA0BE05650018D05DCE86423900013C8004015C046D800A399529CA000641A02845D70847403A8650056DA0A55CB209635028F4890608372B
20400376B00E530003C2650D56D0078620105C033773F908376008A7902C3A420DBBCAD3FF207AAB870B1E7004078001EE600BD2B8300E867CFD609B35970D39
00084C640C7E3029F7F960F6E00DF1F027CA63A80DD00FC6CC798B9C7765739ED7560F7055012AE092CF715FE054CB828049A882830F80399A11C361C002962B
60B590AECFC1019B2007AE11011040BAE74202DB5C55CB577336C0DA9B80B00BE345A1C000DB300098F0CD46F1068860B3347007443C24BFD002E36000DE8C26
45FF670548C000B91424B1B2C5D180C41E9104D3B7001CD0DE967807AD650CEEB00640C0DEED1D56BC4A471240017AE0016D6058856821BF61891EF0052DF050
045102A0000468D5DEF79D0C5F60060F5102B680000EEEE00B900C92B003FEA3045520036F00041CB0C102DE6540F0062FC008291013E370027874E139B0001E
4000355D0F618000F6CD01190E0C05600019C4DE7C84007AC0270CD00141C04718EE0127908533910678D00A5A10E55A5005651188151009C720E55A500397C0
06293C1012600F82A00590F005C070E6C0300290500503100B6D481033D00A44A0E5517E0CC730003EF10F3BB00C594EE744D00A112061DE900414C006CEF005
A23E80E6A23002C3C0051490042EB20D1BC0069750037EBE0C6D720011D00AC760E9525E052020057860049E5E03461009334019CB440F74CEE55C4084321110
003B}}
\par\par \b \uc2 CorePharma, Llc\uc2 ; \uc2 CorePharma \highlight22\uc2 Launches \highlight\uc2  Methylphenidate Hydrochloride Tablets USP\b0\par\par\uc2 152 \uc2 words\par \uc2 23 May 2014\par \uc2 Chemicals & Chemistry\par \uc2 CHEMEC\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Chemicals & Chemistry via NewsRx.com   \par \par \uc2 2014 MAY 23 (VerticalNews) -- By a News Reporter-Staff News Editor at Chemicals & Chemistry -- \uc2 CorePharma, LLC\uc2  ("\uc2 CorePharma\uc2 "), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  Methylphenidate Hydrochloride Tablets USP ("Methylphenidate"), the generic version of \uc2 Novartis\uc2 ' Ritalin(R). Methylphenidate is indicated for the treatment of narcolepsy and attention deficit disorders. \uc2 CorePharma\uc2  received final approval from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) on March 12, 2014. The product is available in the 5, 10, and 20mg strengths and has begun shipping.\par \par \uc2 The methylphenidate immediate release tablet market had U.S. sales of approximately $243 million according to IMS data as of December 2013.\par \par \uc2 Keywords for this news article include: Phenylacetates, Methylphenidate.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document CHEMEC0020140516ea5n0001i\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw182\pich40\picscaley100\picscalex100\picwgoal2730\pichgoal600
47
4946383961B6002800F7000095A4CE3957A34964AAD1D8EAA4B1D5677EB8C2CBE3F0F2F85871B12A4A9C8598C6E1E5F1768BBFB3BEDCF2F4F9FEFEFFEAEDF5FD
FDFEFAFAFDFCFCFDD5DBEBD0D7E9FBFCFDF9FAFCDCE1EFF3F5FAECEFF6D6DCECF4F6FAA7B4D6D3DAEBEEF0F7EFF1F8DEE3F0DADFEEE9ECF5F1F3F8F4F5FAB4BF
DCC9D1E6FBFBFDEAEDF6CFD6E9E6E9F3F8F9FCC6CEE4E4E8F2F5F6FAFEFFFFE2E7F2E3E7F2CDD4E8D3D9EBA8B4D6FAFAFCF6F8FBD3D9EAABB7D7A8B4D7E0E4F0
CED5E8EDEFF6909FCBC0C8E08F9FCBB1BCDA5C74B47488BFE2E6F2A6B3D5BBC5DFB5C0DD9EACD2DFE4F0BDC7E1BEC7E092A2CCE7EAF3B0BCDB6C81BADEE2EFA2
B0D4D9DFEE3855A3C4CDE4FAFBFDD9DEEDA4B1D4E7EAF4BAC4DECCD3E79AA9D0BFC8E1D1D8E9DEE3EFD2D9EA768ABF4561AAC2CAE2ACB8D85C73B4BEC7E1BAC4
DFAAB7D8AFBAD9EFF2F8DBE1EFBBC4DFC1CAE2BDC6E0E5E9F38294C591A1CCD4DAEBB3BEDBCDD5E8D1D7E98899C7A1AFD4F5F7FA97A7CFE8ECF58194C5DDE2EF
5A72B2E8EBF5A8B5D7E9ECF4E8EBF4F6F7FBB0BBDA8B9BC9DDE2F0A3B1D5C2CBE2E8ECF4778BC0E2E6F1CBD3E7E7EBF3DFE3F0ADB9D9E4E8F3EFF1F71B3D95FF
FFFF0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021F90400000000002C00000000B60028000008FF0023091C48B0A0C18308132A5CC8B0A1C38710234A9408A9A20187042A0698C8
B1A3C78F20431AAC08E962C38C90368A5CC9B2A5CB89244D3244A9F2A5CD480048426270B367C7981835FA7C994027A40543933A047A5228C102462B1E201800
128082500714CC191552039C56093680A46061009539B52A14103500D24850A34E1D08154141B66A231D80244060D1A80206B02D2B500124047317329DE9942E
A4BC0601244090E0ADC0AC091324D81A76E058C2090D2376C83671CEAB701F273400092A01827807EEED4BF034C1038323192EF070F1429A58551F5C9000C081
04BC1D432EA899336A819F131E4060154100B50096C386641AD2EBD4DA070AFFB02BA066A4D802673B2F889B6F6B885DE3B70D4E12F465B45E9567DE5C3BBEFD
8267CD751A75C91DC49651FCA5561F675AB1061A7A7AF1B51E7B6C15B8947C18A6145C7863195513660835D7DF73914477907A0351E7DD5ADC0D94116A20B2F7
974E6A4188E240B61964D857F065289F79E01D14808526C66890883876061D5999C5371A42A5B9D899917499771C6D2A1A455B92240EB46344BE2904DC535D1D
F0E57617C5A59385480A94E392FF1164984E022CC0404A5D8AD7D65B6AEA7480895E868592515DBE29677E3D96149486363D1081406368100921492865E9A591
8499D0982F7920874004A410490B5A606AAA4F9A22C4A94B8C1C11890EA26EFFE14224205440C3A9B8B294EA41AB8A54C4061238A157173720B100076CD40081
04B9360BD2AE06F51A520D1844D041241D54104922134C0045242A5020850717386B2E98162D0A6448037C40831109B9F181030E9C6BEF858A36C56848660C11
C92015F440C7420BF0800104F7268C10B40549DBD10A2744B200060E4540020A0A679CB1082EA011057B0CCCC8805616C46005B31AA7DCEC0391E8D186410624
20C077034075D503F3AAACB3A91B4CB1422422DC41D0004ABA28C0011748BAF3D24A95B0864042A84010025B326D75B36F2CC1DE8A0A5907A0879719855496E9
12B4D34067B3A6D3BA57635A470E05B116DED4E62DA0644E0205C053615A79FFDDDFD9670B9436D71959D6F6A5402012C92261583090DC0BF92D90DDCFE11D09
D98A66F95D418167CA93DA24B17DF85076C011C90B3FDC866842924B7C37247A3160D98AAD8FB4B7E791B0B6F9E8B9B640864108D8D5B5519154B576DE465D84
F9EEE719F59AEEBC3BFB872010943174D1A01E1D89041847EF3D474D141209203EC4CD974903507795237B64F0FDFB117900C603384C60909D3A8D2C50062070
00FFFF0F79001FBC6008133424062180000B00C8C085C0E005919801051612087AD5AB81184408049E00032A9C81057838880D2221030AC4010B8ECBA00A0712
817AC9600313984315D2A084481CA20F9130C10C46E0BE15FAB0200EB842243A1AC1840B28220F6A3801112211821D4CF087508CC423AE45822F9460017E8884
06C4C0059645F18B03C9C245381004818CE051604CA31A5B1210003B}}
\par\par \b \uc2 Ethicon \highlight22\uc2 Launches \highlight\uc2  Harmonic Ace+7 Shears with Advanced Hemostasis at ASCRS Annual Scientific Meeting\b0\par\par\uc2 523 \uc2 words\par \uc2 22 May 2014\par \uc2 Health & Beauty Close-Up\par \uc2 HEALBE\par \uc2 English\par \uc2 (c) 2014. Close-Up Media, Inc. All rights reserved.   \par \par \uc2 Ethicon Endo-Surgery, Inc\uc2 . on May 19 \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Harmonic Ace +7 Shears with Advanced Hemostasis, a purely ultrasonic device with a 7 mm sealing indication. Harmonic Ace +7 combines the precision and multi-functionality expected of Harmonic with large vessel sealing.\par \par \uc2 According to a release, the \b \highlight22\uc2 new device\b0 \highlight\uc2  is being featured at The American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Hollywood, FL this week.\par \par \uc2 The company reported that the Harmonic Ace +7 is setting a new standard in ultrasonic energy by demonstrating larger vessel sealing strength using the Advanced Hemostasis mode. Benchtop testing shows:\par \par \uc2 -Greater 5 to 7 mm vessel-sealing reliability than LigaSure devices\par \par \uc2 -140 percent higher median burst pressure vs LigaSure 5 mm Blunt Tip, when sealing 5 to 7 mm vessels in the Advanced Hemostasis mode\par \par \uc2 -112 percent higher median burst pressure vs LigaSure Advance, when sealing 5 to 7 mm vessels in the Advanced Hemostasis mode\par \par \uc2 "The addition of the 7 mm vessel sealing capability to the Harmonic Ace +7 makes it an optimal tool for laparoscopic colon surgery. It provides the same precise dissection that I've become accustomed to from the Harmonic Ace and now with larger vessel sealing capability," said Bartley Pickron, MD, Colon and Rectal Surgeon, Colorectal Surgical Associates, Houston, Texas. "For many years, surgeons have had to choose between precision and sealing strength. With the Harmonic Ace +7, we will no longer need to trade off precision and multi-functionality for sealing strength. Furthermore, the avoidance of using multiple instruments should result in a cost savings for the overall procedure."\par \par \uc2 Additionally, Harmonic Ace +7 is designed for use in numerous procedures and specialties including General, Colorectal, Bariatric, Gynecology, Thoracic, and Urology, enhancing surgeons' ability to handle multiple jobs with precision. The new Harmonic Ace+7 is best suited for cases which require dissection, mobilization and large vessel sealing.\par \par \uc2 "The Harmonic Ace +7 represents a breakthrough in ultrasonic technology that now enhances surgeon choice. Surgeons no longer need to trade off precision and multi-functionality for sealing strength. It may in some cases also reduce the need for additional devices, such as clips, improving procedure efficiency," said Tom O'Brien, Ethicon Vice President, Energy Global Strategic Marketing. "Our goal is to continue bringing to market a strong mix of both meaningful innovation (like Harmonic Ace +7) and value solutions (like our new Performance Certified Harmonic Program) that we believe will change the conversation in clinical practice from an innovation 'or' value conversation to an innovation 'and' value conversation which could ultimately lead to improved outcomes and reduced healthcare costs."\par \par \uc2 Ethicon, Inc\uc2 . and \uc2 Ethicon Endo-Surgery, Inc\uc2 . do business under the \uc2 Ethicon\uc2  brand. Their surgical technologies and products (including sutures, staplers, energy devices, clip appliers, trocars and meshes) are used around the world to treat colorectal and thoracic conditions, women's health conditions, hernias, cancer and obesity.\par \par \uc2 More information:\par \par {\field{\*\fldinst{HYPERLINK "http://www.ethicon.com"}}{\fldrslt{\cf2 \uc2 www.ethicon.com}}}\par \par \uc2 ((Comments on this story may be sent to newsdesk@closeupmedia.com))\par \par \uc2 Document HEALBE0020140522ea5m0001b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Theravance Files 8K - Other Events >THRX\b0\par\par\uc2 292 \uc2 words\par \uc2 20 May 2014\par 16:11\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Theravance Inc\uc2 . (THRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 20, 2014.\par \par \uc2 On May 20, 2014, \uc2 Theravance, Inc\uc2 . announced that results from two Phase 3 studies of umeclidinium/vilanterol (UMEC/VI) in patients with chronic obstructive pulmonary disease have been published online in the Lancet Respiratory Medicine 2014:\par \par \uc2 Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials\par \par \uc2 Dr Prof Marc Decramer MD, Prof Antonio Anzueto MD, Edward Kerwin MD, Thomas Kaelin DO, Nathalie Richard MSc, Glenn Crater MD, Maggie Tabberer MSc, Stephanie Harris BSc, Alison Church MD\par \par \uc2 The Lancet Respiratory Medicine - 15 May 2014\par \par \uc2 DOI: 10.1016/S2213-2600(14)70065 UMEC/VI is a combination of two bronchodilators, a long-acting beta2 agonist (LABA) and an anticholinergic in a single inhaler. UMEC/VI has been developed under the 2002 LABA collaboration between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 .\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414000848/theravance8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414000848/theravance8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110262414000848/0001102624-14-000848-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110262414000848/0001102624-14-000848-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Theravance, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 20, 2014 16:11 ET (20:11 GMT)\par \par \uc2 Document DJDN000020140520ea5k004ks\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Adamas Pharmaceuticals\uc2  receives $25M milestone payment from \uc2 Forest Labs\b0\par\par\uc2 175 \uc2 words\par \uc2 20 May 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Adamas Pharmaceuticals\uc2  (ADMS) announced that it has received a $25M milestone payment from \uc2 Forest Laboratories\uc2  (FRX) related to the development of MDX-8704. MDX-8704, a fixed-dosed combination, or FDC, of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the U.S. The $25M milestone payment was paid to Adamas as a result of the FDA acceptance of the \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for MDX-8704. Pursuant to the license agreement between Forest and Adamas, Forest paid Adamas a $65M upfront payment in November 2012 and $40M in 4Q13 for work related to the development of MDX-8704. Subsequent to this most recent $25M payment, there is up to a $30M milestone payable upon FDA approval. Also under the terms of the license agreement, Adamas will receive royalties on US net sales of Namenda XR and MDX-8704 beginning five years after their \b \highlight22\uc2 launches\b0 \highlight\uc2 . \par \par \uc2 Document FLYWAL0020140520ea5k008et\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Theravance Files 8K - Other Events >THRX\b0\par\par\uc2 260 \uc2 words\par \uc2 20 May 2014\par 06:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Theravance Inc\uc2 . (THRX) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 19, 2014.\par \par \uc2 On May 19, 2014 at the \uc2 American Thoracic Society (ATS) \uc2 2014 International Conference held in San Diego, California, \uc2 GlaxoSmithKline\uc2  (GSK) presented posters containing information from Phase 3 studies of umeclidinium/vilanterol (UMEC/VI) and a Phase 3 study of ELLIPTA(R), the new dry powder inhaler. ANORO ELLIPTA(R) is the proprietary name for UMEC/VI. ANORO ELLIPTA(R) is a combination of two bronchodilators, a long-acting beta2 agonist (LABA) and an anticholinergic in a single inhaler. UMEC/VI has been developed under the 2002 LABA collaboration between \uc2 Glaxo Group Limited\uc2  and \uc2 Theravance, Inc\uc2 . The posters are filed as Exhibits 99.1 to 99.3 to this report and are incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110465914040137/a14-12968_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110465914040137/a14-12968_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1080014/000110465914040137/0001104659-14-040137-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1080014/000110465914040137/0001104659-14-040137-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Theravance, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US88338T1043}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 20, 2014 06:01 ET (10:01 GMT)\par \par \uc2 Document DJDN000020140520ea5k001wz\par }\page {\par\fs20\b \uc2 Biotechnology Companies; BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials\b0\par\par\uc2 1,013 \uc2 words\par \uc2 19 May 2014\par \uc2 Biotech Business Week\par \uc2 BTBW\par 26\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2014 Biotech Business Week via NewsRx.com    \par \par \uc2 2014 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- \uc2 BioDelivery Sciences International, Inc\uc2 . (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the \uc2 U.S. Securities and Exchange Commission\uc2  and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2014.\par \par \uc2 BDSI is expecting to hear from the \uc2 U.S. Food and Drug Administration\uc2  (FDA) on its New Drug Application (NDA) for BUNAVAIL (buprenorphine and naloxone buccal film) on or about June 7, 2014. Assuming BUNAVAIL is approved, BDSI intends to launch BUNAVAIL, a proposed maintenance treatment for opioid dependence, in the latter part of the third quarter of 2014. In March, BDSI announced that it entered into an agreement with \uc2 Quintiles\uc2  to provide a range of services to support the anticipated launch including the establishment of a sales team. Separately, BDSI entered into an agreement with Ashfield Market Access, led by former GSK veteran Steve Stefano, to provide managed markets and trade support for BUNAVAIL.\par \par \uc2 As recently reported, data from clinical studies of BUNAVAIL were presented at the \uc2 American Society of Addiction Medicine\uc2  (ASAM) 45th Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four posters were presented highlighting data from the clinical development program, which included the pivotal bioequivalence study of BUNAVAIL compared to Suboxone tablets. Also highlighted was a safety study conducted in 249 subjects undergoing maintenance treatment for opioid dependence with Suboxone film or tablets who were converted to BUNAVAIL for 12 weeks. The posters are accessible at {\field{\*\fldinst{HYPERLINK "http://www.bdsi.com"}}{\fldrslt{\cf2 \uc2 www.bdsi.com}}}\uc2 .\par \par \uc2 On January 23, 2014, \uc2 Endo Pharmaceuticals\uc2  and BDSI announced positive top-line results from its pivotal Phase 3 efficacy study of BEMA Buprenorphine in opioid "naive" subjects, and in conjunction with database lock, BDSI received a milestone payment from Endo in the amount of $10 million. BEMA Buprenorphine is being developed for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy for an extended period of time. Results of the second Phase 3 study, which was conducted in opioid "experienced" patients, are anticipated in early July. If successful, an NDA for an indication of the treatment of moderate to severe chronic pain would be anticipated to be submitted in late 2014 or early 2015.\par \par \uc2 On April 3, 2014, BDSI announced the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study in 140 subjects to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. As of the beginning of May, over 50% of subjects had been randomized in this trial with the interim analysis anticipated to occur in the third quarter of 2014. The purpose of the interim analysis is to confirm the assumptions regarding the study sample size and allow for an adjustment in size if needed. Clonidine Topical Gel has the opportunity to be the first topical product approved by FDA for the treatment of PDN. As such, BDSI currently estimates annual peak sales potential for this product in excess of $300 million.\par \par \uc2 In February 2014, BDSI closed a $60 million registered common stock financing with a select group of institutional investors led by Federated Kaufmann. This financing strengthened BDSI's balance sheet in front of its anticipated 2014-2015 activities, and at March 31, 2014, BDSI had $88.2 million in cash compared to $23.2 million at December 31, 2013.\par \par \uc2 Research and development costs were $14.6 million in the first quarter of 2014, compared to a corresponding $12.0 million in the first quarter of 2013. The current quarter increase in research and development expense was due primarily to additional research and development costs associated with the BEMA Buprenorphine for chronic pain late stage development program and the initiation of the Clonidine Topical Gel Phase 3 program. Overall R&D costs for 2014 will fall below 2013 levels.\par \par \uc2 "There has never been a more exciting time at BDSI as we move closer to the PDUFA date of June 7(th) and potential launch of BUNAVAIL this year, as well as the data read out of our second pivotal trial for BEMA Buprenorphine for chronic pain in early July," said \uc2 Dr. Mark A. Sirgo\uc2 , President and Chief Executive Officer of BDSI. "As it relates to BUNAVAIL, opioid dependence has unfortunately become a national epidemic and a clear need exists for new treatment options. To help address this need, we are currently readying launch plans for BUNAVAIL and have entered into agreements with \uc2 Quintiles\uc2  and Ashfield Market Access to provide the services and infrastructure needed to support our planned sales and managed markets activities. Additionally, we are working aggressively with our commercial partner Endo to complete the Phase 3 program and believe the market opportunity for BEMA Buprenorphine for chronic pain continues to expand for a differentiated Schedule 3 opioid. Furthermore, we are excited to have expanded our late-stage product pipeline with the initiation of the Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy."\par \par \uc2 "With a strengthened balance sheet, BUNAVAIL approaching its PDUFA date, the final pivotal study for BEMA Buprenorphine for chronic pain reporting out mid-year and Clonidine Topical Gel in Phase 3, we believe BDSI has the strongest potential in it's history to generate sustainable value for our shareholders," concluded Dr. Sirgo.\par \par \uc2 Keywords for this news article include: Antiadrenergic Agents, Pharmaceutical Company, Drugs, Therapy, Clonidine, Chronic Pain, Centrally Acting, Cardiovascular Agents, Investment and Finance, Biotechnology Companies, Nervous System Diseases, Neurologic Manifestations, Clinical Trials and Studies, \uc2 BioDelivery Sciences International Inc\uc2 ..\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC\par \par \uc2 Document BTBW000020140516ea5j00008\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Laboratory Corporation\uc2  Files 8K - Regulation FD >LH\b0\par\par\uc2 217 \uc2 words\par \uc2 19 May 2014\par 08:49\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Laboratory Corp. of America Holdings\uc2  (LH) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on May 19, 2014.\par \par \uc2 On May 19, 2014, \uc2 Laboratory Corporation of America\uc2  (R) Holdings (\uc2 LabCorp\uc2  (R)) (NYSE: LH) announced today the availability of the xTAG (R) CYP2D6 Kit v3 from \uc2 Luminex Corporation\uc2  (NASDAQ: LMNX). The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that aids clinicians in determining strategies for therapeutics metabolized by the CYP2D6 gene product.\par \par \uc2 Exhibits\par \par \uc2 99.1 Press Release dated May 19, 2014\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/920148/000092014814000061/form8-kmay192014pressrelea.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/920148/000092014814000061/form8-kmay192014pressrelea.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/920148/000092014814000061/0000920148-14-000061-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/920148/000092014814000061/0000920148-14-000061-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Laboratory Corp. of America Holdings\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US50540R4092"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US50540R4092}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 19, 2014 08:49 ET (12:49 GMT)\par \par \uc2 Document DJDN000020140519ea5j002ht\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Auxilium Pharmaceuticals\uc2  Files 8K - Regulation FD >AUXL\b0\par\par\uc2 268 \uc2 words\par \uc2 19 May 2014\par 07:02\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Auxilium Pharmaceuticals Inc\uc2 . (AUXL) filed a Form 8K - Regulation FD Disclosure - with the U.S Securities and Exchange Commission on May 19, 2014.\par \par \uc2 On May 19, 2014, \uc2 Auxilium Pharmaceuticals, Inc\uc2 . issued a press release announcing that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLEX(R) (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD). These data were presented at the \uc2 American Urological Association\uc2  (AUA) Meeting held in Orlando, Florida on May 16-21, 2014.\par \par \uc2 The foregoing is qualified in its entirety by the text of the press release attached as Exhibit 99.1 hereto and incorporated herein by reference. All readers are encouraged to read the entire text of the press release attached hereto.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465914039866/a14-12897_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465914039866/a14-12897_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1182129/000110465914039866/0001104659-14-039866-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1182129/000110465914039866/0001104659-14-039866-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 Access Investor Kit for \uc2 Auxilium Pharmaceuticals, Inc\uc2 .\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://www.companyspotlight.com/partner?cp_code=A591&isin=US05334D1072"}}{\fldrslt{\cf2 \uc2 http://www.companyspotlight.com/partner?cp_code=A591&isin=US05334D1072}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 19, 2014 07:02 ET (11:02 GMT)\par \par \uc2 Document DJDN000020140519ea5j0023u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw222\pich44\picscaley100\picscalex100\picwgoal3330\pichgoal660
47
4946383961DE002C00C4000044448FDA44448888B8F1BBBBE78888BBBBD6CF1111EEEEF5E06666D32222EB9999F8DDDD22227AF5CCCCFCEEEE111170DDDDEB33
33856666A3AAAACCEEAAAA7777AD9999C2D63333E47777CCCCE0DD5555555599CC0000000066FFFFFF00000021F90400000000002C00000000DE002C000005FF
A0278E64699E68AAAE6CEBBE702CCF746DDF78AEEF7CEFFFC0A070482C1A8FC8A472C96C3A9F31884500A84A0405A8763B0474BE60F0284C16980A5E3298616E
A5D570705B17570538F83C07511AE8F5035C396F6A6371732215716411072C848B653C7529777F780E247E971C818237906186708812918C8E2AA1A71D883894
289697049A9C9D9FA08BA36A7316AC64152BABA7AE37B027B27F09B59C9EB834C31DBB92220FBF6410AAD761C536C726C97F0A239B97CECF32D1D3DC22BEDB72
DAEFAD937076B61C01E4B6E7E830EA228BDA9882B3A180803800E2BDEB56E35B89707F3C958BD86FC63F0F01453088936A2099070AC9B01140B224C92C3B1CFF
9280A8878F8789802AA6D305F050CD7A220EE244312C218B03023644F80240C28414028676886046E508967A16BCDC57C201010D17F00440408144030260C312
6830422CD8110BCC82CD24C281020D09F25CC0D0D5C5C58C18E3A0D45928454F1602ACC1618072C401A5613C92B1778F032D9879CE1130602B81A7059C6889B8
54F6D285B2946D5D20FB88665E5222107FCCE0014281D7B05F870CE33385E2381648A866C5F89E81A9CD4620688C679C87D02D4534B8449AC02597C3891B203D
5BD44D5E89223114865085A25F473DB8DBD6FB9E02C8783C61209EA72BC47CC0F5D485488B027B3CCBB8C3C25BE014E1187FA100C1360C88108D532240A5C7FF
05E8DD82D97D1C2CE3DC1FBF7930A11E9A65F507597141689C5FA6E1E5C1815F6C908A1B718C64D208B77D11C1466A1C258F3495DC772145D1FD7141877F5060
1F671EACF7874B9C78B0DC251A10A06172D589711D35AD0916C903E19576CD08308611416B705470001C0F40C0D76235B2C7234567E2F1D9837F60C0664CEF19
79493E0A70221564F081B89F4D2364206524C158F9CB3A1DF8044742873EE9642C1052C5097C8F1E774957C8E5F11B64187850E72CF1E9A1DF4E228AE0E72F12
08CA9B075FAA61A8AAA7D1A6E817E5351A9903917A10297DB67262D525E33448005BFE84C827090790F8456E4DEE49C6AACBB60A06B364323A67A5F704526BFF
A437E28140830308A90769BEFD1AACB2D89D10D8290F9C7882B18BCA8328ABCE2E8ACCA3D93A2A6B3E3FEA1140BEE28453A107397262C087A6461B6A09076C40
4CB2A0BEF36EB3F1C25AE61F01BC596DAE8DE663310706D48B070169E6E900B57302CB30A15F6C27C2047F42CC538A269184F2220FBB1A318DD2520C307BD6DE
2B02C9DE561AF0C75EA5798901527DDAD7CDF31814B3CCADED66DDCB89A2004704B165CD5AD5087AC0523E4736D6B38E03946DB6D9A441845CC024D735820343
7B56F0D4190D33C28071644335BC27549D02D73BCD3B6782C48DAD2F0B1EE791781E4997B040DC7A10BC6E8A339B31E6D423C6C1DADE2E9B50750555840E40FF
30802F2DB8CE9A168EF1E14106E0FAEB997AC0EF251BEB911F0A8FDBA281D2646431C122595C0E4661524BCCB9CD26A40A7128353FFB2ACEA7B3EE81D180D03A
B8D7D7D78EDFEA488E80C1EBAF8FD300C9B7A320FC36D9FC7EF50406C5B1A59E7C7B0E6F281228AF25AA5D7FDDD9C5B542E492A4B7BA876676F607CD786C05EA
9B5181B834A30E04EA78CE83E0032C309E30E4260E1BC852B4A2970791890D7B1452C0A6C4F1145BD00272E9D91FEB34703D1568701B7360971AF40641A2A4A0
82ACC846F122112BAD900085B718E17D1A97B8712C0E5861B31DC91CC382046E235D2370E2351E58C342B9F01AA5F2C077C83331E9C9892AD383D0FF644795E7
067D86044B928EC952B0C56B5449042D8A4423781741148C0A5DA9C05B1C5A063D70D4AA84C131D212296432ED89407B63EC546324A782F381E98D2CBA0600D4
55C5DAD8F18522D95C3BE2208116F5101F2510624C9443BD3C24803A2320DF084C6802050C120F038B421CC1F080FAA5000D916000B2E666C3150005936CA0A4
0726F0C26008EF93791A01F5CE6115A325405C7E441D0829628205608064064040E36270000B804E74029880304F20A66F860E0B49700DFB0A304E12A8939D5B
58C0002850B6350E419EF31C002A65C2CF7EFAF39F000DA840074AD0821AF4A0084DA8429F1102003B}}
\par\par \b \uc2 FORM 8-K: CELLDEX THERAPEUTICS FILES CURRENT REPORT\b0\par\par\uc2 747 \uc2 words\par \uc2 16 May 2014\par \uc2 US Fed News\par \uc2 INDFED\par \uc2 English\par \uc2 Copyright 2014. HT Media Limited. All rights reserved.   \par \par \uc2 WASHINGTON, May 16 -- \uc2 Celldex Therapeutics Inc\uc2 ., Hampton, N.J., files Form 8-K (current report) with \uc2 Securities and Exchange Commission\uc2  on May 14.\par \par \uc2 State or other jurisdiction of incorporation: Delaware\par \par \uc2 Other Events. On May 14, 2014, \uc2 Celldex Therapeutics, Inc\uc2 . ("Celldex"), announced that it had entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, \uc2 Bristol-Myers Squibb\uc2 's investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in Phase 1/2 study. Under the terms of this clinical trial collaboration, \uc2 Bristol-Myers Squibb\uc2  will make a one-time payment of $5 million to Celldex and the parties will share development costs. Celldex will be responsible for conducting the Phase 1/2 study, which is expected to begin in the fourth quarter of 2014. Additionally, the parties have re-structured an existing agreement between Celldex and Medarex related to Celldex's CD27 program, and waived certain future milestone payments and reduced future royalty rates that would have been due from Celldex to Medarex. Medarex was acquired by \uc2 Bristol-Myers Squibb\uc2  in September of 2009. The companies will work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. \uc2 Bristol-Myers Squibb\uc2  will have a time-limited right of first negotiation if Celldex wishes to out-license varlilumab. A press release relating to the above matters is attached to this Current Report on Form 8-K as exhibit 99.1. Forward-Looking Statements This Current Report on Form 8-K and the attached press release contain "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the Company's strategic focus and the future development and commercialization (by Celldex and others) of rindopepimut (CDX-110), glembatumumab vedotin ("glemba"; CDX-011), varlilumab (CDX-1127), CDX-1401, CDX-301 and other products and our goals for 2014. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of rindopepimut, glembatumumab vedotin and other drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Financial Statements and Exhibits. (d) Exhibit No. - Description. 99.1 - Press Release dated May 14, 2014\par \par \uc2 More information can be viewed at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/744218/000110465914038370/a14-12733_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/744218/000110465914038370/a14-12733_18k.htm}}}\par \par \uc2 Document INDFED0020140516ea5g000x6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Actavis\uc2  extends exclusive agreement to distribute authorized generic Concerta\b0\par\par\uc2 133 \uc2 words\par \uc2 15 May 2014\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2014. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Actavis\uc2  has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of JPI's Concerta. Under the terms of the extended exclusive agreement originally due to expire on December 31, JPI will continue to manufacture and supply \uc2 Actavis\uc2  with all dosage strengths of the authorized generic product, and \uc2 Actavis\uc2  will continue to market and distribute the product in the U.S. JPI will receive 50% of the net sales from \uc2 Actavis\uc2 ' product. The extended agreement runs until December 31, 2017. During the term of the agreement, \uc2 Actavis\uc2  may continue to pursue FDA approval of its abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  application for a generic version of Concerta and may \b \highlight22\uc2 launch\b0 \highlight\uc2  its own ANDA product at the conclusion of the exclusive supply agreement. \par \par \uc2 Document FLYWAL0020140515ea5f001uy\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Lipocine Files 8K - Other Events >LPCN\b0\par\par\uc2 163 \uc2 words\par \uc2 15 May 2014\par 08:31\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Lipocine Inc\uc2 . (LPCN) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 15, 2014.\par \par \uc2 On May 15, 2014, \uc2 Lipocine Inc\uc2 . issued a press release to report the Phase 1 clinical study results with LPCN 1107. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420414030778/v378741_8-k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420414030778/v378741_8-k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420414030778/0001144204-14-030778-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420414030778/0001144204-14-030778-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 15, 2014 08:31 ET (12:31 GMT)\par \par \uc2 Document DJDN000020140515ea5f002j6\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 TERUMO(R)  \highlight22\uc2 Launches \highlight\uc2  Expanded GLIDEWAY(TM) Access Sheath Portfolio With A  \highlight22\uc2 New Product \highlight\uc2  For Minimally Invasive Urologic Procedures\b0\par\par\uc2 828 \uc2 words\par \uc2 15 May 2014\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 \f2 \par New GLIDEWAY(TM) Ureteral Access Sheath Offers Advanced Features Designed to Minimize Trauma \par  \f28 \par \par \uc2 \f2 SOMERSET, N.J., May 15, 2014 /PRNewswire/ -- TERUMO, a leading global medical device company, today announced the U.S. \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of its new GLIDEWAY(TM) Ureteral Access Sheath. It is the latest addition to the GLIDEWAY(TM) Access Sheath portfolio used in minimally invasive urologic procedures including ureteroscopy and percutaneous nephrolithotomy (PCNL). The sheaths will be \f28 \b \highlight22\uc2 \f2 introduced\f28 \b0 \highlight\uc2 \f2  at the 2014 \f28 \uc2 \f2 American Urological Association\f28 \uc2 \f2  (AUA) Annual Meeting, in Orlando, Florida.\f28 \par \par \uc2 Conventional access sheaths currently used for urologic intervention have been tied to complications and injury including perforation and significant bleeding.(1,2) The new family of GLIDEWAY(TM) Access Sheaths has innovative and refined features designed to minimize trauma while ensuring maximum and efficient access:\par \par \uc2 \f2 \par    -- URETEROSCOPY:  GLIDEWAY(TM) Ureteral Access SheathPrecision linear tip \par       design with ultra smooth transitions engineered to optimize day-to-day \par       urologic access needs \par  \par    -- URETEROSCOPY:  GLIDEWAY(TM) Balloon-Expandable Ureteral \par       SheathRadially-expanding sheath with an integrated balloon designed to \par       minimize sheath profile and friction during insertion \par  \par    -- PCNL:  GLIDEWAY(TM) Balloon-Expandable PCNL SheathOne-step insertion of \par       balloon and radially-expanding sheath designed for easier insertion and \par       reduced trauma \f28 \par \par \uc2 \f2 "GLIDEWAY Access Sheaths offer unique characteristics with the potential to reduce urothelial trauma and simplify access into the kidney," said Duane Baldwin, MD, Professor at Loma Linda University, and one of the primary investigators in early studies of expanding sheath technologies. A study using a one-step balloon-expandable PCNL sheath demonstrated successful access and visualization in patients of different ages, body mass indexes, and renal stone locations without instances of collecting system injuries.(3) Similarly, an observational study demonstrated less insertion force and less urothelial tear length with a radially-dilating ureteral access sheath as compared to conventional sheaths.(4)\f28 \par \par \uc2 \f2 "The GLIDEWAY Access Sheath portfolio launch is an important milestone for TERUMO in advancing our urology interventional platform," said Chris Pearson, Vice President of Marketing, Terumo Interventional Systems. "It builds on our proven performance in urologic access with the GLIDEWIRE(R) Hydrophilic Guidewire and demonstrates our commitment to the urology space. In partnership with healthcare providers, TERUMO will continue to apply our global resources, industry leading innovation and world class manufacturing to accomplish our mission of Contributing to Society Through Healthcare."\f28 \par \par \uc2 \f2 For more information about the GLIDEWAY(TM) Access Sheaths, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.terumois.com/glideway"}}{\fldrslt{\cf2 \uc2 www.terumois.com/glideway}}}\par \par \uc2 \f2 About Ureteroscopy and PCNL Procedures\f28 \par \par \uc2 \f2 Ureteroscopy and PCNL are current standards of care for minimally-invasive urologic intervention especially for stone management in the urinary tract. One in 11 people in the U.S. suffer from kidney stone disease and the prevalence is growing driven by incidence of obesity and diabetes, which are common risk factors for stone disease.(5) In 2013, more than 350,000 ureterosopy and PCNL procedures were performed in the U.S. and that number is expected to grow consistently over the next decade with the need for less invasive surgical procedures.(6)\f28 \par \par \uc2 \f2 Terumo Corporation\f28 \par \par \uc2 \f2 TERUMO is a leading global medical device company with over $4 billion in sales and operations in over 160 countries. TERUMO is committed to establishing a strong leadership position in Urology through a platform of innovation, world-class manufacturing, and a collaborative approach with healthcare providers to meet today's medical challenges.\f28 \par \par \uc2 \f2 TERUMO is the manufacturer and exclusive U.S. distributor of GLIDEWIRE(R) Urologic Hydrophilic-Coated Guidewires as well as GLIDEWAY(TM) Access Sheaths.\f28 \par \par \uc2 \f2 TERUMO combines world-class research and a deep market understanding to deliver technology solutions and high-quality education programs that deliver clinical value, economic benefit, and enhanced patient outcomes.\f28 \par \par \uc2 \f2 For more information, visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.terumois.com"}}{\fldrslt{\cf2 \uc2 www.terumois.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 1. Traxer O and Thomas A. Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. J Urol. 2013 Feb;189:580-4.\f28 \par \par \uc2 \f2 2. Safak M, Gogus C, Soygur T. Nephrostomy tract dilation using a balloon dilator in percutaneous renal surgery: Experience with 95 cases and comparison with the fascial dilator system. Urologia Internationalis. 2003;71:382-4.\f28 \par \par \uc2 \f2 3. Baldwin DD, Maynes LJ, Desai PJ, Jellison FC, Tsai CK, Barker GR. A novel single step percutaneous access sheath: The initial human experience. J Urol. 2006 Jan;175:156-61.\f28 \par \par \uc2 \f2 4. Harper JD, Ebrahimi KY, Auge BK, Lamberton GR, Pham AK, Zuppan C, Albala DM, Preminger GM, and Baldwin DD. Comparison of a novel radially dilating balloon ureteral access sheath to a conventional sheath in the porcine model. J Urol. 2008 May;179:2042-5.\f28 \par \par \uc2 \f2 5. Scales CD, Smith AC, Hanley JM, Saigal CS. Urologic diseases in America project. Prevalence of kidney stones in the United States. Euro Urol. 2012;62:160-5.\f28 \par \par \uc2 \f2 6. Millennium Research Group. US Markets for Urological Devices 2014.\f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Terumo Medical Corporation\f28 \par \par \uc2 \f2 /\f28 \par \par \uc2 Document PRN0000020140515ea5f0004j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Puma Biotechnology Files 8K - Other Events >PBYI\b0\par\par\uc2 194 \uc2 words\par \uc2 14 May 2014\par 08:39\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2014, Dow Jones & Company, Inc.   \par \par \uc2 Puma Biotechnology Inc\uc2 . (PBYI) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on May 14, 2014.\par \par \uc2 On May 14, 2014, \uc2 Puma Biotechnology, Inc\uc2 . issued a press release announcing the expansion of the first cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.\par \par \uc2 The full text of this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514198149/d725174d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514198149/d725174d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this SEC filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1401667/000119312514198149/0001193125-14-198149-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1401667/000119312514198149/0001193125-14-198149-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 14, 2014 08:39 ET (12:39 GMT)\par \par \uc2 Document DJDN000020140514ea5e002fa\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 DigiPath Raises $2.2 Million & Reports 2nd Quarter Financial Results\b0\par\par\uc2 806 \uc2 words\par \uc2 14 May 2014\par 07:30\par \uc2 PR Newswire (U.S.)\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2014  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 AGOURA HILLS, Calif., May 14, 2014 /PRNewswire/ -- \uc2 DigiPath, Inc\uc2 . (OTCBB and OTCQB: DIGP), a life sciences company focused on nutra-pharmaceuticals and pathology, is pleased to announce that it has raised $2.2 million in growth capital from individual accredited investors and filed its second quarter financial results with the SEC for the fiscal period ending March 31, 2014.\par \par \uc2 "With financing in place, we expect renewed growth in revenue over the near-term as we reinvest in sales and prepare to \b \highlight22\uc2 launch new products\b0 \highlight\uc2  in the nutra-pharmaceutical space," said DigiPath's President Todd Denkin.\par \par \uc2 DigiPath raised $2.2 million from individual accredited investors in its second round of financing this year on May 12, 2014. In aggregate, DigiPath has raised $8.2 million so far this year to support its growth initiatives designed to build long-term shareholder value.\par \par \uc2 Revenues for the three months ended March 31, 2014 were $51,000, compared to $202,000 for the same three months last year. Revenues for the six months then ended were $106,000, compared to $307,000 for the same six months last year. The decline in revenue was primarily attributed to insufficient capital available for sales and marketing expenditures required to maintain and grow revenue. Net loss for the three months ended March 31, 2014 and 2013 were $265,000 and $103,000, respectively. Net loss for the six months ended March 31, 2014 and 2013 were $298,000 and $209,000, respectively. The net loss for both the three month and six month periods ending March 31, 2014 was $0.05 per share.\par \par \uc2 The complete 10-Q filing may be viewed on the company's website at {\field{\*\fldinst{HYPERLINK "http://www.digipath.com"}}{\fldrslt{\cf2 \uc2 www.digipath.com}}}\uc2 .\par \par \uc2 About \uc2 DigiPath, Inc\uc2 .\par \par \uc2 DigiPath, Inc\uc2 ., through its subsidiary, DigiPath, Corp., develops and sells the affordable, innovative, and reliable digital pathology solutions for second opinion, consultation, tumor board, archiving, and educational purposes for improved workflow, analysis and data mining in support of pathology in academic medical centers, reference laboratories, biopharma organizations, and life science research institutions. Our digital pathology image-based information environment enabled by computer technology that allows for the management of information generated from a digital slide. Digital pathology is enabled in part by virtual microscopy, which is the practice of converting glass slides into digital slides that can be viewed, managed, and analyzed. Our digital pathology products, PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) provide a digital platform to share and store archive tissue images. \uc2 DigiPath, Inc\uc2 . is also currently exploring new lines of business associated with the research, development, licensing and operation of botanical and nutra-pharmaceutical products and services, including, without limitation, the licensing of brand name nutra-pharmaceutical products. For more information \uc2 DigiPath, Inc\uc2 . please visit: {\field{\*\fldinst{HYPERLINK "http://www.digipath.com"}}{\fldrslt{\cf2 \uc2 www.digipath.com}}}\uc2 .\par \par \uc2 Information about Forward-Looking Statements\par \par \uc2 This press release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the \uc2 United States Securities and Exchange Commission\uc2 . An example of such forward looking statements in this press release include statements regarding the Company developing and completing new products and revenue growth. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent \uc2 Securities and Exchange Commission\uc2  filings, which are available at {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 . The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\par \par \uc2 Company Contact:\par \par \uc2 David Williams, CFO\par \par \uc2 David@DigiPath.com\par \par \uc2 2870 Roadside Drive, Suite 128\par \par \uc2 Agoura Hills, CA 91301\par \par \uc2 SOURCE \uc2 DigiPath, Inc\uc2 .\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.digipath.com"}}{\fldrslt{\cf2 \uc2 http://www.digipath.com}}}\par \par \uc2 Document PRN0000020140514ea5e0003m\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:11\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}